Коронавирусная болезнь 2019 (COVID-19)

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr;5(4):536-44.Полный текст  Аннотация

2. World Health Organization. Tracking SARS-CoV-2 variants. 2022 [internet publication].Полный текст

3. UK Health Security Agency. Investigation of SARS-CoV-2 variants: technical briefing documents on novel SARS-CoV-2 variants. 2022 [internet publication].Полный текст

4. Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. 2022 [internet publication].Полный текст

5. Nyberg T, Twohig KA, Harris RJ, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ. 2021 Jun 15;373:n1412.Полный текст  Аннотация

6. Bager P, Wohlfahrt J, Fonager J, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. Lancet Infect Dis. 2021 Nov;21(11):1507-17.Полный текст  Аннотация

7. Patone M, Thomas K, Hatch R, et al. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. Lancet Infect Dis. 2021 Jun 22 [Epub ahead of print].Полный текст  Аннотация

8. Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021 May;6(5):e335-45.Полный текст  Аннотация

9. Butt AA, Dargham SR, Chemaitelly H, et al. Severity of illness in persons infected with the SARS-CoV-2 Delta variant vs Beta variant in Qatar. JAMA Intern Med. 2021 Dec 22 [Epub ahead of print].Полный текст  Аннотация

10. Mallapaty S. Where did Omicron come from? Three key theories. Nature. 2022 Feb;602(7895):26-8.Полный текст  Аннотация

11. World Health Organization. Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member states. December 10 2021 [internet publication].Полный текст

12. World Health Organization. Statement on Omicron sublineage BA.2. 2022 [internet publication].Полный текст

13. World Health Organization. Severity of disease associated with Omicron variant as compared with Delta variant in hospitalized patients with suspected or confirmed SARS-CoV-2 infection. 2022 [internet publication].Полный текст

14. Kozlov M. Omicron’s feeble attack on the lungs could make it less dangerous. 2021 [internet publication].Полный текст

15. Higdon MM, Baidya A, Walter KK, et al. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. Lancet Infect Dis. 2022 Jun 22 [Epub ahead of print].Полный текст  Аннотация

16. Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022 Jun 22 [Epub ahead of print].Полный текст  Аннотация

17. Kozlov M. Omicron overpowers key COVID antibody treatments in early tests. Nature. 2021 Dec 21 [Epub ahead of print].Полный текст  Аннотация

18. Roskosky M, Borah BF, DeJonge PM, et al. Notes from the field: SARS-CoV-2 omicron variant infection in 10 persons within 90 days of previous SARS-CoV-2 Delta variant infection - four states, October 2021 – January 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 8;71(14):524-6.Полный текст  Аннотация

19. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological updates. 2021 [internet publication].Полный текст

20. Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021 Jan 11;11(1):e044640.Полный текст  Аннотация

21. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2021 Feb 1;175(2):143-56.Полный текст  Аннотация

22. World Health Organization. COVID-19 disease in children and adolescents: scientific brief, 29 September 2021. 2021 [internet publication].Полный текст

23. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020 Sep 1;174(9):882-9.Полный текст  Аннотация

24. Somekh I, Stein M, Karakis I, et al. Characteristics of SARS-CoV-2 infections in Israeli children during the circulation of different SARS-CoV-2 variants. JAMA Netw Open. 2021 Sep 1;4(9):e2124343.Полный текст  Аннотация

25. Chen F, Tian Y, Zhang L, et al. The role of children in household transmission of COVID-19: a systematic review and meta-analysis. Int J Infect Dis. 2022 May 11;122:266-75.Полный текст  Аннотация

26. Chou R, Dana T, Buckley DI, et al. Epidemiology of and risk factors for coronavirus infection in health care workers: a living rapid review. Ann Intern Med. 2020 Jul 21;173(2):120-36.Полный текст  Аннотация

27. Chou R, Dana T, Buckley DI, et al. Update alert 9: epidemiology of and risk factors for coronavirus infection in health care workers. Ann Intern Med. 2021 Jun 1 [Epub ahead of print].Полный текст  Аннотация

28. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020 May 5;133(9):1015-24.Полный текст  Аннотация

29. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-33.Полный текст  Аннотация

30. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-74.Полный текст  Аннотация

31. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506.Полный текст  Аннотация

32. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-13.Полный текст  Аннотация

33. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-207.Полный текст  Аннотация

34. Roberts DL, Rossman JS, Jarić I. Dating first cases of COVID-19. PLoS Pathog. 2021 Jun;17(6):e1009620.Полный текст  Аннотация

35. World Health Organization. WHO-convened global study of the origins of SARS-CoV-2. 2020 [internet publication].Полный текст

36. Meyerowitz EA, Richterman A, Gandhi RT, et al. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2021 Jan;174(1):69-79.Полный текст  Аннотация

37. World Health Organization. Mask use in the context of COVID-19: interim guidance. 2020 [internet publication].Полный текст

38. Duval D, Palmer JC, Tudge I, et al. Long distance airborne transmission of SARS-CoV-2: rapid systematic review. BMJ. 2022 Jun 29;377:e068743.Полный текст  Аннотация

39. Birgand G, Peiffer-Smadja N, Fournier S, et al. Assessment of air contamination by SARS-CoV-2 in hospital settings. JAMA Netw Open. 2020 Dec 1;3(12):e2033232.Полный текст  Аннотация

40. Razani N, Malekinejad M, Rutherford GW. Clarification regarding outdoor transmission of SARS-CoV-2 and other respiratory viruses, a systematic review. J Infect Dis. 2021 Jun 4 [Epub ahead of print].Полный текст  Аннотация

41. Goldstein KM, Ghadimi K, Mystakelis H, et al. Risk of transmitting coronavirus disease 2019 during nebulizer treatment: a systematic review. J Aerosol Med Pulm Drug Deliv. 2021 Apr 21 [Epub ahead of print].Полный текст  Аннотация

42. Onakpoya IJ, Heneghan CJ, Spencer EA, et al. SARS-CoV-2 and the role of fomite transmission: a systematic review. F1000Res. 2021 Mar 24;10:233.Полный текст  Аннотация

43. Trypsteen W, Van Cleemput J, Snippenberg WV, et al. On the whereabouts of SARS-CoV-2 in the human body: a systematic review. PLoS Pathog. 2020 Oct;16(10):e1009037.Полный текст  Аннотация

44. Martinez-Reviejo R, Tejada S, Cipriano A, et al. Solid organ transplantation from donors with recent or current SARS-CoV-2 infection: a systematic review. Anaesth Crit Care Pain Med. 2022 May 6;41(4):101098.Полный текст  Аннотация

45. World Health Organization. Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2: scientific brief. 2021 [internet publication].Полный текст

46. Zhu F, Zozaya C, Zhou Q, et al. SARS-CoV-2 genome and antibodies in breastmilk: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2021 Feb 10 [Epub ahead of print].Полный текст  Аннотация

47. Zhou Q, Gao Y, Wang X, et al. Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):629.Полный текст  Аннотация

48. Centre for Evidence-Based Medicine; Heneghan C, Howdon D, Oke J, et al. The ongoing problem of UK hospital acquired infections. 2020 [internet publication].Полный текст

49. Read JM, Green CA, Harrison EM, et al. Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave. Lancet. 2021 Aug 12 [Epub ahead of print].Полный текст  Аннотация

50. Rhee C, Baker M, Vaidya V, et al. Incidence of nosocomial COVID-19 in patients hospitalized at a large US academic medical center. JAMA Netw Open. 2020 Sep 1;3(9):e2020498.Полный текст  Аннотация

51. Subramaniam A, Lim ZJ, Ponnapa Reddy M, et al. SARS-CoV-2 transmission risk to healthcare workers performing tracheostomies: a systematic review. ANZ J Surg. 2022 Jun 2 [Epub ahead of print].Полный текст  Аннотация

52. Ge Y, Martinez L, Sun S, et al. COVID-19 transmission dynamics among close contacts of index patients with COVID-19: a population-based cohort study in Zhejiang Province, China. JAMA Intern Med. 2021 Aug 23 [Epub ahead of print].Полный текст  Аннотация

53. Johnston C, Hughes H, Lingard S, et al. Immunity and infectivity in covid-19. BMJ. 2022 Jul 1;378:e061402.Полный текст  Аннотация

54. Jefferson T, Spencer EA, Brassey J, et al. Transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from pre and asymptomatic infected individuals: a systematic review. Clin Microbiol Infect. 2022 Feb;28(2):178-89.Полный текст  Аннотация

55. Jefferson T, Spencer EA, Onakpoya IJ, et al. Transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from pre and asymptomatic infected individuals: a systematic review update. Clin Microbiol Infect. 2022 Jun 28 [Epub ahead of print].Полный текст  Аннотация

56. Qiu X, Nergiz AI, Maraolo AE, et al. The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission: a living systematic review. Clin Microbiol Infect. 2021 Apr;27(4):511-9.Полный текст  Аннотация

57. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020 Mar 5;382(10):970-71.Полный текст  Аннотация

58. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020 May;63(5):706-11.Полный текст  Аннотация

59. Luo SH, Liu W, Liu ZJ, et al. A confirmed asymptomatic carrier of 2019 novel coronavirus (SARS-CoV-2). Chin Med J (Engl). 2020 May 5;133(9):1123-5.Полный текст  Аннотация

60. Lu S, Lin J, Zhang Z, et al. Alert for non-respiratory symptoms of coronavirus disease 2019 patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients. J Med Virol. 2021 Jan;93(1):518-21.Полный текст  Аннотация

61. Li C, Ji F, Wang L, et al. Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster, Xuzhou, China. Emerg Infect Dis. 2020 Mar 31;26(7).Полный текст  Аннотация

62. Liu J, Huang J, Xiang D. Large SARS-CoV-2 outbreak caused by asymptomatic traveler, China. Emerg Infect Dis. 2020 Jun 30;29(9).Полный текст  Аннотация

63. Jiang XL, Zhang XL, Zhao XN, et al. Transmission potential of asymptomatic and paucisymptomatic severe acute respiratory syndrome coronavirus 2 infections: a three-family cluster study in China. 2020 Jun 11;221(12):1948-52.Полный текст  Аннотация

64. Gao M, Yang L, Chen X, et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. Respir Med. 2020 May 13;169:106026.Полный текст  Аннотация

65. Chen F, Fu D, Yang Q, et al. Low transmission risk of 9 asymptomatic carriers tested positive for both SARS-CoV-2 nucleic acid and serum IgG. J Infect. 2020 Sep;81(3):452-82.Полный текст  Аннотация

66. Danis K, Epaulard O, Bénet T, et al. Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. Clin Infect Dis. 2020 Jul 28;71(15):825-32.Полный текст  Аннотация

67. Cao S, Gan Y, Wang C, et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. Nat Commun. 2020 Nov 20;11(1):5917.Полный текст  Аннотация

68. Buitrago-Garcia D, Ipekci AM, Heron L, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: update of a living systematic review and meta-analysis. PLoS Med. 2022 May;19(5):e1003987.Полный текст  Аннотация

69. Chen X, Huang Z, Wang J, et al. Ratio of asymptomatic COVID-19 cases among ascertained SARS-CoV-2 infections in different regions and population groups in 2020: a systematic review and meta-analysis including 130 123 infections from 241 studies. BMJ Open. 2021 Dec 7;11(12):e049752.Полный текст  Аннотация

70. Stubblefield WB, Talbot HK, Feldstein L, et al. Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for patients with COVID-19: Nashville, Tennessee. Clin Infect Dis. 2021 May 4;72(9):1645-8.Полный текст  Аннотация

71. Althouse BM, Wenger EA, Miller JC, et al. Superspreading events in the transmission dynamics of SARS-CoV-2: opportunities for interventions and control. PLoS Biol. 2020 Nov 12;18(11):e3000897.Полный текст  Аннотация

72. Lopez AS, Hill M, Antezano J, et al. Transmission dynamics of COVID-19 outbreaks associated with child care facilities: Salt Lake City, Utah, April–July 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1319-23.Полный текст  Аннотация

73. Wilson E, Donovan CV, Campbell M, et al. Multiple COVID-19 clusters on a university campus: North Carolina, August 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 2;69(39):1416-8.Полный текст  Аннотация

74. Xu W, Li X, Dozier M, et al. What is the evidence for transmission of COVID-19 by children in schools? A living systematic review. J Glob Health. 2020 Dec;10(2):021104.Полный текст  Аннотация

75. Caini S, Martinoli C, La Vecchia C, et al. SARS-CoV-2 circulation in the school setting: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022 Apr 28;19(9):5384.Полный текст  Аннотация

76. Karki SJ, Joachim A, Heinsohn T, et al. Risk of infection and contribution to transmission of SARS-CoV-2 in school staff: a systematic review. BMJ Open. 2021 Nov 3;11(11):e052690.Полный текст  Аннотация

77. Young BC, Eyre DW, Kendrick S, et al. Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial. Lancet. 2021 Sep 14 [Epub ahead of print].Полный текст  Аннотация

78. Stein RA. Super-spreaders in infectious diseases. Int J Infect Dis. 2011 Aug;15(8):e510-3.Полный текст  Аннотация

79. World Health Organization. COVID-19 clinical management: living guidance. 2021 [internet publication].Полный текст

80. Xin H, Wong JY, Murphy C, et al. The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Clin Infect Dis. 2021 Jun 12 [Epub ahead of print].Полный текст  Аннотация

81. Li B, Zhang S, Zhang R, et al. Epidemiological and clinical characteristics of COVID-19 in children: a systematic review and meta-analysis. Front Pediatr. 2020 Nov 2;8:591132.Полный текст  Аннотация

82. Ahammed T, Anjum A, Rahman MM, et al. Estimation of novel coronavirus (COVID-19) reproduction number and case fatality rate: a systematic review and meta-analysis. Health Sci Rep. 2021 Jun;4(2):e274.Полный текст  Аннотация

83. Centers for Disease Control and Prevention. COVID-19 pandemic planning scenarios. 2021 [internet publication].Полный текст

84. Hussein M, Toraih E, Elshazli R, et al. Meta-analysis on serial intervals and reproductive rates for SARS-CoV-2. Ann Surg. 2021 Mar 1;273(3):416-23. Аннотация

85. Pung R, Mak TM, Kucharski AJ, et al; CMMID COVID-19 working group. Serial intervals in SARS-CoV-2 B.1.617.2 variant cases. Lancet. 2021 Aug 10 [Epub ahead of print].Полный текст  Аннотация

86. Tian T, Huo X. Secondary attack rates of COVID-19 in diverse contact settings, a meta-analysis. J Infect Dev Ctries. 2020 Dec 31;14(12):1361-7.Полный текст  Аннотация

87. Thompson HA, Mousa A, Dighe A, et al. SARS-CoV-2 setting-specific transmission rates: a systematic review and meta-analysis. Clin Infect Dis. 2021 Feb 9 [Epub ahead of print].Полный текст  Аннотация

88. Madewell ZJ, Yang Y, Longini IM Jr, et al. Factors associated with household transmission of SARS-CoV-2: an updated systematic review and meta-analysis. JAMA Netw Open. 2021 Aug 2;4(8):e2122240.Полный текст  Аннотация

89. Silverberg SL, Zhang BY, Li SNJ, et al. Child transmission of SARS-CoV-2: a systematic review and meta-analysis. BMC Pediatr. 2022 Apr 2;22(1):172.Полный текст  Аннотация

90. Madewell ZJ, Yang Y, Longini IM Jr, et al. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis. JAMA Netw Open. 2022 Apr 1;5(4):e229317.Полный текст  Аннотация

91. Kunasekaran M, Quigley A, Rahman B, et al. Factors associated with SARS-CoV-2 attack rates in aged care: a meta-analysis. Open Forum Infect Dis. 2022 Mar;9(3):ofac033.Полный текст  Аннотация

92. Viner R, Waddington C, Mytton O, et al. Transmission of SARS-CoV-2 by children and young people in households and schools: a meta-analysis of population-based and contact-tracing studies. J Infect. 2021 Dec 22 [Epub ahead of print].Полный текст  Аннотация

93. Jørgensen SB, Nygård K, Kacelnik O, et al. Secondary attack rates for Omicron and Delta variants of SARS-CoV-2 in Norwegian households. JAMA. 2022 Apr 26;327(16):1610-1.Полный текст  Аннотация

94. Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. 2021 May;21(5):629-36.Полный текст  Аннотация

95. Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021 Jan;2(1):e13-22.Полный текст  Аннотация

96. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020 Dec 24;383(26):2586-8.Полный текст  Аннотация

97. Stokel-Walker C. How long does SARS-CoV-2 stay in the body? BMJ. 2022 Jun 28;377:o1555.Полный текст  Аннотация

98. Widders A, Broom A, Broom J. SARS-CoV-2: the viral shedding vs infectivity dilemma. Infect Dis Health. 2020 Aug;25(3):210-5.Полный текст  Аннотация

99. Jung J, Kim JY, Park H, et al. Transmission and infectious SARS-CoV-2 shedding kinetics in vaccinated and unvaccinated individuals. JAMA Netw Open. 2022 May 2;5(5):e2213606.Полный текст  Аннотация

100. Killingley B, Mann A, Kalinova M, et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge [preprint]. 2022 [internet publication].Полный текст

101. Menezes RG, Rizwan T, Saad Ali S, et al. Postmortem findings in COVID-19 fatalities: a systematic review of current evidence. Leg Med (Tokyo). 2021 Dec 7;54:102001.Полный текст  Аннотация

102. Lancet Respiratory Medicine. COVID-19: pathophysiology of acute disease. 2021 [internet publication].Полный текст

103. Peiris S, Mesa H, Aysola A, et al. Pathological findings in organs and tissues of patients with COVID-19: a systematic review. PLoS One. 2021;16(4):e0250708.Полный текст  Аннотация

104. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr 16;181(2):271-80.Полный текст  Аннотация

105. Chen Y, Guo Y, Pan Y, et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020 Feb 17;525(1):135-40.Полный текст  Аннотация

106. Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020 Feb 10;176:104742. Аннотация

107. Piplani S, Singh PK, Winkler DA, et al. In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin. Sci Rep. 2021 Jun 24;11(1):13063.Полный текст  Аннотация

108. Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res. 2021 Apr 30;128(9):1323-6.Полный текст  Аннотация

109. Suzuki YJ, Gychka SG. SARS-CoV-2 spike protein elicits cell signaling in human host cells: implications for possible consequences of COVID-19 vaccines. Vaccines (Basel). 2021 Jan 11;9(1):36.Полный текст  Аннотация

110. Ramanathan M, Ferguson ID, Miao W, et al. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. Lancet Infect Dis. 2021 Aug;21(8):1070.Полный текст  Аннотация

111. Sofizan NMFBN, Rahman AFBA, Soon LP, et al. Autopsy findings in COVID-19 infection-related death: a systematic review. Egypt J Forensic Sci. 2022;12(1):22.Полный текст  Аннотация

112. Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021 Jun;9(6):622-42.Полный текст  Аннотация

113. Milross L, Majo J, Cooper N, et al. Post-mortem lung tissue: the fossil record of the pathophysiology and immunopathology of severe COVID-19. Lancet Respir Med. 2021 Dec 3 [Epub ahead of print].Полный текст  Аннотация

114. Stenton S, McPartland J, Shukla R, et al. SARS-COV2 placentitis and pregnancy outcome: a multicentre experience during the Alpha and early Delta waves of coronavirus pandemic in England. EClinicalMedicine. 2022 May;47:101389.Полный текст  Аннотация

115. Severe Covid-19 GWAS Group; Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020 Oct 15;383(16):1522-34.Полный текст  Аннотация

116. Downes DJ, Cross AR, Hua P, et al. Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus. Nat Genet. 2021 Nov;53(11):1606-15.Полный текст  Аннотация

117. Saengsiwaritt W, Jittikoon J, Chaikledkaew U, et al. Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID-19 severity: a systematic review with meta-analysis. Rev Med Virol. 2022 Jan 8;:e2323.Полный текст  Аннотация

118. Kousathanas A, Pairo-Castineira E, Rawlik K, et al. Whole genome sequencing reveals host factors underlying critical Covid-19. Nature. 2022 Mar 7 [Epub ahead of print].Полный текст  Аннотация

119. World Health Organization. Public health surveillance for COVID-19: interim guidance. 2020 [internet publication].Полный текст

120. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): contact tracing. 2021 [internet publication].Полный текст

121. Romero Starke K, Reissig D, Petereit-Haack G, et al. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health. 2021 Dec;6(12):e006434.Полный текст  Аннотация

122. Centers for Disease Control and Prevention. Risk for COVID-19 infection, hospitalization, and death by age group. 2021 [internet publication].Полный текст

123. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020 Sep;20(9):1034-42.Полный текст  Аннотация

124. Bonanad C, García-Blas S, Tarazona-Santabalbina F, et al. The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects. J Am Med Dir Assoc. 2020 Jul;21(7):915-8.Полный текст  Аннотация

125. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19): United States, February 12 - March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-6.Полный текст  Аннотация

126. Damayanthi HDWT, Prabani KIP. Nutritional determinants and COVID-19 outcomes of older patients with COVID-19: a systematic review. Arch Gerontol Geriatr. 2021 Mar 31;95:104411.Полный текст  Аннотация

127. Pijls BG, Jolani S, Atherley A, et al. Temporal trends of sex differences for COVID-19 infection, hospitalisation, severe disease, intensive care unit (ICU) admission and death: a meta-analysis of 229 studies covering over 10M patients. F1000Res. 2022 Jan 5;11:5.Полный текст  Аннотация

128. Abate BB, Kassie AM, Kassaw MW, et al. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020 Oct 6;10(10):e040129.Полный текст  Аннотация

129. Baldassarri M, Picchiotti N, Fava F, et al. Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. EBioMedicine. 2021 Feb 26;65:103246.Полный текст  Аннотация

130. Hu H, Pan H, Li R, et al. Increased circulating cytokines have a role in COVID-19 severity and death with a more pronounced effect in males: a systematic review and meta-analysis. Front Pharmacol. 2022 Feb 14;13:802228.Полный текст  Аннотация

131. Sze S, Pan D, Nevill CR, et al. Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2020 Dec;29:100630.Полный текст  Аннотация

132. Mackey K, Ayers CK, Kondo KK, et al. Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic review. Ann Intern Med. 2021 Mar;174(3):362-73.Полный текст  Аннотация

133. Khanijahani A, Iezadi S, Gholipour K, et al. A systematic review of racial/ethnic and socioeconomic disparities in COVID-19. Int J Equity Health. 2021 Nov 24;20(1):248.Полный текст  Аннотация

134. Mathur R, Rentsch CT, Morton CE, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021 May 8;397(10286):1711-24.Полный текст  Аннотация

135. Saatci D, Ranger TA, Garriga C, et al. Association between race and COVID-19 outcomes among 2.6 million children in England. JAMA Pediatr. 2021 Jun 21 [Epub ahead of print].Полный текст  Аннотация

136. Acosta AM, Garg S, Pham H, et al. Racial and ethnic disparities in rates of COVID-19–associated hospitalization, intensive care unit admission, and in-hospital death in the United States from March 2020 to February 2021. JAMA Netw Open. 2021 Oct 1;4(10):e2130479.Полный текст  Аннотация

137. Magesh S, John D, Li WT, et al. Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis. JAMA Netw Open. 2021 Nov 1;4(11):e2134147.Полный текст  Аннотация

138. Agyemang C, Richters A, Jolani S, et al. Ethnic minority status as social determinant for COVID-19 infection, hospitalisation, severity, ICU admission and deaths in the early phase of the pandemic: a meta-analysis. BMJ Glob Health. 2021 Nov;6(11):e007433.Полный текст  Аннотация

139. Raharja A, Tamara A, Kok LT. Association between ethnicity and severe COVID-19 disease: a systematic review and meta-analysis. J Racial Ethn Health Disparities. 2020 Nov 12 [Epub ahead of print].Полный текст  Аннотация

140. McMichael TM, Clark S, Pogosjans S, et al. COVID-19 in a long-term care facility: King County, Washington, February 27 – March 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):339-42.Полный текст  Аннотация

141. Centers for Disease Control and Prevention. Underlying medical conditions associated with high risk for severe COVID-19: information for healthcare providers. 2021 [internet publication].Полный текст

142. Burki T. England and Wales see 20 000 excess deaths in care homes. Lancet. 2020 May 23;395(10237):1602.Полный текст  Аннотация

143. Graham N, Junghans C, Downes R, et al. SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes. J Infect. 2020 Sep;81(3):411-9.Полный текст  Аннотация

144. Panagiotou OA, Kosar CM, White EM, et al. Risk factors associated with all-cause 30-day mortality in nursing home residents with COVID-19. JAMA Intern Med. 2021 Apr 1;181(4):439-48.Полный текст  Аннотация

145. Liu H, Chen S, Liu M, et al. Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and meta-analysis. Aging Dis. 2020 May 9;11(3):668-78.Полный текст  Аннотация

146. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020 May 22;369:m1985.Полный текст  Аннотация

147. Norris T, Razieh C, Zaccardi F, et al. Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. Heart. 2021 Dec 15 [Epub ahead of print].Полный текст  Аннотация

148. Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020 – March 2021. Prev Chronic Dis. 2021 Jul 1;18:E66.Полный текст  Аннотация

149. Adams ML, Katz DL, Grandpre J. Updated estimates of chronic conditions affecting risk for complications from coronavirus disease, United States. Emerg Infect Dis. 2020 Jul 3;26(9).Полный текст  Аннотация

150. Adams SH, Park MJ, Schaub JP, et al. Medical vulnerability of young adults to severe COVID-19 illness: data from the National Health Interview Survey. J Adolesc Health. 2020 Jul 9;67(3):362-8.Полный текст  Аннотация

151. Ng WH, Tipih T, Makoah NA, et al. Comorbidities in SARS-CoV-2 patients: a systematic review and meta-analysis. mBio. 2021 Feb 9;12(1):e03647-20.Полный текст  Аннотация

152. Zuin M, Rigatelli G, Bilato C, et al. Prognostic role of metabolic syndrome in COVID-19 patients: a systematic review meta-analysis. Viruses. 2021 Sep 27;13(10):1938.Полный текст  Аннотация

153. Choi JH, Choi SH, Yun KW. Risk factors for severe COVID-19 in children: a systematic review and meta-analysis. J Korean Med Sci. 2022 Feb 7;37(5):e35.Полный текст  Аннотация

154. Cai Z, Yang Y, Zhang J. Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis. BMC Public Health. 2021 Aug 4;21(1):1505.Полный текст  Аннотация

155. World Obesity Federation. COVID-19 and obesity: the 2021 atlas. 2021 [internet publication].Полный текст

156. Gao M, Piernas C, Astbury NM, et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021 Jun;9(6):350-9.Полный текст  Аннотация

157. Kompaniyets L, Goodman AB, Belay B, et al. Body mass index and risk for COVID-19–related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death: United States, March – December 2020. MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):355-61.Полный текст  Аннотация

158. Xu J, Xiao W, Liang X, et al. A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity. BMC Public Health. 2021 Aug 11;21(1):1533.Полный текст  Аннотация

159. Ehwerhemuepha L, Roth B, Patel AK, et al. Association of congenital and acquired cardiovascular conditions with COVID-19 severity among pediatric patients in the US. JAMA Netw Open. 2022 May 2;5(5):e2211967.Полный текст  Аннотация

160. Hessami A, Shamshirian A, Heydari K, et al. Cardiovascular diseases burden in COVID-19: systematic review and meta-analysis. Am J Emerg Med. 2020 Oct 16 [Epub ahead of print].Полный текст  Аннотация

161. Zuin M, Rigatelli G, Bilato C, et al. Pre-existing atrial fibrillation is associated with increased mortality in COVID-19 Patients. J Interv Card Electrophysiol. 2021 Apr 15 [Epub ahead of print].Полный текст  Аннотация

162. Szarpak L, Filipiak KJ, Skwarek A, et al. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19: a systematic review and meta-analysis. Cardiol J. 2021 Dec 13 [Epub ahead of print]. Аннотация

163. Liang C, Zhang W, Li S, et al. Coronary heart disease and COVID-19: a meta-analysis. Med Clin (Engl Ed). 2021 Jun 11;156(11):547-54.Полный текст  Аннотация

164. Li Y, Pei H, Zhou C, et al. Myocardial injury predicts risk of short-term all-cause mortality in patients with COVID-19: a dose-response meta-analysis. Front Cardiovasc Med. 2022 May 2;9:850447.Полный текст  Аннотация

165. Zuin M, Rigatelli G, Bilato MJ, et al. Prevalence of pre-existing peripheral artery disease in COVID-19 patients and relative mortality risk: systematic review and meta-analysis. Vascular. 2022 May 20 [Epub ahead of print].Полный текст  Аннотация

166. Bae S, Kim SR, Kim MN, et al. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2021 Mar;107(5):373-80.Полный текст  Аннотация

167. Pellicori P, Doolub G, Wong CM, et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev. 2021 Mar 11;(3):CD013879.Полный текст  Аннотация

168. Hartmann-Boyce J, Rees K, Perring JC, et al. Risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: a systematic review of reviews. Diabetes Care. 2021 Oct 28 [Epub ahead of print].Полный текст  Аннотация

169. Kastora S, Patel M, Carter B, et al. Impact of diabetes on COVID-19 mortality and hospital outcomes from a global perspective: an umbrella systematic review and meta-analysis. Endocrinol Diabetes Metab. 2022 Apr 20:e338.Полный текст  Аннотация

170. Chen Y, Yang D, Cheng B, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020 Jul;43(7):1399-407.Полный текст  Аннотация

171. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-33.Полный текст  Аннотация

172. Pal R, Banerjee M, Yadav U, et al. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature. Diabetes Metab Syndr. 2020 Aug 18;14(6):1563-9.Полный текст  Аннотация

173. Papadopoulos VP, Koutroulos MV, Zikoudi DG, et al. Diabetes-related acute metabolic emergencies in COVID-19 patients: a systematic review and meta-analysis. Diabetol Int. 2021 Mar 23;1-15.Полный текст  Аннотация

174. Prattichizzo F, de Candia P, Nicolucci A, et al. Impact of pre-infection HbA1c levels on COVID-19 prognosis: systematic review and meta-analysis. Diabetes Metab Res Rev. 2021 May 20:e3476.Полный текст  Аннотация

175. Heidarpour M, Abhari AP, Sadeghpour N, et al. Prediabetes and COVID-19 severity, an underestimated risk factor: a systematic review and meta-analysis. Diabetes Metab Syndr. 2021 Oct 9;15(6):102307.Полный текст  Аннотация

176. Boden I, Bernabeu MO, Dhillon B, et al. Pre-existing diabetic retinopathy as a prognostic factor for COVID-19 outcomes amongst people with diabetes: a systematic review. Diabetes Res Clin Pract. 2022 Apr 5;187:109869.Полный текст  Аннотация

177. Nguyen NN, Ho DS, Nguyen HS, et al. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: a meta-analysis. Metabolism. 2022 Mar 31:155196.Полный текст  Аннотация

178. Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-92.Полный текст  Аннотация

179. Yin Y, Rohli KE, Shen P, et al. The epidemiology, pathophysiological mechanisms, and management toward COVID-19 patients with type 2 diabetes: a systematic review. Prim Care Diabetes. 2021 Sep 6 [Epub ahead of print].Полный текст  Аннотация

180. Halpin DMG, Faner R, Sibila O, et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020 May;8(5):436-8.Полный текст  Аннотация

181. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Otunla A, Drake J, et al. Asthma and COVID-19: risks and management considerations. 2020 [internet publication].Полный текст

182. Gerayeli FV, Milne S, Cheung C, et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021 Mar;33:100789.Полный текст  Аннотация

183. Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021 Mar 4 [Epub ahead of print].Полный текст  Аннотация

184. Otunla A, Rees K, Dennison P, et al. Risks of infection, hospital and ICU admission, and death from COVID-19 in people with asthma: systematic review and meta-analyses. BMJ Evid Based Med. 2021 Dec 21 [Epub ahead of print].Полный текст  Аннотация

185. World Health Organization. Asthma and COVID-19: scientific brief, 19 April 2021. 2021 [internet publication].Полный текст

186. Hariyanto TI, Kurniawan A. Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Sleep Med. 2021 Apr 1;82:47-53.Полный текст  Аннотация

187. Strausz S, Kiiskinen T, Broberg M, et al. Sleep apnoea is a risk factor for severe COVID-19. BMJ Open Respir Res. 2021 Jan;8(1):e000845.Полный текст  Аннотация

188. Mathew HR, Choi MY, Parkins MD, et al. Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic. BMC Pulm Med. 2021 May 20;21(1):173.Полный текст  Аннотация

189. Wang Y, Feng R, Xu J, et al. An updated meta-analysis on the association between tuberculosis and COVID-19 severity and mortality. J Med Virol. 2021 Jun 1 [Epub ahead of print].Полный текст  Аннотация

190. Aggarwal AN, Agarwal R, Dhooria S, et al. Active pulmonary tuberculosis and coronavirus disease 2019: a systematic review and meta-analysis. PLoS One. 2021;16(10):e0259006.Полный текст  Аннотация

191. Ouyang L, Gong J, Yu M. Pre-existing interstitial lung disease in patients with coronavirus disease 2019: a meta-analysis. Int Immunopharmacol. 2021 Sep 9;100:108145.Полный текст  Аннотация

192. Castro-Rodriguez JA, Forno E. Asthma and COVID-19 in children: a systematic review and call for data. Pediatr Pulmonol. 2020 Sep;55(9):2412-8.Полный текст  Аннотация

193. Lin YC, Lai TS, Lin SL, et al. Outcomes of coronavirus 2019 infection in patients with chronic kidney disease: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2021;12:2040622321998860.Полный текст  Аннотация

194. Chung EY, Palmer SC, Natale P, et al. Incidence and outcomes of COVID-19 in people with CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2021 Aug 5 [Epub ahead of print].Полный текст  Аннотация

195. Nopsopon T, Kittrakulrat J, Takkavatakarn K, et al. Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021 Jun 15;15(6):e0009156.Полный текст  Аннотация

196. Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med. 2020 Jul 10;:1-9.Полный текст  Аннотация

197. Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020 Sep;14(5):612-20.Полный текст  Аннотация

198. Liu M, Mei K, Tan Z, et al. Liver fibrosis scores and hospitalization, mechanical ventilation, severity, and death in patients with COVID-19: a systematic review and dose-response meta-analysis. Can J Gastroenterol Hepatol. 2022 Mar 29;2022:7235860.Полный текст  Аннотация

199. Middleton P, Hsu C, Lythgoe MP. Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies. BMJ Open Gastroenterol. 2021 Oct;8(1):e000739.Полный текст  Аннотация

200. Tao Z, Li Y, Cheng B, et al. Risk of severe COVID-19 increased by metabolic dysfunction-associated fatty liver disease: a meta-analysis. J Clin Gastroenterol. 2021 Aug 18 [Epub ahead of print]. Аннотация

201. Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020 Aug;69(8):1545-7.Полный текст  Аннотация

202. Zhou YJ, Zheng KI, Wang XB, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol. 2020 Sep;73(3):719-21.Полный текст  Аннотация

203. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320.Полный текст  Аннотация

204. Allotey J, Stallings E, Bonet M, et al. Update to living systematic review on covid-19 in pregnancy. BMJ. 2021 Mar 10;372:n615.Полный текст  Аннотация

205. Khalil A, Kalafat E, Benlioglu C, et al. SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine. 2020 Aug;25:100446.Полный текст  Аннотация

206. Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status: United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 6;69(44):1641-7.Полный текст  Аннотация

207. Vousden N, Ramakrishnan R, Bunch K, et al. Management and implications of severe COVID-19 in pregnancy in the UK: data from the UK Obstetric Surveillance System national cohort. Acta Obstet Gynecol Scand. 2022 Feb 25 [Epub ahead of print].Полный текст  Аннотация

208. Gajbhiye RK, Sawant MS, Kuppusamy P, et al. Differential impact of COVID-19 in pregnant women from high-income countries and low- to middle-income countries: a systematic review and meta-analysis. Int J Gynaecol Obstet. 2021 Jun 23 [Epub ahead of print].Полный текст  Аннотация

209. Zhang H, Ma S, Han T, et al. Association of smoking history with severe and critical outcome in COVID-19 patients: a systemic review and meta-analysis. Eur J Integr Med. 2021 Feb 18:101313.Полный текст  Аннотация

210. Patanavanich R, Glantz SA. Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis. BMC Public Health. 2021 Aug 16;21(1):1554.Полный текст  Аннотация

211. Salah HM, Sharma T, Mehta J. Smoking doubles the mortality risk in COVID-19: a meta-analysis of recent reports and potential mechanisms. Cureus. 2020 Oct 7;12(10):e10837.Полный текст  Аннотация

212. Cai G, Bossé Y, Xiao F, et al. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1557-9.Полный текст  Аннотация

213. Patanavanich R, Siripoon T, Amponnavarat S, et al. Active smokers are at higher risk of COVID-19 death: a systematic review and meta-analysis. Nicotine Tob Res. 2022 Apr 1 [Epub ahead of print]. Аннотация

214. World Health Organization. Smoking and COVID-19: scientific brief. 2020 [internet publication].Полный текст

215. Yu J Ouyang W, Chua ML, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020 Mar 25;6(7):1108-10.Полный текст  Аннотация

216. Venkatesulu BP, Chandrasekar VT, Girdhar P, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. JNCI Cancer Spectr. 2021 Feb 24;5(2):pkaa102.Полный текст  Аннотация

217. Naimi A, Yashmi I, Jebeleh R, et al. Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: a systematic review and meta-analysis. J Clin Lab Anal. 2022 Apr 6:e24387.Полный текст  Аннотация

218. Zarifkar P, Kamath A, Robinson C, et al. Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2021 Mar;33(3):e180-91.Полный текст  Аннотация

219. Nadkarni AR, Vijayakumaran SC, Gupta S, et al. Mortality in cancer patients with COVID-19 who are admitted to an ICU or who have severe COVID-19: a systematic review and meta-analysis. JCO Glob Oncol. 2021 Aug;7:1286-305.Полный текст  Аннотация

220. Kaur H, Thakur JS, Paika R, et al. Impact of underlying comorbidities on mortality in SARS-COV-2 infected cancer patients: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2021 May 1;22(5):1333-49.Полный текст  Аннотация

221. OnCovid Study Group; Pinato DJ, Patel M, Scotti L, et al. Time-dependent COVID-19 mortality in patients with cancer: an updated analysis of the OnCovid registry. JAMA Oncol. 2021 Nov 24 [Epub ahead of print].Полный текст  Аннотация

222. Chavez-MacGregor M, Lei X, Zhao H, et al. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncol. 2021 Oct 28 [Epub ahead of print].Полный текст  Аннотация

223. Boulad F, Kamboj M, Bouvier N, et al. COVID-19 in children with cancer in New York City. JAMA Oncol. 2020 Sep 1;6(9):1459-60.Полный текст  Аннотация

224. Mukkada S, Bhakta N, Chantada GL, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncol. 2021 Aug 26 [Epub ahead of print].Полный текст  Аннотация

225. Dorantes-Acosta E, Ávila-Montiel D, Klünder-Klünder M, et al. Survival and complications in pediatric patients with cancer and COVID-19: a meta-analysis. Front Oncol. 2020 Jan 21;10:608282.Полный текст  Аннотация

226. Schlage S, Lehrnbecher T, Berner R, et al. SARS-CoV-2 in pediatric cancer: a systematic review. Eur J Pediatr. 2022 Jan 10 [Epub ahead of print].Полный текст  Аннотация

227. Xu J, Xiao W, Liang X, et al. The association of cerebrovascular disease with adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates. J Stroke Cerebrovasc Dis. 2020 Nov;29(11):105283.Полный текст  Аннотация

228. Patel U, Malik P, Shah D, et al. Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis. J Neurol. 2021 Jan;268(1):240-7.Полный текст  Аннотация

229. Fond G, Nemani K, Etchecopar-Etchart D, et al. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Nov 1;78(11):1208-17.Полный текст  Аннотация

230. Ceban F, Nogo D, Carvalho IP, et al. Association between mood disorders and risk of COVID-19 infection, hospitalization, and death: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Oct 1;78(10):1079-91.Полный текст  Аннотация

231. Pardamean E, Roan W, Iskandar KTA, et al. Mortality from coronavirus disease 2019 (Covid-19) in patients with schizophrenia: a systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry. 2022 Feb 4;75:61-7.Полный текст  Аннотация

232. Gatti M, Rinaldi M, Bussini L, et al. Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis. Clin Microbiol Infect. 2022 Mar 11 [Epub ahead of print].Полный текст  Аннотация

233. Shahzad M, Chaudhary SG, Zafar MU, et al. Impact of COVID-19 in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis. 2022 Jan 14:e13792.Полный текст  Аннотация

234. Clift AK, Coupland CAC, Keogh RH, et al. COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults. Ann Intern Med. 2021 Apr;174(4):572-6.Полный текст  Аннотация

235. Williamson EJ, McDonald HI, Bhaskaran K, et al. Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform. BMJ. 2021 Jul 14;374:n1592.Полный текст  Аннотация

236. Bosworth ML, Ayoubkhani D, Nafilyan V, et al. Deaths involving COVID-19 by self-reported disability status during the first two waves of the COVID-19 pandemic in England: a retrospective, population-based cohort study. Lancet Public Health. 2021 Oct 6 [Epub ahead of print].Полный текст  Аннотация

237. Hariyanto TI, Putri C, Arisa J, et al. Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2020 Nov 19;93:104299.Полный текст  Аннотация

238. Saragih ID, Saragih IS, Batubara SO, et al. Dementia as a mortality predictor among older adults with COVID-19: a systematic review and meta-analysis of observational study. Geriatr Nurs. 2021 Mar 14 [Epub ahead of print].Полный текст  Аннотация

239. Office for National Statistics. Deaths involving COVID-19, England and Wales: deaths occurring in June 2020. 2020 [internet publication].Полный текст

240. Wang Q, Davis PB, Gurney ME, et al. COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 2021 Feb 9 [Epub ahead of print].Полный текст  Аннотация

241. Fagni F, Simon D, Tascilar K, et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021 Aug 27 [Epub ahead of print].Полный текст  Аннотация

242. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859-66.Полный текст  Аннотация

243. Nørgård BM, Nielsen J, Knudsen T, et al. Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: a Danish cohort study. Br J Clin Pharmacol. 2021 Apr;87(4):2111-20.Полный текст  Аннотация

244. Tassone D, Thompson A, Connell W, et al. Immunosuppression as a risk factor for COVID-19: a meta-analysis. Intern Med J. 2021 Feb;51(2):199-205.Полный текст  Аннотация

245. Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021 Jan;8(1):e24-32.Полный текст  Аннотация

246. Tesoriero JM, Swain CE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 2021 Feb 1;4(2):e2037069.Полный текст  Аннотация

247. Chanda D, Minchella PA, Kampamba D, et al. COVID-19 severity and COVID-19-associated deaths among hospitalized patients with HIV infection: Zambia, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021 Jun 4;70(22):807-10.Полный текст  Аннотация

248. Yang X, Sun J, Patel RC, et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV. 2021 Nov;8(11):e690-700.Полный текст  Аннотация

249. SeyedAlinaghi S, Karimi A, MohsseniPour M, et al. The clinical outcomes of COVID-19 in HIV-positive patients: a systematic review of current evidence. Immun Inflamm Dis. 2021 Jul 29 [Epub ahead of print].Полный текст  Аннотация

250. Lee KW, Yap SF, Ngeow YF, et al. COVID-19 in people living with HIV: a systematic review and meta-analysis. Int J Environ Res Public Health. 2021 Mar 30;18(7):3554.Полный текст  Аннотация

251. Mellor MM, Bast AC, Jones NR, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. AIDS. 2021 Mar 15;35(4):F1-10.Полный текст  Аннотация

252. Hariyanto TI, Rosalind J, Christian K, et al. Human immunodeficiency virus and mortality from coronavirus disease 2019: a systematic review and meta-analysis. South Afr J HIV Med. 2021 Apr 15;22(1):1220.Полный текст  Аннотация

253. Danwang C, Noubiap JJ, Robert A, et al. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis. AIDS Res Ther. 2022 Jan 14;19(1):3.Полный текст  Аннотация

254. Oyelade T, Alqahtani JS, Hjazi AM, et al. Global and regional prevalence and outcomes of COVID-19 in people living with HIV: a systematic review and meta-analysis. Trop Med Infect Dis. 2022 Feb 3;7(2):22.Полный текст  Аннотация

255. World Health Organization. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection. 2021 [internet publication].Полный текст

256. Bertagnolio S, Thwin SS, Silva R, et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 2022 Jul;9(7):e486-95.Полный текст  Аннотация

257. Wang H, Jonas KJ. The likelihood of severe COVID-19 outcomes among PLHIV with various comorbidities: a comparative frequentist and Bayesian meta-analysis approach. J Int AIDS Soc. 2021 Nov;24(11):e25841.Полный текст  Аннотация

258. Rahmati M, Shamsi MM, Khoramipour K, et al. Baseline physical activity is associated with reduced mortality and disease outcomes in COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2022 Apr 13:e2349.Полный текст  Аннотация

259. Centers for Disease Control and Prevention. Brief summary of findings on the association between physical inactivity and severe COVID-19 outcomes. 2022 [internet publication].Полный текст

260. Sallis R, Young DR, Tartof SY, et al. Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients. Br J Sports Med. 2021 Apr 13 [Epub ahead of print].Полный текст  Аннотация

261. Lee JX, Chieng WK, Lau SCD, et al. COVID-19 and hemoglobinopathies: a systematic review of clinical presentations, investigations, and outcomes. Front Med (Lausanne). 2021 Oct 13;8:757510.Полный текст  Аннотация

262. Clift AK, Saatci D, Coupland CAC, et al. Sickle cell disorders and severe COVID-19 outcomes: a cohort study. Ann Intern Med. 2021 Jul 20 [Epub ahead of print].Полный текст  Аннотация

263. Panepinto JA, Brandow A, Mucalo L, et al. Coronavirus disease among persons with sickle cell disease, United States, March 20 – May 21, 2020. Emerg Infect Dis. 2020 Jul 8;26(10).Полный текст  Аннотация

264. Hussain FA, Njoku FU, Saraf SL, et al. COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020 Jun;189(5):851-2.Полный текст  Аннотация

265. Nur E, Gaartman AE, van Tuijn CFJ, et al. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Am J Hematol. 2020 Jun;95(6):725-6.Полный текст  Аннотация

266. World Health Organization. Hypertension and COVID-19. 2021 [internet publication].Полный текст

267. Qian Z, Li Z, Peng J, et al. Association between hypertension and prognosis of patients with COVID-19: a systematic review and meta-analysis. Clin Exp Hypertens. 2022 May 8:1-8. Аннотация

268. Pranata R, Lim MA, Huang I, et al. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926899.Полный текст  Аннотация

269. de Almeida-Pititto B, Dualib PM, Zajdenverg L, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr. 2020 Aug 31;12:75.Полный текст  Аннотация

270. Du Y, Zhou N, Zha W, et al. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: a meta-analysis. Nutr Metab Cardiovasc Dis. 2021 Mar 10;31(3):745-55.Полный текст  Аннотация

271. Goldstein MR, Poland GA, Graeber CW. Are certain drugs associated with enhanced mortality in COVID-19? QJM. 2020 Jul 1;113(7):509-10.Полный текст  Аннотация

272. Mackey K, King VJ, Gurley S, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med. 2020 Aug 4;173(3):195-203.Полный текст  Аннотация

273. Mackey K, Kansagara D, Vela K. Update alert 7: risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. Ann Intern Med. 2021 Feb;174(2):W25-9.Полный текст  Аннотация

274. Baillargeon J, Polychronopoulou E, Kuo YF, et al. The impact of substance use disorder on COVID-19 outcomes. Psychiatr Serv. 2021 May 1;72(5):578-81.Полный текст  Аннотация

275. Allen B, El Shahawy O, Rogers ES, et al. Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January-October 2020. J Public Health (Oxf). 2020 Dec 26 [Epub ahead of print].Полный текст  Аннотация

276. Qeadan F, Tingey B, Bern R, et al. Opioid use disorder and health service utilization among COVID-19 patients in the US: a nationwide cohort from the Cerner Real-World Data. EClinicalMedicine. 2021 Jun 4:100938.Полный текст  Аннотация

277. Kompaniyets L, Agathis NT, Nelson JM, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open. 2021 Jun 1;4(6):e2111182.Полный текст  Аннотация

278. Akbar MR, Wibowo A, Pranata R, et al. Low serum 25-hydroxyvitamin d (vitamin d) level is associated with susceptibility to COVID-19, severity, and mortality: a systematic review and meta-analysis. Front Nutr. 2021 Mar 29;8:660420.Полный текст  Аннотация

279. Crafa A, Cannarella R, Condorelli RA, et al. Influence of 25-hydroxy-cholecalciferol levels on SARS-CoV-2 infection and COVID-19 severity: a systematic review and meta-analysis. EClinicalMedicine. 2021 Jul;37:100967.Полный текст  Аннотация

280. Szarpak L, Rafique Z, Gasecka A, et al. A systematic review and meta-analysis of effect of vitamin D levels on the incidence of COVID-19. Cardiol J. 2021 Jul 26 [Epub ahead of print]. Аннотация

281. Shah K, V P V, Pandya A, et al. Low vitamin D levels and prognosis in a COVID-19 paediatric population: a systematic review. QJM. 2021 Jul 22 [Epub ahead of print].Полный текст  Аннотация

282. Borsche L, Glauner B, von Mendel J. COVID-19 mortality risk correlates inversely with vitamin D3 status, and a mortality rate close to zero could theoretically be achieved at 50 ng/mL 25(OH)D3: results of a systematic review and meta-analysis. Nutrients. 2021 Oct 14;13(10):3596.Полный текст  Аннотация

283. Ebrahimzadeh A, Mohseni S, Narimani B, et al. Association between vitamin D status and risk of covid-19 in-hospital mortality: a systematic review and meta-analysis of observational studies. Crit Rev Food Sci Nutr. 2021 Dec 9:1-11. Аннотация

284. Dissanayake HA, de Silva NL, Sumanatilleke M, et al. Prognostic and therapeutic role of vitamin D in COVID-19: systematic review and meta-analysis. J Clin Endocrinol Metab. 2021 Dec 11 [Epub ahead of print].Полный текст  Аннотация

285. Bassatne A, Basbous M, Chakhtoura M, et al. The link between COVID-19 and vitamin D (VIVID): a systematic review and meta-analysis. Metabolism. 2021 Mar 24:154753.Полный текст  Аннотация

286. Grove A, Osokogu O, Al-Khudairy L, et al. Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review. BMJ Open. 2021 May 28;11(5):e043737.Полный текст  Аннотация

287. Chen J, Mei K, Xie L, et al. Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs. Nutr J. 2021 Oct 31;20(1):89.Полный текст  Аннотация

288. Fatima K, Almas T, Lakhani S, et al. The use of proton pump inhibitors and COVID-19: a systematic review and meta-analysis. Trop Med Infect Dis. 2022 Feb 28;7(3):37.Полный текст  Аннотация

289. Li GF, An XX, Yu Y, et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut. 2020 Nov 10 [Epub ahead of print].Полный текст  Аннотация

290. Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020 Oct 13 [Epub ahead of print].Полный текст  Аннотация

291. Conway R, Grimshaw AA, Konig MF, et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis Rheumatol. 2021 Nov 22 [Epub ahead of print].Полный текст  Аннотация

292. Izadi Z, Brenner EJ, Mahil SK, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021 Oct 1;4(10):e2129639.Полный текст  Аннотация

293. Andersen KM, Bates BA, Rashidi ES, et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatol. 2021 Nov 15 [Epub ahead of print].Полный текст  Аннотация

294. Tripathi K, Godoy Brewer G, Thu Nguyen M, et al. COVID-19 and outcomes in patients with inflammatory bowel disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2021 Oct 27 [Epub ahead of print].Полный текст  Аннотация

295. Alrashed F, Battat R, Abdullah I, et al. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2021 Oct;8(1):e000774.Полный текст  Аннотация

296. Bezzio C, Saibeni S, Variola A, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020 Jul;69(7):1213-7.Полный текст  Аннотация

297. Singh S, Khan A, Chowdhry M, et al. Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the united states: a multicenter research network study. Gastroenterology. 2020 Oct;159(4):1575-8.Полный текст  Аннотация

298. Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021 Apr;70(4):725-32.Полный текст  Аннотация

299. Singh AK, Jena A, Kumar-M P, et al. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. United European Gastroenterol J. 2021 Mar;9(2):159-76.Полный текст  Аннотация

300. Sperger J, Shah KS, Lu M, et al. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. BMJ Open. 2021 Nov 12;11(11):e049740.Полный текст  Аннотация

301. Sakthiswary R, Chuah HY, Chiang KS, et al. COVID-19 in systemic lupus erythematosus: a pooled analysis and systematic review of case reports and series. Lupus. 2021 Sep 27 [Epub ahead of print]. Аннотация

302. Rutherford MA, Scott J, Karabayas M, et al. Risk factors for severe outcomes in patients with systemic vasculitis and COVID-19: a binational, registry-based cohort study. Arthritis Rheumatol. 2021 Sep;73(9):1713-9.Полный текст  Аннотация

303. Sattui SE, Conway R, Putman MS, et al. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatol. 2021 Dec;3(12):e855-64.Полный текст  Аннотация

304. Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020 Sep 1;77(9):1079-88.Полный текст  Аннотация

305. Salter A, Fox RJ, Newsome SD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 2021 Mar 19 [Epub ahead of print].Полный текст  Аннотация

306. Barzegar M, Mirmosayyeb O, Gajarzadeh M, et al. COVID-19 among patients with multiple sclerosis: a systematic review. Neurol Neuroimmunol Neuroinflamm. 2021 Jul;8(4):e1001.Полный текст  Аннотация

307. Giovanella L, Ruggeri RM, Ovčariček PP, et al. Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review. Clin Transl Imaging. 2021 Mar 11:1-8.Полный текст  Аннотация

308. Malik J, Zaidi SMJ, Waqar AU, et al. Association of hypothyroidism with acute COVID-19: a systematic review. Expert Rev Endocrinol Metab. 2021 Aug 23 [Epub ahead of print]. Аннотация

309. Damara FA, Muchamad GR, Ikhsani R, et al. Thyroid disease and hypothyroidism are associated with poor COVID-19 outcomes: a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2021 Oct 22;15(6):102312.Полный текст  Аннотация

310. Permana H, Soeriadi EA, Damara FA, et al. The prognostic values of thyroid disorders in predicting COVID-19 composite poor outcomes: a systematic review and meta-analysis. Diabetes Metab Syndr. 2022 Mar 18;16(5):102464.Полный текст  Аннотация

311. Putri C, Hariyanto TI, Hananto JE, et al. Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: a systematic review, meta-analysis, and meta-regression. Parkinsonism Relat Disord. 2021 Apr 24 [Epub ahead of print].Полный текст  Аннотация

312. Chambergo-Michilot D, Barros-Sevillano S, Rivera-Torrejón O, et al. Factors associated with COVID-19 in people with Parkinson's disease: a systematic review and meta-analysis. Eur J Neurol. 2021 May 13 [Epub ahead of print].Полный текст  Аннотация

313. Khoshnood RJ, Zali A, Tafreshinejad A, et al. Parkinson's disease and COVID-19: a systematic review and meta-analysis. Neurol Sci. 2021 Nov 17 [Epub ahead of print].Полный текст  Аннотация

314. Jaiswal V, Alquraish D, Sarfraz Z, et al. The influence of coronavirus disease-2019 (COVID-19) on Parkinson's disease: an updated systematic review. J Prim Care Community Health. 2021 Jan-Dec;12:21501327211039709.Полный текст  Аннотация

315. Topless RK, Gaffo A, Stamp LK, et al. Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study. Lancet Rheumatol. 2022 Jan 28 [Epub ahead of print].Полный текст  Аннотация

316. Choi GJ, Kim HM, Kang H. The potential role of dyslipidemia in COVID-19 severity: an umbrella review of systematic reviews. J Lipid Atheroscler. 2020 Sep;9(3):435-48.Полный текст  Аннотация

317. Zuin M, Rigatelli G, Bilato C, et al. Dyslipidaemia and mortality in COVID-19 patients: a meta-analysis. QJM. 2021 Apr 2 [Epub ahead of print].Полный текст  Аннотация

318. Liu Y, Pan Y, Yin Y, et al. Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis. Virol J. 2021 Jul 27;18(1):157.Полный текст  Аннотация

319. Atmosudigdo IS, Pranata R, Lim MA, et al. Dyslipidemia increases the risk of severe COVID-19: a systematic review, meta-analysis, and meta-regression. J Clin Exp Hepatol. 2021 Feb 8 [Epub ahead of print].Полный текст  Аннотация

320. Kow CS, Hasan SS. The association between the use of statins and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2021 Aug 3 [Epub ahead of print].Полный текст  Аннотация

321. Daniels LB, Ren J, Kumar K, et al. Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry. PLoS One. 2021 Jul 15;16(7):e0254635.Полный текст  Аннотация

322. Bergqvist R, Ahlqvist VH, Lundberg M, et al. HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: a registry-based cohort study. PLoS Med. 2021 Oct;18(10):e1003820.Полный текст  Аннотация

323. Doglietto F, Vezzoli M, Gheza F, et al. Factors associated with surgical mortality and complications among patients with and without coronavirus disease 2019 (COVID-19) in Italy. JAMA Surg. 2020 Jun 12;155(8):1-14.Полный текст  Аннотация

324. Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020 Apr 5:100331.Полный текст  Аннотация

325. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020 Jul 4;396(10243):27-38.Полный текст  Аннотация

326. Liu N, Zhang T, Ma L, et al. The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. Blood Rev. 2020 Dec 8:100785.Полный текст  Аннотация

327. Gutiérrez-Valencia M, Leache L, Librero J, et al. ABO blood group and risk of COVID-19 infection and complications: a systematic review and meta-analysis. Transfusion. 2021 Nov 12 [Epub ahead of print].Полный текст  Аннотация

328. Soo KM, Chung KM, Mohd Azlan MAA, et al. The association of ABO and Rhesus blood type with the risks of developing SARS-CoV-2 infection: a meta-analysis. Trop Biomed. 2022 Mar 1;39(1):126-34.Полный текст  Аннотация

329. Franchini M, Cruciani M, Mengoli C, et al. ABO blood group and COVID-19: an updated systematic literature review and meta-analysis. Blood Transfus. 2021 May 12 [Epub ahead of print].Полный текст  Аннотация

330. Wu SC, Arthur CM, Wang J, et al. The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A. Blood Adv. 2021 Mar 9;5(5):1305-9.Полный текст  Аннотация

331. Yamamoto S, Saito M, Tamura A, et al. The human microbiome and COVID-19: a systematic review. PLoS One. 2021 Jun 23;16(6):e0253293.Полный текст  Аннотация

332. Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020 May 13;285:198018.Полный текст  Аннотация

333. Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020 Sep;159(3):944-55.Полный текст  Аннотация

334. Gu S, Chen Y, Wu Z, et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis. 2020 Dec 17;71(10):2669-78.Полный текст  Аннотация

335. Yeoh YK, Zuo T, Lui GC, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021 Apr;70(4):698-706.Полный текст  Аннотация

336. Zheng HL, Guo ZL, Wang ML, et al. Effects of climate variables on the transmission of COVID-19: a systematic review of 62 ecological studies. Environ Sci Pollut Res Int. 2021 Aug 16 [Epub ahead of print].Полный текст  Аннотация

337. Centre for Evidence-Based Medicine; Hoang U, Jones NR. Is there an association between exposure to air pollution and severity of COVID-19 infection? 2020 [internet publication].Полный текст

338. Copat C, Cristaldi A, Fiore M, et al. The role of air pollution (PM and NO₂) in COVID-19 spread and lethality: a systematic review. Environ Res. 2020 Aug 24;191:110129.Полный текст  Аннотация

339. Frontera A, Cianfanelli L, Vlachos K, et al. Severe air pollution links to higher mortality in COVID-19 patients: the “double-hit” hypothesis. J Infect. 2020 Aug;81(2):255-9.Полный текст  Аннотация

340. Ogen Y. Assessing nitrogen dioxide (NO2) levels as a contributing factor to coronavirus (COVID-19) fatality. Sci Total Environ. 2020 Apr 11;726:138605.Полный текст  Аннотация

341. Yu Z, Bellander T, Bergström A, et al. Association of short-term air pollution exposure with SARS-CoV-2 infection among young adults in Sweden. JAMA Netw Open. 2022 Apr 1;5(4):e228109.Полный текст  Аннотация

342. Bowyer RCE, Varsavsky T, Thompson EJ, et al. Geo-social gradients in predicted COVID-19 prevalence in Great Britain: results from 1 960 242 users of the COVID-19 Symptoms Study app. Thorax. 2020 Dec 29 [Epub ahead of print].Полный текст  Аннотация

343. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-15.Полный текст  Аннотация

344. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403-16.Полный текст  Аннотация

345. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021 Apr 21 [Epub ahead of print].Полный текст  Аннотация

346. Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021 Sep 29 [Epub ahead of print].Полный текст  Аннотация

347. World Health Organization. Interim statement on booster doses for COVID-19 vaccination. 2021 [internet publication].Полный текст

348. Zeng B, Gao L, Zhou Q, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022 May 23;20(1):200.Полный текст  Аннотация

349. World Health Organization. Interim statement on the composition of current COVID-19 vaccines. 2022 [internet publication].Полный текст

350. World Health Organization. Interim statement on decision-making considerations for the use of variant updated COVID-19 vaccines. 2022 [internet publication].Полный текст

351. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA recommends inclusion of omicron BA.4/5 component for COVID-19 vaccine booster doses. 2022 [internet publication].Полный текст

352. World Health Organization. Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons. 2021 [internet publication].Полный текст

353. Centers for Disease Control and Prevention. ACIP evidence to recommendations for use of an additional COVID-19 vaccine dose in immunocompromised people. 2021 [internet publication].Полный текст

354. European Medicines Agency. Comirnaty and Spikevax: EMA recommendations on extra doses and boosters. 2021 [internet publication].Полный текст

355. World Health Organization. Interim statement on the use of additional booster doses of emergency use listed mRNA vaccines against COVID-19. 2022 [internet publication].Полный текст

356. Centers for Disease Control and Prevention. ACIP evidence to recommendations for use of COVID-19 vaccine booster doses. 2021 [internet publication].Полный текст

357. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021 Oct 7;385(15):1393-400.Полный текст  Аннотация

358. Falsey AR, Frenck RW Jr, Walsh EE, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med. 2021 Sep 15 [Epub ahead of print].Полный текст  Аннотация

359. Hause AM, Baggs J, Gee J, et al. Safety monitoring of an additional dose of COVID-19 vaccine: United States, August 12 – September 19, 2021. MMWR Morb Mortal Wkly Rep. 2021 Oct 1;70(39):1379-84.Полный текст  Аннотация

360. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021 Oct 29 [Epub ahead of print].Полный текст  Аннотация

361. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021 Dec 2 [Epub ahead of print].Полный текст  Аннотация

362. Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to Covid-19. N Engl J Med. 2021 Dec 8 [Epub ahead of print].Полный текст  Аннотация

363. Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2 booster across age groups. N Engl J Med. 2021 Dec 8 [Epub ahead of print].Полный текст  Аннотация

364. Spitzer A, Angel Y, Marudi O, et al. Association of a third dose of BNT162b2 vaccine with incidence of SARS-CoV-2 infection among health care workers in Israel. JAMA. 2022 Jan 25;327(4):341-9.Полный текст  Аннотация

365. Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron. N Engl J Med. 2022 Mar 16 [Epub ahead of print].Полный текст  Аннотация

366. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022 Apr 5 [Epub ahead of print].Полный текст  Аннотация

367. Magen O, Waxman JG, Makov-Assif M, et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2022 Apr 28;386(17):1603-14.Полный текст  Аннотация

368. World Health Organization. Interim recommendations for heterologous COVID-19 vaccine schedules. 2021 [internet publication].Полный текст

369. Au WY, Cheung PP. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ. 2022 May 31;377:e069989.Полный текст  Аннотация

370. World Health Organization. Coadministration of seasonal inactivated influenza and COVID-19 vaccines. 2021 [internet publication].Полный текст

371. Lazarus R, Baos S, Cappel-Porter H, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021 Nov 11 [Epub ahead of print].Полный текст  Аннотация

372. World Health Organization. Questions and answers: COVID-19 vaccines and pregnancy. 2022 [internet publication].Полный текст

373. Prasad S, Kalafat E, Blakeway H, et al. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. Nat Commun. 2022 May 10;13(1):2414.Полный текст  Аннотация

374. Carlsen EØ, Magnus MC, Oakley L, et al. Association of COVID-19 vaccination during pregnancy with incidence of SARS-CoV-2 infection in infants. JAMA Intern Med. 2022 Jun 1 [Epub ahead of print].Полный текст  Аннотация

375. Halasa NB, Olson SM, Staat MA, et al. Maternal vaccination and risk of hospitalization for Covid-19 among infants. N Engl J Med. 2022 Jun 22 [Epub ahead of print].Полный текст  Аннотация

376. World Health Organization. Frequently asked questions: COVID-19 vaccines and breastfeeding based on WHO interim recommendations, 12 August 2021. 2021 [internet publication].Полный текст

377. Whited N, Cervantes J. Antibodies against SARS-CoV-2 in human breast milk after vaccination: a systematic review and meta-analysis. Breastfeed Med. 2022 Mar 22 [Epub ahead of print].Полный текст  Аннотация

378. Golan Y, Prahl M, Cassidy A, et al. Evaluation of messenger RNA from COVID-19 BTN162b2 and mRNA-1273 vaccines in human milk. JAMA Pediatr. 2021 Jul 6 [Epub ahead of print].Полный текст  Аннотация

379. Du Y, Chen L, Shi Y. Safety, immunogenicity, and efficacy of COVID-19 vaccines in adolescents, children, and infants: a systematic review and meta-analysis. Front Public Health. 2022 Apr 14;10:829176.Полный текст  Аннотация

380. Hause AM, Gee J, Baggs J, et al. COVID-19 vaccine safety in adolescents aged 12-17 years: United States, December 14, 2020 – July 16, 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1053-8.Полный текст  Аннотация

381. Hause AM, Baggs J, Marquez P, et al. COVID-19 vaccine safety in children aged 5-11 years: United States, November 3 – December 19, 2021. MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1755-60.Полный текст  Аннотация

382. Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022 Mar 2;376:e068632.Полный текст  Аннотация

383. Li J, Ayada I, Wang Y, et al. Factors associated with COVID-19 vaccine response in transplant recipients: a systematic review and meta-analysis. Transplantation. 2022 Jun 28 [Epub ahead of print]. Аннотация

384. Manothummetha K, Chuleerarux N, Sanguankeo A, et al. Immunogenicity and risk factors associated with poor humoral immune response of SARS-CoV-2 vaccines in recipients of solid organ transplant: a systematic review and meta-analysis. JAMA Netw Open. 2022 Apr 1;5(4):e226822.Полный текст  Аннотация

385. Zong K, Peng D, Yang H, et al. Risk factors for weak antibody response of SARS-CoV-2 vaccine in adult solid organ transplant recipients: a systemic review and meta-analysis. Front Immunol. 2022 Jun 14;13:888385.Полный текст  Аннотация

386. Abhishek A, Boyton RJ, Peckham N, et al. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respir Med. 2022 Jun 27 [Epub ahead of print].Полный текст  Аннотация

387. Jena A, Mishra S, Deepak P, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev. 2021 Aug 30:102927.Полный текст  Аннотация

388. Mahil SK, Bechman K, Raharja A, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021 Jul 8 [Epub ahead of print].Полный текст  Аннотация

389. Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021 Sep 7 [Epub ahead of print].Полный текст  Аннотация

390. Wu X, Wang L, Shen L, et al. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: a meta-analysis. EBioMedicine. 2022 Jun 24;81:104102.Полный текст  Аннотация

391. Ishay Y, Kenig A, Tsemach-Toren T, et al. Autoimmune phenomena following SARS-CoV-2 vaccination. Int Immunopharmacol. 2021 Jul 10;99:107970.Полный текст  Аннотация

392. Cabreira V, Abreu P, Soares-Dos-Reis R, et al. Multiple sclerosis, disease-modifying therapies and COVID-19: a systematic review on immune response and vaccination recommendations. Vaccines (Basel). 2021 Jul 11;9(7):773.Полный текст  Аннотация

393. Felten R, Kawka L, Dubois M, et al. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol. 2021 Jul 21 [Epub ahead of print].Полный текст  Аннотация

394. Obeid M, Fenwick C, Pantaleo G. Reactivation of IgA vasculitis after COVID-19 vaccination. Lancet Rheumatol. 2021 Jul 6 [Epub ahead of print].Полный текст  Аннотация

395. Gagelmann N, Passamonti F, Wolschke C, et al. Antibody response after vaccination against SARS-CoV-2 in adults with haematological malignancies: a systematic review and meta-analysis. Haematologica. 2021 Dec 16 [Epub ahead of print].Полный текст  Аннотация

396. Zhang M, Liang Y, Yu D, et al. A systematic review of vaccine breakthrough infections by SARS-CoV-2 Delta variant. Int J Biol Sci. 2022;18(2):889-900.Полный текст  Аннотация

397. Gopinath S, Ishak A, Dhawan N, et al. Characteristics of COVID-19 breakthrough infections among vaccinated individuals and associated risk factors: a systematic review. Trop Med Infect Dis. 2022 May 22;7(5):81.Полный текст  Аннотация

398. Juthani PV, Gupta A, Borges KA, et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis. 2021 Sep 7 [Epub ahead of print].Полный текст  Аннотация

399. Butt AA, Yan P, Shaikh OS, et al. Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population. EClinicalMedicine. 2021 Aug 28;40:101117.Полный текст  Аннотация

400. Lee CJ, Woo W, Kim AY, et al. Clinical manifestations of COVID-19 breakthrough infections: a systematic review and meta-analysis. J Med Virol. 2022 May 19 [Epub ahead of print].Полный текст  Аннотация

401. Kampf G. The epidemiological relevance of the COVID-19-vaccinated population is increasing. Lancet Reg Health Eur. 2021 Dec;11:100272.Полный текст  Аннотация

402. Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings: Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1059-62.Полный текст  Аннотация

403. Pouwels KB, Pritchard E, Matthews PC, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. 2021 [internet publication].Полный текст

404. Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2021 Oct 29 [Epub ahead of print].Полный текст  Аннотация

405. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2021 Sep 1 [Epub ahead of print].Полный текст  Аннотация

406. Sun J, Zheng Q, Madhira V, et al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med. 2021 Dec 28 [Epub ahead of print].Полный текст  Аннотация

407. Song Q, Bates B, Shao YR, et al. Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the National COVID Cohort Collaborative. J Clin Oncol. 2022 Mar 14 [Epub ahead of print].Полный текст  Аннотация

408. Wang W, Kaelber DC, Xu R, et al. Breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in vaccinated patients with cancer in the US between December 2020 and November 2021. JAMA Oncol. 2022 Apr 8 [Epub ahead of print].Полный текст  Аннотация

409. Wang L, Davis PB, Kaelber DC, et al. COVID-19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021. Alzheimers Dement. 2022 Apr 13 [Epub ahead of print].Полный текст  Аннотация

410. Agrawal U, Katikireddi SV, McCowan C, et al. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir Med. 2021 Sep 29 [Epub ahead of print].Полный текст  Аннотация

411. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA. 2021 Nov 1 [Epub ahead of print].Полный текст  Аннотация

412. Kuhlmann C, Mayer CK, Claassen M, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 2022 Jan 18 [Epub ahead of print].Полный текст  Аннотация

413. Fall A, Eldesouki RE, Sachithanandham J, et al. The displacement of the SARS-CoV-2 variant Delta with Omicron: an investigation of hospital admissions and upper respiratory viral loads. EBioMedicine. 2022 Apr 20;79:104008.Полный текст  Аннотация

414. Truong DT, Dionne A, Muniz JC, et al. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults. Circulation. 2021 Dec 6 [Epub ahead of print].Полный текст  Аннотация

415. Gundry SR. Abstract 10712: MRNA COVID vaccines dramatically increase endothelial inflammatory markers and ACS risk as measured by the PULS cardiac test: a warning. Circulation. 2021 Nov 16;144 (Suppl 1):A10712.Полный текст

416. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2021 Dec 14 [Epub ahead of print].Полный текст  Аннотация

417. European Medicines Agency. COVID-19 vaccines safety update: 17 June 2022. 2022 [internet publication].Полный текст

418. Lane S, Yeomans A, Shakir S. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature. BMJ Open. 2022 May 25;12(5):e059223.Полный текст  Аннотация

419. Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022 Jan 25;327(4):331-40.Полный текст  Аннотация

420. Matta A, Kunadharaju R, Osman M, et al. Clinical presentation and outcomes of myocarditis post mRNA vaccination: a meta-analysis and systematic review. Cureus. 2021 Nov;13(11):e19240.Полный текст  Аннотация

421. Wong HL, Hu M, Zhou CK, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet. 2022 Jun 11;399(10342):2191-9.Полный текст  Аннотация

422. Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents. JAMA Cardiol. 2022 Apr 20 [Epub ahead of print].Полный текст  Аннотация

423. Friedensohn L, Levin D, Fadlon-Derai M, et al. Myocarditis following a third BNT162b2 vaccination dose in military recruits in Israel. JAMA. 2022 Mar 17 [Epub ahead of print].Полный текст  Аннотация

424. Lane S, Yeomans A, Shakir S. Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination. BMJ Open. 2022 Jul 1;12(7):e060425.Полный текст  Аннотация

425. UK Health Security Agency. Myocarditis and pericarditis after COVID-19 vaccination: guidance for healthcare professionals. 2021 [internet publication].Полный текст

426. Dionne A, Sperotto F, Chamberlain S, et al. Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children. JAMA Cardiol. 2021 Aug 10 [Epub ahead of print].Полный текст  Аннотация

427. Buchan SA, Seo CY, Johnson C, et al. Epidemiology of myocarditis and pericarditis following mrna vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada. JAMA Netw Open. 2022 Jun 1;5(6):e2218505.Полный текст  Аннотация

428. Shafiq A, Salameh MA, Laswi I, et al. Neurological immune related adverse events post-COVID-19 vaccination: a systematic review. J Clin Pharmacol. 2021 Dec 18 [Epub ahead of print].Полный текст  Аннотация

429. Hanson KE, Goddard K, Lewis N, et al. Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the Vaccine Safety Datalink. JAMA Netw Open. 2022 Apr 1;5(4):e228879.Полный текст  Аннотация

430. Woo EJ, Mba-Jonas A, Dimova RB, et al. Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barré syndrome, February-July 2021. JAMA. 2021 Oct 7 [Epub ahead of print].Полный текст  Аннотация

431. Rizk JG, Gupta A, Sardar P, et al. Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review. JAMA Cardiol. 2021 Aug 10 [Epub ahead of print].Полный текст  Аннотация

432. Hafeez MU, Ikram M, Shafiq Z, et al. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): a systematic review and post hoc analysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211048815.Полный текст  Аннотация

433. Dag Berild J, Bergstad Larsen V, Myrup Thiesson E, et al. Analysis of thromboembolic and thrombocytopenic events after the AZD1222, BNT162b2, and MRNA-1273 COVID-19 vaccines in 3 Nordic countries. JAMA Netw Open. 2022 Jun 1;5(6):e2217375.Полный текст  Аннотация

434. Andrews NJ, Stowe J, Ramsay ME, et al. Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: a national cohort study in England. Lancet Reg Health Eur. 2022 Feb;13:100260.Полный текст  Аннотация

435. See I, Lale A, Marquez P, et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: United States, December 2020 to August 2021. Ann Intern Med. 2022 Jan 18 [Epub ahead of print].Полный текст  Аннотация

436. Mani A, Ojha V. Thromboembolism after COVID-19 vaccination: a systematic review of such events in 286 patients. Ann Vasc Surg. 2022 May 11 [Epub ahead of print].Полный текст  Аннотация

437. Warren CM, Snow TT, Lee AS, et al. Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system. JAMA Netw Open. 2021 Sep 1;4(9):e2125524.Полный текст  Аннотация

438. Greenhawt M, Abrams EM, Shaker M, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021 Jun 18 [Epub ahead of print].Полный текст  Аннотация

439. Alhumaid S, Al Mutair A, Al Alawi Z, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021 Oct 16;17(1):109.Полный текст  Аннотация

440. Sobczak M, Pawliczak R. The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis. Clin Mol Allergy. 2022 Jan 17;20(1):1.Полный текст  Аннотация

441. Chu DK, Abrams EM, Golden DBK, et al. Risk of second allergic reaction to SARS-CoV-2 vaccines: a systematic review and meta-analysis. JAMA Intern Med. 2022 Feb 21 [Epub ahead of print].Полный текст  Аннотация

442. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 September 2021. 2021 [internet publication].Полный текст

443. Maroufi SF, Naderi Behdani F, Rezania F, et al. Longitudinally extensive transverse myelitis after Covid-19 vaccination: case report and review of literature. Hum Vaccin Immunother. 2022 Mar 3 [Epub ahead of print].Полный текст  Аннотация

444. Eom H, Kim SW, Kim M, et al. Case reports of acute transverse myelitis associated with mRNA vaccine for COVID-19. J Korean Med Sci. 2022 Feb 21;37(7):e52.Полный текст  Аннотация

445. Fazlollahi A, Zahmatyar M, Noori M, et al. Cardiac complications following mRNA COVID-19 vaccines: a systematic review of case reports and case series. Rev Med Virol. 2021 Dec 17:e2318.Полный текст  Аннотация

446. Angeli F, Reboldi G, Trapasso M, et al. Blood pressure increase following COVID-19 vaccination: a systematic overview and meta-analysis. J Cardiovasc Dev Dis. 2022 May 9;9(5):150.Полный текст  Аннотация

447. EPI-PHARE. Covid-19 vaccines and cardiovascular events in 18-74 year olds [in French]. 2022 [internet publication].Полный текст

448. European Medicines Agency. COVID-19 vaccines safety update. 2022 [internet publication].Полный текст

449. Elboraey MO, Essa EESF. Stevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Oct;132(4):e139-42.Полный текст  Аннотация

450. Cavalli G, Colafrancesco S, De Luca G, et al. Cutaneous vasculitis following COVID-19 vaccination. Lancet Rheumatol. 2021 Sep 30 [Epub ahead of print].Полный текст  Аннотация

451. Askenase PW. Rare skin reactions after mRNA vaccination, similar to Jones-Mote basophil responses. N Engl J Med. 2021 Oct 28;385(18):1720-1.Полный текст  Аннотация

452. Birkett L, Singh P, Mosahebi A, et al. Possible associations between alopecia areata and COVID-19 vaccination and infection. Aesthet Surg J. 2022 Jun 20 [Epub ahead of print].Полный текст  Аннотация

453. Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, et al. Two cases of Graves' disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid. 2021 Sep;31(9):1436-9.Полный текст  Аннотация

454. Edelman A, Boniface ER, Benhar E, et al. Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination: a U.S. cohort. Obstet Gynecol. 2022 Jan 5 [Epub ahead of print].Полный текст  Аннотация

455. Ippolito S, Gallo D, Rossini A, et al. SARS-CoV-2 vaccine-associated subacute thyroiditis: insights from a systematic review. J Endocrinol Invest. 2022 Jan 29 [Epub ahead of print].Полный текст  Аннотация

456. Walter T, Connor S, Stedman C, et al. A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine. Br J Clin Pharmacol. 2021 Aug 22 [Epub ahead of print].Полный текст  Аннотация

457. Chen Y, Xu Z, Wang P, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2021 Dec 27 [Epub ahead of print].Полный текст  Аннотация

458. Chow KW, Pham NV, Ibrahim BM, et al. Autoimmune hepatitis-like syndrome following COVID-19 vaccination: a systematic review of the literature. Dig Dis Sci. 2022 Apr 29 [Epub ahead of print].Полный текст  Аннотация

459. Roy A, Verma N, Singh S, et al. Immune-mediated liver injury following COVID-19 vaccination: a systematic review. Hepatol Commun. 2022 May 4 [Epub ahead of print].Полный текст  Аннотация

460. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 April 2022. 2022 [internet publication].Полный текст

461. Marconi E, Crescioli G, Bonaiuti R, et al. Acute appendicitis in a patient immunised with COVID-19 vaccine: a case report with morphological analysis. Br J Clin Pharmacol. 2022 May 27 [Epub ahead of print].Полный текст  Аннотация

462. Leone MC, Canovi S, Pilia A, et al. Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine. Thromb Res. 2022 Mar;211:60-2.Полный текст  Аннотация

463. Patone M, Mei XW, Handunnetthi L, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021 Dec 14 [Epub ahead of print].Полный текст  Аннотация

464. Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022 Jan;43(1):3-40.Полный текст  Аннотация

465. Toljan K, Amin M, Kunchok A, et al. New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure. J Neuroimmunol. 2022 Jan 15;362:577785.Полный текст  Аннотация

466. Préta LH, Contejean A, Salvo F, et al. Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273). Br J Clin Pharmacol. 2022 Feb 16 [Epub ahead of print].Полный текст  Аннотация

467. Yanir Y, Doweck I, Shibli R, et al. Association between the BNT162b2 messenger RNA COVID-19 vaccine and the risk of sudden sensorineural hearing loss. JAMA Otolaryngol Head Neck Surg. 2022 Feb 24 [Epub ahead of print].Полный текст  Аннотация

468. Anamnart C, Tisavipat N, Owattanapanich W, et al. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: case report and systematic review. Mult Scler Relat Disord. 2022 Feb;58:103414. Аннотация

469. Sriwastava S, Sharma K, Khalid SH, et al. COVID-19 vaccination and neurological manifestations: a review of case reports and case series. Brain Sci. 2022 Mar 18;12(3):407.Полный текст  Аннотация

470. Avasarala J, McLouth CJ, Pettigrew LC, et al. VAERS-reported new-onset seizures following use of COVID-19 vaccinations as compared to influenza vaccinations. Br J Clin Pharmacol. 2022 May 23 [Epub ahead of print].Полный текст  Аннотация

471. Wu HHL, Kalra PA, Chinnadurai R. New-onset and relapsed kidney histopathology following COVID-19 vaccination: a systematic review. Vaccines (Basel). 2021 Oct 29;9(11):1252.Полный текст  Аннотация

472. Maramattom BV, Philips G, Thomas J, et al. Inflammatory myositis after ChAdOx1 vaccination. Lancet Rheumatol. 2021 Sep 23 [Epub ahead of print].Полный текст  Аннотация

473. Leone F, Cerasuolo PG, Bosello SL, et al. Adult-onset Still's disease following COVID-19 vaccination. Lancet Rheumatol. 2021 Oct;3(10):e678-80.Полный текст  Аннотация

474. Nguyen B, Lalama MJ, Gamret AC, et al. Cutaneous symptoms of connective tissue diseases after COVID-19 vaccination: a systematic review. Int J Dermatol. 2022 Jul;61(7):e238-41.Полный текст  Аннотация

475. Sessa F, Salerno M, Esposito M, et al. Autopsy findings and causality relationship between death and COVID-19 vaccination: a systematic review. J Clin Med. 2021 Dec 15;10(24):5876.Полный текст  Аннотация

476. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain Individuals. 2021 [internet publication].Полный текст

477. Medicines and Healthcare products Regulatory Agency. Evusheld approved to prevent COVID-19 in people whose immune response is poor. 2022 [internet publication].Полный текст

478. European Medicines Agency. EMA recommends authorisation of COVID-19 medicine Evusheld. 2022 [internet publication].Полный текст

479. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2021 [internet publication].Полный текст

480. Bhimraj A, Morgan RL, Hirsch Shumaker A, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 infection. 2021 [internet publication].Полный текст

481. AstraZeneca. Evusheld long-acting antibody combination retains neutralising activity against Omicron variants including BA.2 in new independent studies. 2022 [internet publication].Полный текст

482. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022 Apr 20 [Epub ahead of print].Полный текст  Аннотация

483. Goulenok T, Delaval L, Delory N, et al. Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases. Lancet Rheumatol. 2022 Apr 11 [Epub ahead of print].Полный текст  Аннотация

484. World Health Organization. Infection prevention and control during health care when coronavirus disease (‎COVID-19) is suspected or confirmed: interim guidance. 2020 [internet publication].Полный текст

485. World Health Organization. COVID-19 infection prevention and control living guideline: mask use in community settings, 22 December 2021. 2021 [internet publication].Полный текст

486. Schoberer D, Osmancevic S, Reiter L, et al. Rapid review and meta-analysis of the effectiveness of personal protective equipment for healthcare workers during the COVID-19 pandemic. Public Health Pract (Oxf). 2022 Dec;4:100280.Полный текст  Аннотация

487. Razai MS, Doerholt K, Ladhani S, et al. Coronavirus disease 2019 (covid-19): a guide for UK GPs. BMJ. 2020 Mar 5;368:m800.Полный текст  Аннотация

488. World Health Organization. Coronavirus disease (COVID-19) advice for the public. 2021 [internet publication].Полный текст

489. Centers for Disease Control and Prevention. How to protect yourself and others. 2021 [internet publication].Полный текст

490. Bendavid E, Oh C, Bhattacharya J, et al. Assessing mandatory stay-at-home and business closure effects on the spread of COVID-19. Eur J Clin Invest. 2021 Jan 5:e13484.Полный текст  Аннотация

491. Chu IY, Alam P, Larson H, et al. Social consequences of mass quarantine during epidemics: a systematic review with implications for the COVID-19 response. J Travel Med. 2020 Oct 13 [Epub ahead of print].Полный текст  Аннотация

492. Bundgaard H, Bundgaard JS, Raaschou-Pedersen DET, et al. Effectiveness of adding a mask recommendation to other public health measures to prevent SARS-CoV-2 infection in Danish mask wearers: a randomized controlled trial. Ann Intern Med. 2021 Mar;174(3):335-43.Полный текст  Аннотация

493. Nanda A, Hung I, Kwong A, et al. Efficacy of surgical masks or cloth masks in the prevention of viral transmission: systematic review, meta-analysis, and proposal for future trial. J Evid Based Med. 2021 May;14(2):97-111.Полный текст  Аннотация

494. Jefferson T, Del Mar CB, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2020 Nov 20;(11):CD006207.Полный текст  Аннотация

495. Chou R, Dana T, Jungbauer R, et al. Masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings: a living rapid review. Ann Intern Med. 2020 Oct 6;173(7):542-55.Полный текст  Аннотация

496. Chou R, Dana T, Jungbauer R, et al. Update alert 5: masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings. Ann Intern Med. 2021 Mar 9 [Epub ahead of print].Полный текст  Аннотация

497. Sharma SK, Mishra M, Mudgal SK. Efficacy of cloth face mask in prevention of novel coronavirus infection transmission: a systematic review and meta-analysis. J Educ Health Promot. 2020 Jul 28;9:192.Полный текст  Аннотация

498. MacIntyre CR, Seale H, Dung TC, et al. A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. BMJ Open. 2015 Apr 22;5(4):e006577.Полный текст  Аннотация

499. Lazzarino AI, Steptoe A, Hamer M, et al. Covid-19: important potential side effects of wearing face masks that we should bear in mind. BMJ. 2020 May 21;369:m2003.Полный текст  Аннотация

500. Bakhit M, Krzyzaniak N, Scott AM, et al. Downsides of face masks and possible mitigation strategies: a systematic review and meta-analysis. BMJ Open. 2021 Feb 22;11(2):e044364.Полный текст  Аннотация

501. Burns J, Movsisyan A, Stratil JM, et al. Travel-related control measures to contain the COVID-19 pandemic: a rapid review. Cochrane Database Syst Rev. 2020 Oct 5;(10):CD013717.Полный текст  Аннотация

502. Viswanathan M, Kahwati L, Jahn B, et al. Universal screening for SARS-CoV-2 infection: a rapid review. Cochrane Database Syst Rev. 2020 Sep 15;(9):CD013718.Полный текст  Аннотация

503. Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev. 2020 Sep 15;(9):CD013574.Полный текст  Аннотация

504. Mahase E. China coronavirus: what do we know so far? BMJ. 2020 Jan 24;368:m308.Полный текст  Аннотация

505. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020 Mar 14;395(10227):912-20.Полный текст  Аннотация

506. Ho FK, Celis-Morales CA, Gray SR, et al. Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. BMJ Open. 2020 Nov 19;10(11):e040402.Полный текст  Аннотация

507. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2021 Feb 23;(2):CD013665.Полный текст  Аннотация

508. World Health Organization. Diagnostic testing for SARS-CoV-2: interim guidance. 2020 [internet publication].Полный текст

509. Irfan O, Muttalib F, Tang K, et al. Clinical characteristics, treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysis. Arch Dis Child. 2021 Feb 16;106(5):440-8.Полный текст  Аннотация

510. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19: scientific brief. 2020 [internet publication].Полный текст

511. British Society of Thoracic Imaging. Thoracic imaging in COVID-19 infection: guidance for the reporting radiologist - version 2. 2020 [internet publication].Полный текст

512. NHS England. Coronavirus (COVID-19) symptoms in adults. 2022 [internet publication].Полный текст

513. ZOE COVID Symptom Study. What are the new top 5 COVID symptoms? 2021 [internet publication].Полный текст

514. ZOE COVID Study. Omicron and cold-like symptoms rapidly taking over in London. 2021 [internet publication].Полный текст

515. Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022 Apr 23;399(10335):1618-24.Полный текст  Аннотация

516. Matar R, Alrahmani L, Monzer N, et al. Clinical presentation and outcomes of pregnant women with coronavirus disease 2019: a systematic review and meta-analysis. Clin Infect Dis. 2021 Feb 1;72(3):521-33.Полный текст  Аннотация

517. Lechien JR, Chetrit A, Chekkoury-Idrissi Y, et al. Parotitis-like symptoms associated with COVID-19, France, March-April 2020. Emerg Infect Dis. 2020 Jun 3;26(9).Полный текст  Аннотация

518. Martín Carreras-Presas C, Amaro Sánchez J, López-Sánchez AF, et al. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Dis. 2021 Apr;27 Suppl 3:710-2.Полный текст  Аннотация

519. Marinho PM, Marcos AAA, Romano AC, et al. Retinal findings in patients with COVID-19. Lancet. 2020 May 23;395(10237):1610.Полный текст  Аннотация

520. Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of hospitalized COVID-19 patients: the "Gabrin sign". J Am Acad Dermatol. 2020 May 21;83(2):680-2.Полный текст  Аннотация

521. Giannos P, Katsikas Triantafyllidis K, Geropoulos G, et al. Persistent hiccups as an atypical presentation of SARS-CoV-2 infection: a systematic review of case reports. Front Neurol. 2022 Apr 4;13:819624.Полный текст  Аннотация

522. Musuuza JS, Watson L, Parmasad V, et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS One. 2021 May 6;16(5):e0251170.Полный текст  Аннотация

523. Wang Y, Xu J, Wang Y, et al. Prevalence of comorbid tuberculosis amongst COVID-19 patients: a rapid review and meta-analysis. Int J Clin Pract. 2021 Nov;75(11):e14867.Полный текст  Аннотация

524. Achan J, Serwanga A, Wanzira H, et al. Current malaria infection, previous malaria exposure, and clinical profiles and outcomes of COVID-19 in a setting of high malaria transmission: an exploratory cohort study in Uganda. Lancet Microbe. 2021 Oct 25 [Epub ahead of print].Полный текст  Аннотация

525. Dadashi M, Dadashi A, Sameni F, et al. SARS-CoV-2 and HIV co-infection; clinical features, diagnosis, and treatment strategies: a systematic review and meta-analysis. Gene Rep. 2022 Jun;27:101624.Полный текст  Аннотация

526. Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids: an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021 Mar 6;:1-8.Полный текст  Аннотация

527. Mahase E. Covid-19: Children less likely to report fever, persistent cough, or appetite loss, large UK study finds. BMJ. 2021 Feb 10;372:n408.Полный текст  Аннотация

528. Bolia R, Dhanesh Goel A, Badkur M, et al. Gastrointestinal manifestations of pediatric coronavirus disease and their relationship with a severe clinical course: a systematic review and meta-analysis. J Trop Pediatr. 2021 May 29 [Epub ahead of print].Полный текст  Аннотация

529. Lorenz N, Treptow A, Schmidt S, et al. Neonatal early-onset infection with SARS-CoV-2 in a newborn presenting with encephalitic symptoms. Pediatr Infect Dis J. 2020 Aug;39(8):e212. Аннотация

530. Chacón-Aguilar R, Osorio-Cámara JM, Sanjurjo-Jimenez I, et al. COVID-19: fever syndrome and neurological symptoms in a neonate. An Pediatr (Engl Ed). 2020 Apr 27;92(6):373-4.Полный текст  Аннотация

531. Sinelli MT, Paterlini G, Citterio M, et al. Early neonatal SARS-CoV-2 infection manifesting with hypoxemia requiring respiratory support. Pediatrics. 2020 Jul;146(1):e20201121.Полный текст  Аннотация

532. Rubens JH, Akindele NP, Tschudy MM, et al. Acute covid-19 and multisystem inflammatory syndrome in children. BMJ. 2021 Mar 1;372:n385.Полный текст  Аннотация

533. Garazzino S, Montagnani C, Donà D, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill. 2020 May;25(18).Полный текст  Аннотация

534. DeBiasi RL, Song X, Delaney M, et al. Severe COVID-19 in children and young adults in the Washington, DC metropolitan region. J Pediatr. 2020 Aug;223:199-203.Полный текст  Аннотация

535. Vasudevan RS, Bin Thani K, Aljawder D, et al. The stethoscope: a potential vector for COVID-19? Eur Heart J. 2020 Sep 21;41(36):3393-5.Полный текст  Аннотация

536. Ikeuchi K, Saito M, Yamamoto S, et al. Relative bradycardia in patients with mild-to-moderate coronavirus disease, Japan. Emerg Infect Dis. 2020 Jul 1;26(10).Полный текст  Аннотация

537. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. 2021 [internet publication].Полный текст

538. Xie J, Tong Z, Guan X, et al. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med. 2020 May;46(5):837-40.Полный текст  Аннотация

539. Centers for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). 2021 [internet publication].Полный текст

540. US Food and Drug Administration. Pulse oximeter accuracy and limitations: FDA safety communication. 2021 [internet publication].Полный текст

541. Royal College of Physicians. NEWS2 and deterioration in COVID-19. 2020 [internet publication].Полный текст

542. Zhang K, Zhang X, Ding W, et al. The prognostic accuracy of national early warning score 2 on predicting clinical deterioration for patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Jul 9;8:699880.Полный текст  Аннотация

543. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020 Jun;92(6):577-83.Полный текст  Аннотация

544. Zhu J, Zhong Z, Ji P, et al. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Fam Med Community Health. 2020 Apr;8(2).Полный текст  Аннотация

545. Zhang ZL, Hou YL, Li DT, et al. Laboratory findings of COVID-19: a systematic review and meta-analysis. Scand J Clin Lab Invest. 2020 May 23:1-7.Полный текст  Аннотация

546. Wu H, Zhu H, Yuan C, et al. Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China. JAMA Netw Open. 2020 Jun 1;3(6):e2010895.Полный текст  Аннотация

547. Henry BM, Benoit SW, de Oliveira MHS, et al. Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): a pooled analysis and review. Clin Biochem. 2020 Jul;81:1-8.Полный текст  Аннотация

548. Kronbichler A, Kresse D, Yoon S, et al. Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis. Int J Infect Dis. 2020 Sep;98:180-6.Полный текст  Аннотация

549. Peeling RW, Heymann DL, Teo YY, et al. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2021 Dec 20 [Epub ahead of print].Полный текст  Аннотация

550. World Health Organization. WHO information notice for IVD users 2020/05. 2021 [internet publication].Полный текст

551. US Food and Drug Administration. SARS-CoV-2 viral mutations: impact on COVID-19 tests. 2021 [internet publication].Полный текст

552. World Health Organization. Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities: interim guidance. 2021 [internet publication].Полный текст

553. UK Health Security Agency. Changes to COVID-19 testing in England from 1 April. 2022 [internet publication].Полный текст

554. NHS England. Living with COVID-19: testing update. 2022 [internet publication].Полный текст

555. Centers for Disease Control and Prevention. Overview of testing for SARS-CoV-2 (COVID-19). 2021 [internet publication].Полный текст

556. Tsang NNY, So HC, Ng KY, et al. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. Lancet Infect Dis. 2021 Apr 12 [Epub ahead of print].Полный текст  Аннотация

557. Bastos ML, Perlman-Arrow S, Menzies D, et al. The sensitivity and costs of testing for SARS-CoV-2 infection with saliva versus nasopharyngeal swabs: a systematic review and meta-analysis. Ann Intern Med. 2021 Apr;174(4):501-10.Полный текст  Аннотация

558. Butler-Laporte G, Lawandi A, Schiller I, et al. Comparison of saliva and nasopharyngeal swab nucleic acid amplification testing for detection of SARS-CoV-2: a systematic review and meta-analysis. JAMA Intern Med. 2021 Mar 1;181(3):353-60.Полный текст  Аннотация

559. Cañete MG, Valenzuela IM, Garcés PC, et al. Saliva sample for the massive screening of SARS-CoV-2 infection: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Feb 1 [Epub ahead of print].Полный текст  Аннотация

560. Moreira VM, Mascarenhas P, Machado V, et al. Diagnosis of SARS-Cov-2 infection by RT-PCR using specimens other than naso- and oropharyngeal swabs: a systematic review and meta-analysis. Diagnostics (Basel). 2021 Feb 21;11(2):363.Полный текст  Аннотация

561. Atieh MA, Guirguis M, Alsabeeha NHM, et al. The diagnostic accuracy of saliva testing for SARS-CoV-2: a systematic review and meta-analysis. Oral Dis. 2021 Jun 3 [Epub ahead of print].Полный текст  Аннотация

562. Ibrahimi N, Delaunay-Moisan A, Hill C, et al. Screening for SARS-CoV-2 by RT-PCR: saliva or nasopharyngeal swab? Rapid review and meta-analysis. PLoS One. 2021 Jun 10;16(6):e0253007.Полный текст  Аннотация

563. Centers for Disease Control and Prevention. Interim guidelines for collecting and handling of clinical specimens for COVID-19 testing. 2021 [internet publication].Полный текст

564. Centers for Disease Control and Prevention. Nucleic acid amplification tests (NAATs). 2021 [internet publication].Полный текст

565. Zhou Y, O'Leary TJ. Relative sensitivity of anterior nares and nasopharyngeal swabs for initial detection of SARS-CoV-2 in ambulatory patients: Rapid review and meta-analysis. PLoS One. 2021 Jul 20;16(7):e0254559.Полный текст  Аннотация

566. Gupta K, Bellino PM, Charness ME. Adverse effects of nasopharyngeal swabs: three-dimensional printed versus commercial swabs. Infect Control Hosp Epidemiol. 2020 Jun 11 [Epub ahead of print].Полный текст  Аннотация

567. Koskinen A, Tolvi M, Jauhiainen M, et al. Complications of COVID-19 nasopharyngeal swab test. JAMA Otolaryngol Head Neck Surg. 2021 Apr 29 [Epub ahead of print].Полный текст  Аннотация

568. Sullivan CB, Schwalje AT, Jensen M, et al. Cerebrospinal fluid leak after nasal swab testing for coronavirus disease 2019. JAMA Otolaryngol Head Neck Surg. 2020 Dec 1;146(12):1179-81.Полный текст  Аннотация

569. Knížek Z, Michálek R, Vodicka J, et al. Cribriform plate injury after nasal swab testing for COVID-19. JAMA Otolaryngol Head Neck Surg. 2021 Sep 9 [Epub ahead of print].Полный текст  Аннотация

570. Jarrom D, Elston L, Washington J, et al. Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review. BMJ Evid Based Med. 2020 Oct 1 [Epub ahead of print].Полный текст  Аннотация

571. Centre for Evidence-Based Medicine; Jefferson T, Heneghan C, Spencer EA, et al. Are you infectious if you have a positive PCR test result for COVID-19? 2020 [internet publication].Полный текст

572. Jefferson T, Spencer EA, Brassey J, et al. Viral cultures for COVID-19 infectious potential assessment: a systematic review. Clin Infect Dis. 2020 Dec 3 [Epub ahead of print].Полный текст  Аннотация

573. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. BMJ. 2020 May 12;369:m1808.Полный текст  Аннотация

574. Bullard J, Dust K, Funk D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis. 2020 Dec 17;71(10):2663-6.Полный текст  Аннотация

575. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-61.Полный текст  Аннотация

576. Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19 results: hidden problems and costs. Lancet Respir Med. 2020 Dec;8(12):1167-8.Полный текст  Аннотация

577. Floriano I, Silvinato A, Bernardo WM, et al. Accuracy of the polymerase chain reaction (PCR) test in the diagnosis of acute respiratory syndrome due to coronavirus: a systematic review and meta-analysis. Rev Assoc Med Bras (1992). 2020 Jul;66(7):880-8.Полный текст  Аннотация

578. Public Health Laboratory Network. PHLN statement on nucleic acid test false positive results for SARS-CoV-2. 2020 [internet publication].Полный текст

579. Australian Government Department of Health. COVID-19 testing in Australia: information for health professionals. 2020 [internet publication].Полный текст

580. US Food and Drug Administration. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. 2020 [internet publication].Полный текст

581. Government Office for Science; Scientific Advisory Group for Emergencies. Impact of false-positives and false-negatives in the UK’s COVID-19 RT-PCR testing programme. 2020 [internet publication].Полный текст

582. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al. False-negative results of initial RT-PCR assays for COVID-19: a systematic review. PLoS One. 2020 Dec 10;15(12):e0242958.Полный текст  Аннотация

583. Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020 Aug 18;173(4):262-7.Полный текст  Аннотация

584. Watson J, Richter A, Deeks J. Testing for SARS-CoV-2 antibodies. BMJ. 2020 Sep 8;370:m3325.Полный текст  Аннотация

585. Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody testing. 2021 [internet publication].Полный текст

586. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: serologic testing. 2020 [internet publication].Полный текст

587. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Jun;26(6):845-8.Полный текст  Аннотация

588. Qu J, Wu C, Li X, et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Nov 19;71(16):2255-8.Полный текст  Аннотация

589. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020 Jun 25;(6):CD013652.Полный текст  Аннотация

590. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: interim guidance. 2020 [internet publication].Полный текст

591. World Health Organization. Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing. 2022 [internet publication].Полный текст

592. Government of the United Kingdom. Order coronavirus (COVID-19) rapid lateral flow tests. 2022 [internet publication].Полный текст

593. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: antigen testing. 2021 [internet publication].Полный текст

594. Centers for Disease Control and Prevention. Interim guidance for antigen testing for SARS-CoV-2. 2021 [internet publication].Полный текст

595. US Food and Drug Administration. Potential for false positive results with antigen tests for rapid detection of SARS-CoV-2: letter to clinical laboratory staff and health care providers. 2020 [internet publication].Полный текст

596. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021 Mar 24;(3):CD013705.Полный текст  Аннотация

597. Mistry DA, Wang JY, Moeser ME, et al. A systematic review of the sensitivity and specificity of lateral flow devices in the detection of SARS-CoV-2. BMC Infect Dis. 2021 Aug 18;21(1):828.Полный текст  Аннотация

598. Fujita-Rohwerder N, Beckmann L, Zens Y, et al. Diagnostic accuracy of rapid point-of-care tests for diagnosis of current SARS-CoV-2 infections in children: a systematic review and meta-analysis. BMJ Evid Based Med. 2022 Jan 18 [Epub ahead of print].Полный текст  Аннотация

599. García-Fiñana M, Hughes DM, Cheyne CP, et al. Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study. BMJ. 2021 Jul 6;374:n1637.Полный текст  Аннотация

600. Wagenhäuser I, Knies K, Rauschenberger V, et al. Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR. EBioMedicine. 2021 Jun 26;69:103455.Полный текст  Аннотация

601. Brümmer LE, Katzenschlager S, Gaeddert M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis. PLoS Med. 2021 Aug;18(8):e1003735.Полный текст  Аннотация

602. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief. 2020 [internet publication].Полный текст

603. Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020 Jul 1;370:m2516.Полный текст  Аннотация

604. Poon LC, Yang H, Kapur A, et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: information for healthcare professionals. Int J Gynaecol Obstet. 2020 Jun;149(3):273-86.Полный текст  Аннотация

605. Sadiq Z, Rana S, Mahfoud Z, et al. Systematic review and meta-analysis of chest radiograph (CXR) findings in COVID-19. Clin Imaging. 2021 Jul 27;80:229-38.Полный текст  Аннотация

606. Islam N, Ebrahimzadeh S, Salameh JP, et al. Thoracic imaging tests for the diagnosis of COVID-19. Cochrane Database Syst Rev. 2021 Mar 16;(3):CD013639.Полный текст  Аннотация

607. World Health Organization. Use of chest imaging in COVID-19: a rapid advice guide. 2020 [internet publication].Полный текст

608. Centre for Evidence-Based Medicine; Park JY, Freer R, Stevens R, et al. The accuracy of chest CT in the diagnosis of COVID-19: an umbrella review. 2021 [internet publication].Полный текст

609. Tavare AN, Braddy A, Brill S, et al. Managing high clinical suspicion COVID-19 inpatients with negative RT-PCR: a pragmatic and limited role for thoracic CT. Thorax. 2020 Jul;75(7):537-8.Полный текст  Аннотация

610. American College of Radiology. ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection. 2020 [internet publication].Полный текст

611. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020 Sep;92(9):1518-24.Полный текст  Аннотация

612. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020 Apr;80(4):388-93.Полный текст  Аннотация

613. Long C, Xu H, Shen Q, et al. Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol. 2020 Mar 25;126:108961.Полный текст  Аннотация

614. Chen C, Zhu C, Yan D, et al. The epidemiological and radiographical characteristics of asymptomatic infections with the novel coronavirus (COVID-19): a systematic review and meta-analysis. Int J Infect Dis. 2021 Mar;104:458-64.Полный текст  Аннотация

615. Oshay RR, Chen MYC, Fields BKK, et al. COVID-19 in pregnancy: a systematic review of chest CT findings and associated clinical features in 427 patients. Clin Imaging. 2021 Jan 13;75:75-82.Полный текст  Аннотация

616. Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020 Jun;92(6):612-7.Полный текст  Аннотация

617. Ojha V, Mani A, Pandey NN, et al. CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients. Eur Radiol. 2020 Nov;30(11):6129-38.Полный текст  Аннотация

618. Garg M, Gupta P, Maralakunte M, et al. Diagnostic accuracy of CT and radiographic findings for novel coronavirus 2019 pneumonia: systematic review and meta-analysis. Clin Imaging. 2020 Nov 11;72:75-82.Полный текст  Аннотация

619. Hossein H, Ali KM, Hosseini M, et al. Value of chest computed tomography scan in diagnosis of COVID-19: a systematic review and meta-analysis. Clin Transl Imaging. 2020 Oct 12:1-13.Полный текст  Аннотация

620. Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020 Jul 28;71(15):756-61.Полный текст  Аннотация

621. Wang JG, Mo YF, Su YH, et al. Computed tomography features of COVID-19 in children: a systematic review and meta-analysis. Medicine (Baltimore). 2021 Sep 24;100(38):e22571.Полный текст  Аннотация

622. Ghodsi A, Bijari M, Alamdaran SA, et al. Chest computed tomography findings of COVID-19 in children younger than 1 year: a systematic review. World J Pediatr. 2021 May 7 [Epub ahead of print].Полный текст  Аннотация

623. Gil-Rodríguez J, Pérez de Rojas J, Aranda-Laserna P, et al. Ultrasound findings of lung ultrasonography in COVID-19: a systematic review. Eur J Radiol. 2022 Jan 20;148:110156.Полный текст  Аннотация

624. Moro F, Buonsenso D, Moruzzi MC, et al. How to perform lung ultrasound in pregnant women with suspected COVID-19 infection. Ultrasound Obstet Gynecol. 2020 May;55(5):593-8.Полный текст  Аннотация

625. Denina M, Scolfaro C, Silvestro E, et al. Lung ultrasound in children with COVID-19. Pediatrics. 2020 Jul;146(1):e20201157.Полный текст  Аннотация

626. Caroselli C, Blaivas M, Falzetti S. Diagnostic imaging in newborns, children and adolescents infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): is there a realistic alternative to lung high-resolution computed tomography (HRCT) and chest x-rays? A systematic review of the literature. Ultrasound Med Biol. 2021 Jul 24 [Epub ahead of print].Полный текст  Аннотация

627. Pillai K, Hewage S, Harky A. The role of the lung ultrasound in coronavirus disease 2019: a systematic review. J Med Ultrasound. 2020 Oct-Dec;28(4):207-12.Полный текст  Аннотация

628. Song G, Qiao W, Wang X, et al. Association of lung ultrasound score with mortality and severity of COVID-19: a meta-analysis and trial sequential analysis. Int J Infect Dis. 2021 Jun 16 [Epub ahead of print].Полный текст  Аннотация

629. Park GS, Ku K, Baek SH, et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2. J Mol Diagn. 2020 Jun;22(6):729-35.Полный текст  Аннотация

630. Baek YH, Um J, Antigua KJC, et al. Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. Emerg Microbes Infect. 2020 Apr 20:1-31.Полный текст  Аннотация

631. Lu R, Wu X, Wan Z, et al. A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2. Int J Mol Sci. 2020 Apr 18;21(8).Полный текст  Аннотация

632. Baba MM, Bitew M, Fokam J, et al. Diagnostic performance of a colorimetric RT-LAMP for the identification of SARS-CoV-2: a multicenter prospective clinical evaluation in sub-Saharan Africa. EClinicalMedicine. 2021 Aug 28;40:101101.Полный текст  Аннотация

633. Subali AD, Wiyono L. Reverse Transcriptase Loop Mediated Isothermal AmplifiCation (RT-LAMP) for COVID-19 diagnosis: a systematic review and meta-analysis. Pathog Glob Health. 2021 Jun 4:1-11.Полный текст  Аннотация

634. Ganbaatar U, Liu C. CRISPR-based COVID-19 testing: toward next-generation point-of-care diagnostics Front Cell Infect Microbiol. 2021 Apr 30;11:663949.Полный текст  Аннотация

635. Wang S, Hu J, Sui C, et al. Accuracy of clustered regularly interspaced short palindromic repeats (CRISPR) to diagnose COVID-19, a meta-analysis. Microb Pathog. 2022 Mar 25;165:105498.Полный текст  Аннотация

636. Huang PY, Yin X, Huang YT, et al. Evaluation of CRISPR-based assays for rapid detection of SARS-CoV-2: a systematic review and meta-analysis. Yonsei Med J. 2022 May;63(5):480-9.Полный текст  Аннотация

637. Abumeeiz M, Elliott L, Olla P. Use of breath analysis for diagnosing COVID-19: opportunities, challenges, and considerations for future pandemic responses. Disaster Med Public Health Prep. 2021 Oct 15:1-4.Полный текст  Аннотация

638. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first COVID-19 diagnostic test using breath samples. 2022 [internet publication].Полный текст

639. Udeh R, Advani S, de Guadiana Romualdo LG, et al. Calprotectin, an emerging biomarker of interest in COVID-19: a systematic review and meta-analysis. J Clin Med. 2021 Feb 15;10(4):775.Полный текст  Аннотация

640. Mao Q, Wang C, Wen W, et al. A meta-analysis of the association between calprotectin and the severity of COVID-19. J Infect. 2022 Jan 21 [Epub ahead of print].Полный текст  Аннотация

641. Xie Y, Wang Z, Liao H, et al. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis. 2020 Aug 31;20(1):640.Полный текст  Аннотация

642. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-20.Полный текст  Аннотация

643. Islam MA, Kundu S, Alam SS, et al. Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of 17515 patients. PLoS One. 2021;16(4):e0249788.Полный текст  Аннотация

644. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020 Apr 23;382(17):1663-5.Полный текст  Аннотация

645. Song WJ, Hui CKM, Hull JH, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med. 2021 May;9(5):533-44.Полный текст  Аннотация

646. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7;323(11):1061-9.Полный текст  Аннотация

647. Grant MC, Geoghegan L, Arbyn M, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020 Jun 23;15(6):e0234765.Полный текст  Аннотация

648. Talukder A, Razu SR, Alif SM, et al. Association between symptoms and severity of disease in hospitalised novel coronavirus (COVID-19) patients: a systematic review and meta-analysis. J Multidiscip Healthc. 2022 May 12;15:1101-10.Полный текст  Аннотация

649. Cardoso CC, Rossi ÁD, Galliez RM, et al. Olfactory dysfunction in patients with mild COVID-19 during Gamma, Delta, and Omicron waves in Rio de Janeiro, Brazil. JAMA. 2022 Jun 24 [Epub ahead of print].Полный текст  Аннотация

650. Hariyanto TI, Rizki NA, Kurniawan A. Anosmia/hyposmia is a good predictor of coronavirus disease 2019 (COVID-19) infection: a meta-analysis. Int Arch Otorhinolaryngol. 2021 Jan;25(1):e170-4.Полный текст  Аннотация

651. Esmaeili M, Abdi F, Shafiee G, et al. Olfactory and gustatory dysfunction in 2019 novel coronavirus: an updated systematic review and meta-analysis. Int J Prev Med. 2021 Dec 14;12:170.Полный текст  Аннотация

652. Agyeman AA, Chin KL, Landersdorfer CB, et al. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Aug;95(8):1621-31.Полный текст  Аннотация

653. Eliezer M, Hautefort C, Hamel AL, et al. Sudden and complete olfactory loss function as a possible symptom of COVID-19. JAMA Otolaryngol Head Neck Surg. 2020 Jul 1;146(7):674-5.Полный текст  Аннотация

654. Santos REA, da Silva MG, do Monte Silva MCB, et al. Onset and duration of symptoms of loss of smell/taste in patients with COVID-19: a systematic review. Am J Otolaryngol. 2021 Jan 6;42(2):102889.Полный текст  Аннотация

655. Jafar A, Lasso A, Shorr R, et al. Olfactory recovery following infection with COVID-19: a systematic review. PLoS One. 2021 Nov 9;16(11):e0259321.Полный текст  Аннотация

656. Renaud M, Thibault C, Le Normand F, et al. Clinical outcomes for patients with anosmia 1 year after COVID-19 diagnosis. JAMA Netw Open. 2021 Jun 1;4(6):e2115352.Полный текст  Аннотация

657. Tan HQM, Pendolino AL, Andrews PJ, et al. Prevalence of olfactory dysfunction and quality of life in hospitalised patients 1 year after SARS-CoV-2 infection: a cohort study. BMJ Open. 2022 Jan 25;12(1):e054598.Полный текст  Аннотация

658. Walker A, Kelly C, Pottinger G, et al. Parosmia: a common consequence of covid-19. BMJ. 2022 Apr 27;377:e069860.Полный текст  Аннотация

659. Ferraro S, Tuccori M, Convertino I, et al. Olfactory and gustatory impairments in COVID-19 patients: role in early diagnosis and interferences by concomitant drugs. Br J Clin Pharmacol. 2021 May;87(5):2186-8.Полный текст  Аннотация

660. Yan Q, Qiu D, Liu X, et al. Prevalence of smell or taste dysfunction among children with COVID-19 infection: a systematic review and meta-analysis. Front Pediatr. 2021 Aug 3;9:686600.Полный текст  Аннотация

661. Mutiawati E, Syahrul S, Fahriani M, et al. Global prevalence and pathogenesis of headache in COVID-19: a systematic review and meta-analysis. F1000Res. 2020 Nov 12;9:1316.Полный текст  Аннотация

662. Parisi S, Borrelli R, Bianchi S, et al. Viral arthritis and COVID-19. Lancet Rheumatol. 2020 Nov;2(11):e655-7.Полный текст  Аннотация

663. Chaudhry ZS, Nellessen N, Reis C, et al. The development of inflammatory arthritis following SARS-CoV-2 infection: a systematic review of the literature. Fam Pract. 2022 Apr 8 [Epub ahead of print]. Аннотация

664. Tariq R, Saha S, Furqan F, et al. Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Aug;95(8):1632-48.Полный текст  Аннотация

665. Chen A, Agarwal A, Ravindran N, et al. Are gastrointestinal symptoms specific for coronavirus infection? A prospective case-control study from the United States. Gastroenterology. 2020 Sep;159(3):1161-3.Полный текст  Аннотация

666. Aziz M, Haghbin H, Lee-Smith W, et al. Gastrointestinal predictors of severe COVID-19: systematic review and meta-analysis. Ann Gastroenterol. 2020 Nov-Dec;33(6):615-30.Полный текст  Аннотация

667. Zeng W, Qi K, Ye M, et al. Gastrointestinal symptoms are associated with severity of coronavirus disease 2019: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2021 Jan 18 [Epub ahead of print].Полный текст  Аннотация

668. Shehab M, Alrashed F, Shuaibi S, et al. Gastroenterological and hepatic manifestations of patients with COVID-19, prevalence, mortality by country, and intensive care admission rate: systematic review and meta-analysis. BMJ Open Gastroenterol. 2021 Mar;8(1):e000571.Полный текст  Аннотация

669. Wang Y, Li Y, Zhang Y, et al. Are gastrointestinal symptoms associated with higher risk of mortality in COVID-19 patients? A systematic review and meta-analysis. BMC Gastroenterol. 2022 Mar 7;22(1):106.Полный текст  Аннотация

670. Guotao L, Xingpeng Z, Zhihui D, et al. SARS-CoV-2 infection presenting with hematochezia. Med Mal Infect. 2020 May;50(3):293-6.Полный текст  Аннотация

671. Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y). 2022 Jun 10;3(6):371-87.Полный текст  Аннотация

672. Shao SC, Lai CC, Chen YH, et al. Prevalence, incidence and mortality of delirium in patients with COVID-19: A systematic review and meta-analysis. Age Ageing. 2021 May 12 [Epub ahead of print].Полный текст  Аннотация

673. Pun BT, Badenes R, Heras La Calle G, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. Lancet Respir Med. 2021 Mar;9(3):239-50.Полный текст  Аннотация

674. Cénat JM, Blais-Rochette C, Kokou-Kpolou CK, et al. Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: a systematic review and meta-analysis. Psychiatry Res. 2020 Nov 26;295:113599.Полный текст  Аннотация

675. Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020 Oct;7(10):875-82.Полный текст  Аннотация

676. Nasiri N, Sharifi H, Bazrafshan A, et al. Ocular manifestations of COVID-19: a systematic review and meta-analysis. J Ophthalmic Vis Res. 2021 Jan-Mar;16(1):103-12.Полный текст  Аннотация

677. Inomata T, Kitazawa K, Kuno T, et al. Clinical and prodromal ocular symptoms in coronavirus disease: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):29.Полный текст  Аннотация

678. Ma N, Li P, Wang X, et al. Ocular manifestations and clinical characteristics of children with laboratory-confirmed COVID-19 in Wuhan, China. JAMA Ophthalmol. 2020 Oct 1;138(10):1079-86.Полный текст  Аннотация

679. Zhong Y, Wang K, Zhu Y, et al. Ocular manifestations in COVID-19 patients: A systematic review and meta-analysis. Travel Med Infect Dis. 2021 Nov-Dec;44:102191.Полный текст  Аннотация

680. Sen S, Kannan NB, Kumar J, et al. Retinal manifestations in patients with SARS-CoV-2 infection and pathogenetic implications: a systematic review. Int Ophthalmol. 2021 Aug 11 [Epub ahead of print].Полный текст  Аннотация

681. Ullah I, Sohail A, Shah MUFA, et al. Central retinal vein occlusion in patients with COVID-19 infection: a systematic review. Ann Med Surg (Lond). 2021 Oct 8:102898.Полный текст  Аннотация

682. Modjtahedi BS, Do D, Luong TQ, et al. Changes in the incidence of retinal vascular occlusions after COVID-19 diagnosis. JAMA Ophthalmol. 2022 Apr 14 [Epub ahead of print].Полный текст  Аннотация

683. Almufarrij I, Munro KJ. One year on: an updated systematic review of SARS-CoV-2, COVID-19 and audio-vestibular symptoms. Int J Audiol. 2021 Mar 22:1-11.Полный текст  Аннотация

684. Meng X, Wang J, Sun J, et al. COVID-19 and sudden sensorineural hearing loss: a systematic review. Front Neurol. 2022 Apr 28;13:883749.Полный текст  Аннотация

685. Casey K, Iteen A, Nicolini R, et al. COVID-19 pneumonia with hemoptysis: acute segmental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med. 2020 Jul;38(7):1544.Полный текст  Аннотация

686. Bandhala Rajan M, Kumar-M P, Bhardwaj A. The trend of cutaneous lesions during COVID-19 pandemic: lessons from a meta-analysis and systematic review. Int J Dermatol. 2020 Nov;59(11):1358-70.Полный текст  Аннотация

687. Kashetsky N, Mukovozov IM, Bergman J. Chilblain-like lesions (CLL) associated with COVID-19 ("COVID toes"): a systematic review. J Cutan Med Surg. 2021 Apr 13 [Epub ahead of print].Полный текст  Аннотация

688. Visconti A, Bataille V, Rossi N, et al. Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection. Br J Dermatol 2021 May;184(5):880-7.Полный текст

689. Schwartzberg LN, Advani S, Clancy DC, et al. A systematic review of dermatologic manifestations among adult patients with COVID-19 diagnosis. Skin Health Dis. 2021 Jun;1(2):e20.Полный текст  Аннотация

690. Shah S, Akhade K, Ganguly S, et al. Cutaneous manifestations associated with COVID-19 in children: A systematic review. J Family Med Prim Care. 2021 Jan;10(1):93-101.Полный текст  Аннотация

691. Discepolo V, Catzola A, Pierri L, et al. Bilateral chilblain-like lesions of the toes characterized by microvascular remodeling in adolescents during the COVID-19 pandemic. JAMA Netw Open. 2021 Jun 1;4(6):e2111369.Полный текст  Аннотация

692. Gehlhausen JR, Little AJ, Ko CJ, et al. Lack of association between pandemic chilblains and SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2122090119.Полный текст  Аннотация

693. Christie B. Sixty seconds on . . . covid toe. BMJ. 2022 Mar 21;376:o742.Полный текст  Аннотация

694. Erbaş GS, Botsali A, Erden N, et al. COVID-19-related oral mucosa lesions among confirmed SARS-CoV-2 patients: a systematic review. Int J Dermatol. 2021 Sep 22 [Epub ahead of print].Полный текст  Аннотация

695. Holcomb ZE, Hussain S, Huang JT, et al. Reactive infectious mucocutaneous eruption associated with SARS-CoV-2 infection. JAMA Dermatol. 2021 May 1;157(5):603-5.Полный текст  Аннотация

696. Mashayekhi F, Seirafianpour F, Pour Mohammad A, et al. Severe and life-threatening COVID-19-related mucocutaneous eruptions: a systematic review. Int J Clin Pract. 2021 Aug 19:e14720.Полный текст  Аннотация

697. Bhujel N, Zaheer K, Singh RP. Oral mucosal lesions in patients with COVID-19: a systematic review. Br J Oral Maxillofac Surg. 2021 Jun 25 [Epub ahead of print].Полный текст  Аннотация

698. Creta M, Sagnelli C, Celentano G, et al. SARS-CoV-2 infection affects the lower urinary tract and male genital system: a systematic review. J Med Virol. 2021 May;93(5):3133-42.Полный текст  Аннотация

699. Haghpanah A, Masjedi F, Salehipour M, et al. Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms? A systematic review. Prostate Cancer Prostatic Dis. 2021 May 18 [Epub ahead of print].Полный текст  Аннотация

700. Xie Y, Mirzaei M, Kahrizi MS, et al. SARS-CoV-2 effects on sperm parameters: a meta-analysis study. J Assist Reprod Genet. 2022 Jun 18 [Epub ahead of print].Полный текст  Аннотация

701. US Food and Drug Administration. Genetic variants of SARS-CoV-2 may lead to false negative results with molecular tests for detection of SARS-CoV-2: letter to clinical laboratory staff and health care providers. 2021 [internet publication].Полный текст

702. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: molecular diagnostic testing. 2020 [internet publication].Полный текст

703. Danwang C, Endomba FT, Nkeck JR, et al. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020 Aug 31;8:37.Полный текст  Аннотация

704. Zuin M, Rigatelli G, Quadretti L, et al. Prognostic role of anemia in COVID-19 patients: a meta-analysis. Infect Dis Rep. 2021 Oct 31;13(4):930-7.Полный текст  Аннотация

705. Foy BH, Carlson JCT, Reinertsen E, et al. Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection. JAMA Netw Open. 2020 Sep 1;3(9):e2022058.Полный текст  Аннотация

706. Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry A. 2020 Aug;97(8):772-6.Полный текст  Аннотация

707. Chen W, Li Z, Yang B, et al. Delayed-phase thrombocytopenia in patients of coronavirus disease 2019 (COVID-19). Br J Haematol. 2020 Jul;190(2):179-84.Полный текст  Аннотация

708. Chen D, Li X, Song Q, et al. Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China. JAMA Netw Open. 2020 Jun 1;3(6):e2011122.Полный текст  Аннотация

709. Alemzadeh E, Alemzadeh E, Ziaee M, et al. The effect of low serum calcium level on the severity and mortality of Covid patients: a systematic review and meta-analysis. Immun Inflamm Dis. 2021 Sep 17 [Epub ahead of print].Полный текст  Аннотация

710. Akbar MR, Pranata R, Wibowo A, et al. The prognostic value of hyponatremia for predicting poor outcome in patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Jun 14;8:666949.Полный текст  Аннотация

711. Lazarus G, Audrey J, Kharisma Wangsaputra V, et al. High admission blood glucose independently predicts poor prognosis in COVID-19 patients: a systematic review and dose-response meta-analysis. Diabetes Res Clin Pract. 2020 Dec 9:108561.Полный текст  Аннотация

712. Handayani DR, Juliastuti H, Nawangsih EN, et al. Prognostic value of fasting hyperglycemia in patients with COVID-19: diagnostic test accuracy meta-analysis. Obes Med. 2021 Apr 4:100333.Полный текст  Аннотация

713. Klonoff DC, Messler JC, Umpierrez GE, et al. Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis. Diabetes Care. 2021 Feb;44(2):578-85.Полный текст  Аннотация

714. Nugroho J, Wardhana A, Mulia EP, et al. Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: a meta-analysis. Clin Hemorheol Microcirc. 2021;77(2):221-31.Полный текст  Аннотация

715. Shah S, Shah K, Patel SB, et al. Elevated D-dimer levels are associated with increased risk of mortality in COVID-19: a systematic review and meta-analysis. Cardiol Rev. 2020 Nov/Dec;28(6):295-302. Аннотация

716. Leonard-Lorant I, Delabranche X, Severac F, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. Radiology. 2020 Apr 23:201561.Полный текст  Аннотация

717. Mucha SR, Dugar S, McCrae K, et al. Coagulopathy in COVID-19. Cleve Clin J Med. 2020 Jul 31;87(8):461-8.Полный текст  Аннотация

718. Zinellu A, Paliogiannis P, Carru C, et al. INR and COVID-19 severity and mortality: a systematic review with meta-analysis and meta-regression. Adv Med Sci. 2021 Jul 21;66(2):372-80.Полный текст  Аннотация

719. Rostami M, Mansouritorghabeh H, Parsa-Kondelaji M. High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis. Clin Exp Med. 2021 Nov 6 [Epub ahead of print].Полный текст  Аннотация

720. Wungu CDK, Khaerunnisa S, Putri EAC, et al. Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19. Int J Infect Dis. 2021 Mar 9;105:551-9.Полный текст  Аннотация

721. Yitbarek GY, Walle Ayehu G, Asnakew S, et al. The role of C-reactive protein in predicting the severity of COVID-19 disease: a systematic review. SAGE Open Med. 2021 Oct 11;9:20503121211050755.Полный текст  Аннотация

722. Smilowitz NR, Kunichoff D, Garshick M, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 Jan 15 [Epub ahead of print].Полный текст  Аннотация

723. Soraya GV, Ulhaq ZS. Interleukin-6 levels in children developing SARS-CoV-2 infection. Pediatr Neonatol. 2020 Jun;61(3):253-4.Полный текст  Аннотация

724. Qin R, He L, Yang Z, et al. Identification of parameters representative of immune dysfunction in patients with severe and fatal COVID-19 infection: a systematic review and meta-analysis. Clin Rev Allergy Immunol. 2022 Jan 18 [Epub ahead of print].Полный текст  Аннотация

725. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020 May;55(5):1169-74.Полный текст  Аннотация

726. Cheng L, Li H, Li L, et al. Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Lab Anal. 2020 Oct 19:e23618.Полный текст  Аннотация

727. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-4.Полный текст  Аннотация

728. Fu J, Huang PP, Zhang S, et al. The value of serum amyloid A for predicting the severity and recovery of COVID-19. Exp Ther Med. 2020 Oct;20(4):3571-7.Полный текст  Аннотация

729. Li Y, Xiaojing H, Zhuanyun L, et al. Prognostic value of serum amyloid A in COVID-19: a meta-analysis. Medicine (Baltimore). 2022 Feb 18;101(7):e28880.Полный текст  Аннотация

730. Kumar J, Meena J, Yadav A, et al. Radiological findings of COVID-19 in children: a systematic review and meta-analysis. J Trop Pediatr. 2020 Jul 21 [Epub ahead of print].Полный текст  Аннотация

731. Kim H, Hong H, Yoon SH. Diagnostic performance of CT and reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: a meta-analysis. Radiology. 2020 Apr 17:201343.Полный текст  Аннотация

732. Lv M, Wang M, Yang N, et al. Chest computed tomography for the diagnosis of patients with coronavirus disease 2019 (COVID-19): a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):622.Полный текст  Аннотация

733. Mair MDD, Hussain M, Siddiqui S, et al. A systematic review and meta-analysis comparing the diagnostic accuracy of initial RT-PCR and CT scan in suspected COVID-19 patients. Br J Radiol. 2020 Dec 22:20201039.Полный текст  Аннотация

734. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020 Feb 26:200642.Полный текст  Аннотация

735. US Food and Drug Administration. Stop using Innova Medical Group SARS-CoV-2 antigen rapid qualitative test: FDA safety communication. 2021 [internet publication].Полный текст

736. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes antigen test as first over-the-counter fully at-home diagnostic test for COVID-19. 2020 [internet publication].Полный текст

737. Jari R, Alfuraih AM, McLaughlan JR. The diagnostic performance of lung ultrasound for detecting COVID-19 in emergency departments: a systematic review and meta-analysis. J Clin Ultrasound. 2022 Mar 9 [Epub ahead of print].Полный текст  Аннотация

738. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first COVID-19 test for self-testing at home. 2020 [internet publication].Полный текст

739. Centre for Evidence-Based Medicine; Heneghan C, Pluddemann A, Mahtani KR. Differentiating viral from bacterial pneumonia. 2020 [internet publication].Полный текст

740. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging. 2020 May;101(5):263-8.Полный текст  Аннотация

741. Pormohammad A, Ghorbani S, Khatami A, et al. Comparison of influenza type A and B with COVID-19: a global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Rev Med Virol. 2020 Oct 9:e2179.Полный текст  Аннотация

742. Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 era. JAMA. 2020 Oct 6;324(13):1342-3.Полный текст  Аннотация

743. Song X, Delaney M, Shah RK, et al. Comparison of clinical features of COVID-19 vs seasonal influenza A and B in US children. JAMA Netw Open. 2020 Sep 1;3(9):e2020495.Полный текст  Аннотация

744. Czubak J, Stolarczyk K, Orzeł A, et al. Comparison of the clinical differences between COVID-19, SARS, influenza, and the common cold: a systematic literature review. Adv Clin Exp Med. 2021 Jan;30(1):109-14.Полный текст  Аннотация

745. Beltrán-Corbellini Á, Chico-García JL, Martínez-Poles J, et al. Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicenter PCR-based case-control study. Eur J Neurol. 2020 Sep;27(9):1738-41.Полный текст  Аннотация

746. Guan Z, Chen C, Li Y, et al. Impact of coinfection with SARS-CoV-2 and influenza on disease severity: a systematic review and meta-analysis. Front Public Health. 2021 Dec 10;9:773130.Полный текст  Аннотация

747. Dao TL, Hoang VT, Colson P, et al. Co-infection of SARS-CoV-2 and influenza viruses: a systematic review and meta-analysis. J Clin Virol Plus. 2021 Sep;1(3):100036.Полный текст  Аннотация

748. Liu M, Zeng W, Wen Y, et al. COVID-19 pneumonia: CT findings of 122 patients and differentiation from influenza pneumonia. Eur Radiol. 2020 Oct;30(10):5463-9.Полный текст  Аннотация

749. Yin Z, Kang Z, Yang D, et al. A comparison of clinical and chest CT findings in patients with influenza A (H1N1) virus infection and coronavirus disease (COVID-19). AJR Am J Roentgenol. 2020 May 26:1-7.Полный текст  Аннотация

750. Luo Y, Yuan X, Xue Y, et al. Using the diagnostic model based on routine laboratory tests to distinguish patients infected with SARS-CoV-2 from those infected with influenza virus. Int J Infect Dis. 2020 May 1;95:436-40.Полный текст  Аннотация

751. Zarei F, Reza J, Sefidbakht S, et al. Aspiration pneumonia or COVID-19 infection: a diagnostic challenge. Acad Radiol. 2020 Jul;27(7):1046.Полный текст  Аннотация

752. National Institute for Health and Care Excellence. COVID-19 rapid guideline: delivery of systemic anticancer treatments. 2020 [internet publication].Полный текст

753. Kaya T, Dilek A, Ozaras R, et al. COVID 19 and febrile neutropenia: case report and systematic review. Travel Med Infect Dis. 2022 Mar 7;47:102305.Полный текст  Аннотация

754. Fistera D, Härtl A, Pabst D, et al. What about the others: differential diagnosis of COVID-19 in a German emergency department. BMC Infect Dis. 2021 Sep 17;21(1):969.Полный текст  Аннотация

755. World Health Organization. Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022. 2022 [internet publication].Полный текст

756. UK Health Security Agency. People with symptoms of a respiratory infection including COVID-19. 2022 [internet publication].Полный текст

757. Centers for Disease Control and Prevention. COVID-19: quarantine and isolation. 2022 [internet publication].Полный текст

758. Kwon KT, Ko JH, Shin H, et al. Drive-through screening center for COVID-19: a safe and efficient screening system against massive community outbreak. J Korean Med Sci. 2020 Mar 23;35(11):e123.Полный текст  Аннотация

759. Medicines and Healthcare products Regulatory Agency. Don’t rely on temperature screening products for detection of coronavirus (COVID-19), says MHRA. 2020 [internet publication].Полный текст

760. Aggarwal N, Garg M, Dwarakanathan V, et al. Diagnostic accuracy of non-contact infrared thermometers and thermal scanners: a systematic review and meta-analysis. J Travel Med. 2020 Oct 10 [Epub ahead of print].Полный текст  Аннотация

761. Khan DS, Saultry MB, Adams DS, et al. Comparative accuracy testing of non-contact infrared thermometers and temporal artery thermometers in an adult hospital setting. Am J Infect Control. 2021 May;49(5):597-602.Полный текст  Аннотация

762. World Health Organization. Therapeutics and COVID-19: living guideline. 2021 [internet publication].Полный текст

763. Rochwerg B, Siemieniuk RA, Agoritsas T, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020 Sep 4;370:m3379.Полный текст  Аннотация

764. Rochwerg B, Siemieniuk RA, Lamontagne R, et al. Update to living WHO guideline on drugs for covid-19. BMJ. 2021 Jul 6;374:n1703. Аннотация

765. Mahase E. Covid-19: is it safe to reduce the self-isolation period? BMJ. 2021 Dec 30;375:n3164.Полный текст  Аннотация

766. Suter F, Consolaro E, Pedroni S, et al. A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: a retrospective observational matched-cohort study. EClinicalMedicine. 2021 Jun 9:100941.Полный текст  Аннотация

767. World Health Organization. Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance. 2020 [internet publication].Полный текст

768. Abuelgasim H, Albury C, Lee J. Effectiveness of honey for symptomatic relief in upper respiratory tract infections: a systematic review and meta-analysis. BMJ Evid Based Med. 2021 Apr;26(2):57-64.Полный текст  Аннотация

769. Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA. 2020 Jun 23;323(24):2512-4.Полный текст  Аннотация

770. Webster KE, O'Byrne L, MacKeith S, et al. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev. 2021 Jul 22;(7):CD013877.Полный текст  Аннотация

771. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the omicron variant. 2022 [internet publication].Полный текст

772. US Food and Drug Administration. FDA updates sotrovimab emergency use authorization. 2022 [internet publication].Полный текст

773. McCreary EK, Bariola JR, Wadas RJ, et al. Association of subcutaneous or intravenous administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in adults with COVID-19. JAMA Netw Open. 2022 Apr 1;5(4):e226920.Полный текст  Аннотация

774. Kreuzberger N, Hirsch C, Chai KL, et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;(9):CD013825.Полный текст  Аннотация

775. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA approves first COVID-19 treatment for young children. 2022 [internet publication].Полный текст

776. Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2021 Dec 22 [Epub ahead of print].Полный текст  Аннотация

777. Department of Health and Social Care. Defining the highest-risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group report. 2022 [internet publication].Полный текст

778. Zou Y, Han M, Wang J, et al. Predictive value of frailty in the mortality of hospitalized patients with COVID-19: a systematic review and meta-analysis. Ann Transl Med. 2022 Feb;10(4):166.Полный текст  Аннотация

779. Pranata R, Henrina J, Lim MA, et al. Clinical frailty scale and mortality in COVID-19: a systematic review and dose-response meta-analysis. Arch Gerontol Geriatr. 2021 Mar-Apr;93:104324.Полный текст  Аннотация

780. Rottler M, Ocskay K, Sipos Z, et al. Clinical Frailty Scale (CFS) indicated frailty is associated with increased in-hospital and 30-day mortality in COVID-19 patients: a systematic review and meta-analysis. Ann Intensive Care. 2022 Feb 20;12(1):17.Полный текст  Аннотация

781. Subramaniam A, Shekar K, Afroz A, et al. Frailty and mortality associations in patients with COVID-19: a systematic review and meta-analysis. Intern Med J. 2022 Jan 23 [Epub ahead of print].Полный текст  Аннотация

782. Cosco TD, Best J, Davis D, et al. What is the relationship between validated frailty scores and mortality for adults with COVID-19 in acute hospital care? A systematic review. Age Ageing. 2021 May 5;50(3):608-16.Полный текст  Аннотация

783. Centre for Evidence-Based Medicine; Allsop M, Ziegler L, Fu Y, et al. Is oxygen an effective treatment option to alleviate the symptoms of breathlessness for patients dying with COVID-19 and what are the potential harms? 2020 [internet publication].Полный текст

784. Alhazzani W, Evans L, Alshamsi F, et al. Surviving Sepsis Campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021 Mar 1;49(3):e219-34.Полный текст  Аннотация

785. Ponnapa Reddy M, Subramaniam A, Afroz A, et al. Prone positioning of nonintubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Crit Care Med. 2021 Apr 30 [Epub ahead of print].Полный текст  Аннотация

786. Chua EX, Zahir SMISM, Ng KT, et al. Effect of prone versus supine position in COVID-19 patients: a systematic review and meta-analysis. J Clin Anesth. 2021 Jun 22;74:110406.Полный текст  Аннотация

787. Beran A, Mhanna M, Srour O, et al. Effect of prone positioning on clinical outcomes of non-intubated subjects with COVID-19: a comparative systematic review and meta-analysis. Respir Care. 2021 Nov 9 [Epub ahead of print].Полный текст  Аннотация

788. Li J, Luo J, Pavlov I, et al. Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis. Lancet Respir Med. 2022 Mar 16 [Epub ahead of print].Полный текст  Аннотация

789. Qian ET, Gatto CL, Amusina O, et al. Assessment of awake prone positioning in hospitalized adults with COVID-19: a nonrandomized controlled trial. JAMA Intern Med. 2022 Apr 18 [Epub ahead of print].Полный текст  Аннотация

790. Mojoli F, Mongodi S, Orlando A, et al. Our recommendations for acute management of COVID-19. Crit Care. 2020 May 8;24(1):207.Полный текст  Аннотация

791. Centre for Evidence-Based Medicine; Jones L, Candy B, Roberts N, et al. How can healthcare workers adapt non-pharmacological treatment – whilst maintaining safety – when treating people with COVID-19 and delirium? 2020 [internet publication].Полный текст

792. Public Health England. Mouth care for hospitalised patients with confirmed or suspected COVID-19. 2020 [internet publication].Полный текст

793. Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the Anticoagulation Forum. J Thromb Thrombolysis. 2020 Jul;50(1):72-81.Полный текст  Аннотация

794. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020 Sep;158(3):1143-63.Полный текст  Аннотация

795. American Society Of Hematology. COVID-19 and VTE/anticoagulation: frequently asked questions. 2020 [internet publication].Полный текст

796. Pawlowski C, Venkatakrishnan AJ, Kirkup C, et al. Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients. EClinicalMedicine. 2021 Mar 9:100774.Полный текст  Аннотация

797. Lopes RD, de Barros E Silva PGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021 Jun 4 [Epub ahead of print].Полный текст  Аннотация

798. Kyriakoulis KG, Kollias A, Kyriakoulis IG, et al. Thromboprophylaxis in patients with COVID-19: systematic review of national and international clinical guidance reports. Curr Vasc Pharmacol. 2021 Aug 24 [Epub ahead of print]. Аннотация

799. Flumignan RL, Civile VT, Tinôco JDS, et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2022 Mar 4;(3):CD013739.Полный текст  Аннотация

800. Zeng J, Liu F, Wang Y, et al. The effect of previous oral anticoagulant use on clinical outcomes in COVID-19: a systematic review and meta-analysis. Am J Emerg Med. 2022 Feb 3;54:107-10.Полный текст  Аннотация

801. Wong AY, Tomlinson L, Brown JP, et al. Association between oral anticoagulants and COVID-19-related outcomes: a population-based cohort study. Br J Gen Pract. 2022 Feb 16 [Epub ahead of print].Полный текст  Аннотация

802. Li P, Zhao W, Kaatz S, et al. Factors associated with risk of postdischarge thrombosis in patients with COVID-19. JAMA Netw Open. 2021 Nov 1;4(11):e2135397.Полный текст  Аннотация

803. Ramacciotti E, Barile Agati L, Calderaro D, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022 Jan 1;399(10319):50-9.Полный текст  Аннотация

804. Flumignan RL, Tinôco JDS, Pascoal PI, et al. Prophylactic anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2020 Oct 2;(10):CD013739.Полный текст  Аннотация

805. Moonla C, Sosothikul D, Chiasakul T, et al. Anticoagulation and in-hospital mortality from coronavirus disease 2019: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211008999.Полный текст  Аннотация

806. Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022 Jul;23(7):e334-47.Полный текст  Аннотация

807. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021 Apr;27(4):520-31.Полный текст  Аннотация

808. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020 Oct 6;324(13):1330-41.Полный текст  Аннотация

809. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704.Полный текст  Аннотация

810. Wagner C, Griesel M, Mikolajewska A, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Aug 16;(8):CD014963.Полный текст  Аннотация

811. WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19: interim WHO Solidarity trial results. N Engl J Med. 2021 Feb 11;384(6):497-511.Полный текст  Аннотация

812. WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022 May 2 [Epub ahead of print].Полный текст  Аннотация

813. Ansems K, Grundeis F, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Aug 5;(8):CD014962.Полный текст  Аннотация

814. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637-45.Полный текст  Аннотация

815. REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021 Apr 22;384(16):1491-502.Полный текст  Аннотация

816. Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 Mar 18;(3):CD013881.Полный текст  Аннотация

817. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020 Jul 30;370:m2980.Полный текст  Аннотация

818. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021 Mar 31;372:n858.Полный текст  Аннотация

819. Zeraatkar D, Cusano E, Martínez JPD, et al. Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis. BMJ Medicine 2022 Mar 2;1:e000036.Полный текст

820. Patoulias D, Doumas M, Papadopoulos C, et al. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol. 2021 Aug 24 [Epub ahead of print].Полный текст  Аннотация

821. Selvaraj V, Finn A, Lal A, et al. Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials. EClinicalMedicine. 2022 Jul;49:101489.Полный текст  Аннотация

822. RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022 Feb 12;399(10325):665-76.Полный текст  Аннотация

823. Heath L, Carey M, Lowney AC, et al. Pharmacological strategies used to manage symptoms of patients dying of COVID-19: a rapid systematic review. Palliat Med. 2021 May 13 [Epub ahead of print].Полный текст  Аннотация

824. Abate SM, Ahmed Ali S, Mantfardo B, et al. Rate of intensive care unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis. PLoS One. 2020 Jul 10;15(7):e0235653.Полный текст  Аннотация

825. Armstrong RA, Kane AD, Kursumovic E, et al. Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies. Anaesthesia. 2021 Apr;76(4):537-48.Полный текст  Аннотация

826. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region: case series. N Engl J Med. 2020 May 21;382(21):2012-22.Полный текст  Аннотация

827. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020 May 29;369:m1996.Полный текст  Аннотация

828. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 May 22;369:m1966.Полный текст  Аннотация

829. Chang R, Elhusseiny KM, Yeh YC, et al. COVID-19 ICU and mechanical ventilation patient characteristics and outcomes: a systematic review and meta-analysis. PLoS One. 2021 Feb 11;16(2):e0246318.Полный текст  Аннотация

830. Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020 Sep;4(9):653-61.Полный текст  Аннотация

831. Williams N, Radia T, Harman K, et al. COVID-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. Eur J Pediatr. 2021 Mar;180(3):689-97.Полный текст  Аннотация

832. Schmid B, Griesel M, Fischer AL, et al. Awake prone positioning, high-flow nasal oxygen and non-invasive ventilation as non-invasive respiratory strategies in COVID-19 acute respiratory failure: a systematic review and meta-analysis. J Clin Med. 2022 Jan 13;11(2):391.Полный текст  Аннотация

833. Weerakkody S, Arina P, Glenister J, et al. Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research. Lancet Respir Med. 2021 Nov 9 [Epub ahead of print].Полный текст  Аннотация

834. Schünemann HJ, Khabsa J, Solo K, et al. Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2020 Aug 4;173(3):204-16.Полный текст  Аннотация

835. Ute Muti-Schüenemann GE, Szczeklik W, Solo K, et al. Update alert 3: ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2021 Dec 14 [Epub ahead of print].Полный текст  Аннотация

836. Glenardi G, Chriestya F, Oetoro BJ, et al. Comparison of high-flow nasal oxygen therapy and noninvasive ventilation in COVID-19 patients: a systematic review and meta-analysis. Acute Crit Care. 2022 Feb;37(1):71-83.Полный текст  Аннотация

837. Beran A, Srour O, Malhas SE, et al. High-flow nasal cannula oxygen versus non-invasive ventilation in subjects with COVID-19: a systematic review and meta-analysis of comparative studies. Respir Care. 2022 Mar 22 [Epub ahead of print].Полный текст  Аннотация

838. Perkins GD, Ji C, Connolly BA, et al. Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized clinical trial. JAMA. 2022 Jan 24 [Epub ahead of print].Полный текст  Аннотация

839. Ospina-Tascón GA, Calderón-Tapia LE, García AF, et al. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a randomized clinical trial. JAMA. 2021 Dec 7;326(21):2161-71. Аннотация

840. Winslow RL, Zhou J, Windle EF, et al. SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures. Thorax. 2021 Nov 4 [Epub ahead of print].Полный текст  Аннотация

841. Elsayed HH, Hassaballa AS, Ahmed TA, et al. Variation in outcome of invasive mechanical ventilation between different countries for patients with severe COVID-19: a systematic review and meta-analysis. PLoS One. 2021;16(6):e0252760.Полный текст  Аннотация

842. Xixi NA, Kremmydas P, Xourgia E, et al. Association between timing of intubation and clinical outcomes of critically ill patients: a meta-analysis. J Crit Care. 2022 May 16;71:154062. Аннотация

843. Gattinoni L, Coppola S, Cressoni M, et al. Covid-19 does not lead to a "typical" acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020 May 15;201(10):1299-300.Полный текст  Аннотация

844. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020 Apr 16;24(1):154.Полный текст  Аннотация

845. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020 Jun;46(6):1099-102.Полный текст  Аннотация

846. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020 Jun 9;323(22):2329-30.Полный текст  Аннотация

847. Rello J, Storti E, Belliato M, et al. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J. 2020 May 21;55(5):2001028.Полный текст  Аннотация

848. Tsolaki V, Siempos I, Magira E, et al. PEEP levels in COVID-19 pneumonia. Crit Care. 2020 Jun 6;24(1):303.Полный текст  Аннотация

849. Bos LD, Paulus F, Vlaar APJ, et al. Subphenotyping acute respiratory distress syndrome in patients with COVID-19: consequences for ventilator management. Ann Am Thorac Soc. 2020 Sep;17(9):1161-3.Полный текст  Аннотация

850. Jain A, Doyle DJ. Stages or phenotypes? A critical look at COVID-19 pathophysiology. Intensive Care Med. 2020 May 18;:1-2.Полный текст  Аннотация

851. Bos LDJ, Sjoding M, Sinha P, et al. Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts. Lancet Respir Med. 2021 Oct 12 [Epub ahead of print].Полный текст  Аннотация

852. Rice TW, Janz DR. In defense of evidence-based medicine for the treatment of COVID-19 ARDS. Ann Am Thorac Soc. 2020 Jul;17(7):787-9.Полный текст  Аннотация

853. Dondorp AM, Hayat M, Aryal D, et al. Respiratory support in COVID-19 patients, with a focus on resource-limited settings. Am J Trop Med Hyg. 2020 Jun;102(6):1191-7.Полный текст  Аннотация

854. Carsetti A, Damia Paciarini A, Marini B, et al. Prolonged prone position ventilation for SARS-CoV-2 patients is feasible and effective. Crit Care. 2020 May 15;24(1):225.Полный текст  Аннотация

855. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020 May;8(5):518-26.Полный текст  Аннотация

856. Bertini P, Guarracino F, Falcone M, et al. ECMO in COVID-19 patients: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2021 Nov 12 [Epub ahead of print].Полный текст  Аннотация

857. Ling RR, Ramanathan K, Sim JJL, et al. Evolving outcomes of extracorporeal membrane oxygenation during the first 2 years of the COVID-19 pandemic: a systematic review and meta-analysis. Crit Care. 2022 May 23;26(1):147.Полный текст  Аннотация

858. Urner M, Barnett AG, Bassi GL, et al. Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study. BMJ. 2022 May 4;377:e068723.Полный текст  Аннотация

859. Mustafa AK, Alexander PJ, Joshi DJ, et al. Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure. JAMA Surg. 2020 Aug 11;155(10):990-2.Полный текст  Аннотация

860. Kannapadi NV, Jami M, Premraj L, et al. Neurological complications in COVID-19 patients with ECMO support: a systematic review and meta-analysis. Heart Lung Circ. 2021 Oct 28 [Epub ahead of print].Полный текст  Аннотация

861. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-6.Полный текст  Аннотация

862. Zhang S, Li Y, Liu G, et al. Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis. Thromb J. 2021 Nov 24;19(1):91.Полный текст  Аннотация

863. Sarfraz A, Sarfraz Z, Razzack AA, et al. Venous thromboembolism, corticosteroids and COVID-19: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029621993573.Полный текст  Аннотация

864. Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022 Feb 3 [Epub ahead of print].Полный текст  Аннотация

865. Chen L, Jiang H, Zhao Y. Pregnancy with Covid-19: management considerations for care of severe and critically ill cases. Am J Reprod Immunol. 2020 Jul 4:e13299.Полный текст  Аннотация

866. Girolamo RD, Khalil A, Rizzo G, et al. Systematic review and critical evaluation of quality of clinical practice guidelines on the management of SARS-CoV-2 infection in pregnancy. Am J Obstet Gynecol MFM. 2022 Apr 30 [Epub ahead of print].Полный текст  Аннотация

867. Favre G, Pomar L, Qi X, et al. Guidelines for pregnant women with suspected SARS-CoV-2 infection. Lancet Infect Dis. 2020 Jun;20(6):652-3.Полный текст  Аннотация

868. Chen D, Yang H, Cao Y, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet. 2020 May;149(2):130-6. Аннотация

869. Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID-19) infection in pregnancy: information for healthcare professionals. 2021 [internet publication].Полный текст

870. Nana M, Hodson K, Lucas N, et al. Diagnosis and management of covid-19 in pregnancy. BMJ. 2022 Apr 26;377:e069739.Полный текст  Аннотация

871. American Academy of Pediatrics. Management of infants born to mothers with suspected or confirmed COVID-19. 2021 [internet publication].Полный текст

872. Dumitriu D, Emeruwa UN, Hanft E, et al. Outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection at a large medical center in New York City. JAMA Pediatr. 2021 Feb 1;175(2):157-67.Полный текст  Аннотация

873. World Health Organization. Breastfeeding and COVID-19: scientific brief. 2020 [internet publication].Полный текст

874. Ronchi A, Pietrasanta C, Zavattoni M, et al. Evaluation of rooming-in practice for neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection in Italy. JAMA Pediatr. 2021 Mar 1;175(3):260-6.Полный текст  Аннотация

875. World Health Organization. COVID-19 clinical management: living guidance. 2021 [internet publication]Полный текст

876. Chinnadurai R, Ogedengbe O, Agarwal P, et al. Older age and frailty are the chief predictors of mortality in COVID-19 patients admitted to an acute medical unit in a secondary care setting: a cohort study. BMC Geriatr. 2020 Oct 16;20(1):409Полный текст  Аннотация

877. National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. December 2019 [internet publication]Полный текст

878. Hsu CY, Ordoñez JD, Chertow GM, et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008 Apr 2;74(1):101-7Полный текст  Аннотация

879. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. 2021 [internet publication]Полный текст

880. Center for the Study of Traumatic Stress. Taking care of patients during the coronavirus outbreak: a guide for psychiatrists. 2020 [internet publication]Полный текст

881. Shore JH, Schneck CD, Mishkind MC. Telepsychiatry and the coronavirus disease 2019 pandemic-current and future outcomes of the rapid virtualization of psychiatric care. JAMA Psychiatry. 2020 Dec 1;77(12):1211-2Полный текст  Аннотация

882. Hubley S, Lynch SB, Schneck C, et al. Review of key telepsychiatry outcomes. World J Psychiatry. 2016 Jun 22;6(2):269-82Полный текст  Аннотация

883. Fritz Z, Slowther AM, Perkins GD. Resuscitation policy should focus on the patient, not the decision. BMJ. 2017 Feb 28;356:j813.Полный текст  Аннотация

884. National Institute for Health and Care Excellence. Decision making and mental capacity. 2018 [internet publication].Полный текст

885. Department of Health. Mental Capacity Act 2005 [internet publication].Полный текст

886. Social Care Institute for Excellence. Independent mental capacity advocate (IMCA). 2011 [internet publication].Полный текст

887. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2021 [internet publication]Полный текст

888. Department of Health and Social Care. Defining the highest-risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group. 2022 [internet publication]Полный текст

889. World Health Organization. COVID-19 clinical care pathway. 2022 [internet publication]Полный текст

890. Izcovich A, Siemieniuk RA, Bartoszko JJ, et al. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. BMJ Open. 2022 Mar 2;12(3):e048502.Полный текст  Аннотация

891. British Thoracic Society. Advice for healthcare professionals treating people with asthma (adults) in relation to COVID-19. 2020 [internet publication].Полный текст

892. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2021 [internet publication].Полный текст

893. National Institute for Health and Care Excellence. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD). 2020 [internet publication].Полный текст

894. Hasan SS, Capstick T, Zaidi STR, et al. Use of corticosteroids in asthma and COPD patients with or without COVID-19. Respir Med. 2020 Aug-Sep;170:106045.Полный текст  Аннотация

895. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Hobbs R. Inhaled steroids in asthma during the COVID-19 outbreak. 2020 [internet publication].Полный текст

896. National Institute for Health and Care Excellence. COVID-19 rapid guideline: severe asthma. 2020 [internet publication].Полный текст

897. Primary Care Respiratory Society. PCRS pragmatic guidance: diagnosing and managing asthma attacks and people with COPD presenting in crisis during the UK Covid 19 epidemic. 2020 [internet publication].Полный текст

898. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. 2019 [internet publication].Полный текст

899. British Thoracic Society. COPD and COVID-19 for healthcare professionals. 2020 [internet publication].Полный текст

900. Walters JA, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018 Mar 19;(3):CD006897.Полный текст  Аннотация

901. American Heart Association; Heart Failure Society of America; American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. 2020 [internet publication].Полный текст

902. European Society of Cardiology Council on Hypertension. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. 2020 [internet publication].Полный текст

903. British Cardiovascular Society; British Society for Heart Failure. BSH & BCS joint statement on ACEi or ARB in relation to COVID-19. 2020 [internet publication].Полный текст

904. The Renal Association. The Renal Association, UK position statement on COVID-19 and ACE inhibitor/angiotensin receptor blocker use. 2020 [internet publication].Полный текст

905. Clark AL, Kalra PR, Petrie MC, et al. Change in renal function associated with drug treatment in heart failure: national guidance. Heart. 2019 Jun;105(12):904-10.Полный текст  Аннотация

906. European Society of Endocrinology. COVID-19 and endocrine diseases: a statement from the European Society of Endocrinology. 2020 [internet publication].Полный текст

907. American Diabetes Association. COVID-19: If you do get sick, know what to do. 2020 [internet publication].Полный текст

908. Trend Diabetes. Trend releases updated sick-day rules leaflets. 2020 [internet publication].Полный текст

909. Primary Care Diabetes Society. How to advise on sick day rules. 2020 [internet publication].Полный текст

910. NHS England. Diabetes COVID-19 key information: sick day rules. 2020 [internet publication].Полный текст

911. International Diabetes Federation Europe. How to manage diabetes during an illness. 2020 [internet publication].Полный текст

912. Diabetes Australia; Royal Australian College of General Practitioners. Diabetes management during the coronavirus pandemic: be proactive and prepared. 2020 [internet publication].Полный текст

913. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Morris E, Goyder C, et al. Managing diabetes during the COVID-19 pandemic. 2020 [internet publication].Полный текст

914. National Inpatient Diabetes COVID-19 Response Group. Concise advice on inpatient diabetes during COVID-19: front door guidance. 2020 [internet publication].Полный текст

915. Hartmann-Boyce J, Morris E, Goyder C, et al. Diabetes and COVID-19: risks, management, and learnings from other national disasters. Diabetes Care. 2020 Aug;43(8):1695-703.Полный текст  Аннотация

916. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Sep;38(9):1687-93.Полный текст  Аннотация

917. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis. 2016 [internet publication].Полный текст

918. Trend Diabetes. Type 2 diabetes: what to do when you’re ill. 2020 [internet publication].Полный текст

919. NHS London Clinical Networks. Sick day rules: how to manage type 2 diabetes if you become unwell with coronavirus and what to do with your medication. 2020 [internet publication].Полный текст

920. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020 Jun;8(6):546-50.Полный текст  Аннотация

921. Verbrugge FH, Grieten L, Mullens W. Management of the cardiorenal syndrome in decompensated heart failure. Cardiorenal Med. 2014 Dec;4(3-4):176-88Полный текст  Аннотация

922. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010 Dec;6(12):681-94. Аннотация

923. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 2000 Oct;31(10):2307-13.Полный текст  Аннотация

924. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016 Jun;47(6):e98-169.Полный текст  Аннотация

925. Pendlebury ST, Klaus SP, Mather M, et al. Routine cognitive screening in older patients admitted to acute medicine: abbreviated mental test score (AMTS) and subjective memory complaint versus Montreal Cognitive Assessment and IQCODE. Age Ageing. 2015 Nov;44(6):1000-5.Полный текст  Аннотация

926. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972 Nov;1(4):233-8. Аннотация

927. National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and management. 2019 [internet publication].Полный текст

928. National Institute for Health and Clinical Excellence. Dementia: assessment, management and support for people living with dementia and their carers. 2018 [internet publication].Полный текст

929. Scottish Intercollegiate Guidelines Network. Risk reduction and management of delirium: a national clinical guideline. 2019 [internet publication].Полный текст

930. Nova Scotia Health Authority. This is not my Mom. 2012 [internet publication].Полный текст

931. Inouye SK, Schlesinger MJ, Lydon TJ. Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Am J Med. 1999 May;106(5):565-73. Аннотация

932. Bellelli G, Morandi A, Davis DH, et al. Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234 hospitalised older people. Age Ageing. 2014 Jul;43(4):496-502.Полный текст  Аннотация

933. MacLullich AM, Shenkin SD, Goodacre S, et al. The 4 'A's test for detecting delirium in acute medical patients: a diagnostic accuracy study. Health Technol Assess. 2019 Aug;23(40):1-194.Полный текст  Аннотация

934. Public Health England. Coronavirus (COVID-19): admission and care of people in care homes. 2020 [internet publication].Полный текст

935. British Geriatrics Society. Coronavirus: managing delirium in confirmed and suspected cases. 2020 [internet publication].Полный текст

936. Ma H, Huang Y, Cong Z, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42(3):915-37. Аннотация

937. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012 Feb 23;344:e977.Полный текст  Аннотация

938. Van Leeuwen E, Petrovic M, van Driel ML, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018 Mar 30;(3):CD007726.Полный текст  Аннотация

939. Centers for Disease Control and Prevention. Clinical questions about COVID-19: questions and answers – patients with asthma. 2020 [internet publication].Полный текст

940. American Diabetes Association. Diabetes care in the hospital: standards of medical care in diabetes - 2021. Diabetes Care. 2021 Jan;44(Suppl 1):S211-20.Полный текст  Аннотация

941. Joint British Diabetes Societies for inpatient care. The use of variable rate intravenous insulin infusion (VRIII) in medical inpatients. 2014 [internet publication].Полный текст

942. Joint British Diabetes Societies for inpatient care. Inpatient care of the frail older adult with diabetes. 2019 [internet publication].Полный текст

943. National Inpatient Diabetes COVID-19 Response Group. Concise advice on inpatient diabetes during COVID-19 (COVID:Diabetes): guidance for managing inpatient hyperglycaemia. 2020 [internet publication].Полный текст

944. Rehman A, Setter SM, Vue MH. Drug-induced glucose alterations part 2: drug-induced hyperglycemia. Diabetes Spect. 2011 Nov;24(4):234-8.Полный текст

945. National Inpatient Diabetes COVID-19 Response Group. Concise advice on inpatient diabetes during COVID-19 (COVID:Diabetes): guideline for managing DKA using subcutaneous insulin. 2020 [internet publication].Полный текст

946. NHS Digital. National diabetes inpatient audit (NaDIA) - 2019. 2020 [internet publication].Полный текст

947. Joint British Diabetes Societies for inpatient care. The hospital management of hypoglycaemia in adults with diabetes mellitus. 5th ed. 2021 [internet publication].Полный текст

948. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. 2019 [internet publication].Полный текст

949. Rayman G, Vas PR, Baker N, et al. The Ipswich Touch Test: a simple and novel method to identify inpatients with diabetes at risk of foot ulceration. Diabetes Care. 2011 Jul;34(7):1517-8.Полный текст  Аннотация

950. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.Полный текст  Аннотация

951. Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011 May;106(5):906-14. Аннотация

952. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015 May;29(5):459-525.Полный текст  Аннотация

953. National Institute for Health and Care Excellence. Depression in adults with a chronic physical health problem: recognition and management. 2009 [internet publication].Полный текст

954. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th edition. Chichester: Wiley-Blackwell; 2018.

955. Flowers L. Nicotine replacement therapy. Am J Psychiatry Resid J. 2016 Jun;11(6):4-7.Полный текст

956. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469-94. Аннотация

957. Oliveira P, Ribeiro J, Donato H, et al. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry. 2017 Mar 6;16:17.Полный текст  Аннотация

958. National Centre for Smoking Cessation and Training. Smoking cessation and mental health: a briefing for front-line staff. 2014 [internet publication].Полный текст

959. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112-20.Полный текст  Аннотация

960. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014 Feb 19;348:g1626. Аннотация

961. National Institute for Health and Care Excellence. Liaison psychiatry. In: Emergency acute medical care in over 16s: service delivery and organisation. 2018 [internet publication].Полный текст

962. National Confidential Enquiry into Patient Outcome and Death. Treat as one: bridging the gap between mental and physical healthcare in general hospitals. 2017 [internet publication].Полный текст

963. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000 Jul 24;160(14):2101-7.Полный текст  Аннотация

964. Prina AM, Cosco TD, Dening T, et al. The association between depressive symptoms in the community, non-psychiatric hospital admission and hospital outcomes: a systematic review. J Psychosom Res. 2015 Jan;78(1):25-33.Полный текст  Аннотация

965. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust. 2009 Apr 6;190(s7):S54-60. Аннотация

966. World Health Organization. Excess mortality in persons with severe mental disorders. 2016 [internet publication].Полный текст

967. National Institute for Health and Care Excellence. Smoking: acute, maternity and mental health services. 2013 [internet publication].Полный текст

968. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010 Dec;6(12):681-94 Аннотация

969. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 2000 Oct;31(10):2307-13Полный текст  Аннотация

970. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016 May 4;47(6):e98-e169Полный текст  Аннотация

971. O'Driscoll BR, Howard LS, Earis J, et al; British Thoracic Society Emergency Oxygen Guideline Group; BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(suppl 1):ii1-90 Аннотация

972. O'Driscoll BR, Howard LS, Earis J, et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(suppl 1):ii1-90.Полный текст  Аннотация

973. British Thoracic Society. BTS guidance: respiratory support of patients on medical wards. 2020 [internet publication].Полный текст

974. Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018 Apr 28;391(10131):1693-705. Аннотация

975. Siemieniuk RAC, Chu DK, Kim LH, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ. 2018 Oct 24;363:k4169. Аннотация

976. National Institute for Health and Care Excellence. Intravenous fluid therapy in adults in hospital. 2017 [internet publication].Полный текст

977. Chowdhury TA, Cheston H, Claydon A. Managing adults with diabetes in hospital during an acute illness. BMJ. 2017 Jun 22;357:j2551. Аннотация

978. Karslioglu French E, Donihi AC, Korytkowski MT. Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients. BMJ. 2019 May 29;365:l1114.Полный текст  Аннотация

979. Law JP, Pickup L, Townend JN, et al. Anticoagulant strategies for the patient with chronic kidney disease. Clin Med (Lond). 2020 Mar;20(2):151-5.Полный текст  Аннотация

980. National Inpatient Diabetes COVID-19 Response Group. Concise advice on inpatient diabetes during COVID-19 (COVID:Diabetes): dexamethasone/glucocorticosteroid therapy in COVID-19 patients – implications and guidance for the management of blood glucose in people with and without diabetes. 2020 [internet publication]Полный текст

981. Joint British Diabetes Societies for inpatient care. Management of hyperglycaemia and steroid (glucocorticosteroid) therapy. 2021 [internet publication]Полный текст

982. Rayman G, Lumb AN, Kennon B, et al. Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes. Diabet Med. 2021 Jan;38(1):e14378Полный текст  Аннотация

983. Judd LL, Schettler PJ, Brown ES, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014 Oct;171(10):1045-51.Полный текст  Аннотация

984. Kenna HA, Poon AW, de los Angeles CP, et al. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011 Oct;65(6):549-60.Полный текст  Аннотация

985. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006 Oct;81(10):1361-7.Полный текст  Аннотация

986. Fardet L, Nazareth I, Whitaker HJ, et al. Severe neuropsychiatric outcomes following discontinuation of long-term glucocorticoid therapy: a cohort study. J Clin Psychiatry. 2013 Apr;74(4):e281-6. Аннотация

987. US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021 [internet publication].Полный текст

988. World Health Organization. Therapeutics and COVID-19: living guideline. 2022 [internet publication]Полный текст

989. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016 Jul 14;37(27):2129-200.Полный текст  Аннотация

990. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011 Apr;21(2):69-72. Аннотация

991. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J. 2020 May 14;55(5):2000892.Полный текст  Аннотация

992. Centers for Disease Control and Prevention. COVID-19 rebound after Paxlovid treatment. 2022 [internet publication].Полный текст

993. Malden DE, Hong V, Lewin BJ, et al. Hospitalization and emergency department encounters for COVID-19 after Paxlovid treatment: California, December 2021-May 2022. MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):830-3.Полный текст  Аннотация

994. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022 Feb 16 [Epub ahead of print].Полный текст  Аннотация

995. Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe COVID-19 and mortality in high risk patients. Clin Infect Dis. 2022 Jun 2 [Epub ahead of print].Полный текст  Аннотация

996. Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022 Feb;198:105252.Полный текст  Аннотация

997. Merck. Merck and Ridgeback Biotherapeutics provide update on results from MOVe-OUT study of molnupiravir, an investigational oral antiviral medicine, in at risk adults with mild-to-moderate COVID-19. 2021 [internet publication].Полный текст

998. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2021 Dec 16 [Epub ahead of print].Полный текст  Аннотация

999. Caraco Y, Crofoot GE, Moncada PA, et al. Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults. NEJM Evid. 2021 Dec 16;1(2).Полный текст

1000. Johnson MG, Puenpatom A, Moncada PA, et al. Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial. Ann Intern Med. 2022 Jun 7 [Epub ahead of print].Полный текст  Аннотация

1001. Singh AK, Singh A, Singh R, et al. Molnupiravir in COVID-19: a systematic review of literature. Diabetes Metab Syndr. 2021 Oct 30;15(6):102329.Полный текст  Аннотация

1002. European Medicines Agency. EMA recommends approval for use of Kineret in adults with COVID-19. 2021 [internet publication].Полный текст

1003. National Institute for Health and Care Excellence. COVID 19 rapid evidence summary: anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis. 2020 [internet publication].Полный текст

1004. Davidson M, Menon S, Chaimani A, et al. Interleukin-1 blocking agents for treating COVID-19. Cochrane Database Syst Rev. 2022 Jan 26;(1):CD015308.Полный текст  Аннотация

1005. Kyriazopoulou E, Huet T, Cavalli G, et al. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021 Aug 9 [Epub ahead of print].Полный текст  Аннотация

1006. Barkas F, Ntekouan SF, Kosmidou M, et al. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Rheumatology (Oxford). 2021 May 17 [Epub ahead of print].Полный текст  Аннотация

1007. Somagutta MKR, Lourdes Pormento MK, Hamid P, et al. The safety and efficacy of anakinra, an interleukin-1 antagonist in severe cases of COVID-19: a systematic review and meta-analysis. Infect Chemother. 2021 Jun;53(2):221-37.Полный текст  Аннотация

1008. Reyes AZ, Hu KA, Teperman J, et al. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis. 2020 Dec 8 [Epub ahead of print].Полный текст  Аннотация

1009. Mikolajewska A, Fischer AL, Piechotta V, et al. Colchicine for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Oct 18;(10):CD015045.Полный текст  Аннотация

1010. Mehta KG, Patel T, Chavda PD, et al. Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials. RMD Open. 2021 Oct;7(3):e001746.Полный текст  Аннотация

1011. Dorward J, Yu L, Hayward G, et al. Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial. Br J Gen Pract. 2022 Mar 23 [Epub ahead of print].Полный текст

1012. RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med. 2021 Oct 18 [Epub ahead of print].Полный текст  Аннотация

1013. Humanigen. FDA has declined Humanigen’s emergency use authorization (EUA) request for lenzilumab in hospitalized COVID-19 patients. 2021 [internet publication].Полный текст

1014. Temesgen Z, Burger CD, Baker J, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2021 Dec 1 [Epub ahead of print].Полный текст  Аннотация

1015. Cremer PC, Abbate A, Hudock K, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Jun;3(6):e410-8.Полный текст  Аннотация

1016. US Food and Drug Administration. FDA in brief: FDA updates emergency use authorization for COVID-19 convalescent plasma to reflect new data. 2021 [internet publication].Полный текст

1017. Medicines and Healthcare products Regulatory Agency. Convalescent plasma in the management of hospitalised patients with COVID-19. 2021 [internet publication].Полный текст

1018. Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. 2021 Sep 23;374:n2231.Полный текст  Аннотация

1019. Piechotta V, Iannizzi C, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 May 20;5(5):CD013600.Полный текст  Аннотация

1020. Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021 Mar 23;325(12):1185-95.Полный текст  Аннотация

1021. Gupta T, Kannan S, Kalra B, et al. Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): evidence-base for practise and implications for research. Transfus Med. 2021 Jun 29 [Epub ahead of print].Полный текст  Аннотация

1022. Klassen SA, Senefeld JW, Johnson PW, et al. The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis. Mayo Clin Proc. 2021 May;96(5):1262-75.Полный текст  Аннотация

1023. Wardhani SO, Fajar JK, Wulandari L, et al. Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. F1000Res. 2021 Feb 3;10:64.Полный текст  Аннотация

1024. Kloypan C, Saesong M, Sangsuemoon J, et al. Convalescent plasma for COVID-19: a meta-analysis of clinical trials and real-world evidence. Eur J Clin Invest. 2021 Aug 10:e13663.Полный текст  Аннотация

1025. Axfors C, Janiaud P, Schmitt AM, et al. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infect Dis. 2021 Nov 20;21(1):1170.Полный текст  Аннотация

1026. Troxel AB, Petkova E, Goldfeld K, et al. Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a meta-analysis. JAMA Netw Open. 2022 Jan 4;5(1):e2147331.Полный текст  Аннотация

1027. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021 May 14 [Epub ahead of print].Полный текст  Аннотация

1028. Sullivan DJ, Gebo KA, Shoham S, et al. Early outpatient treatment for Covid-19 with convalescent plasma. N Engl J Med. 2022 Mar 30 [Epub ahead of print].Полный текст  Аннотация

1029. Park H, Tarpey T, Liu M, et al. Development and validation of a treatment benefit index to identify hospitalized patients with COVID-19 who may benefit from convalescent plasma. JAMA Netw Open. 2022 Jan 4;5(1):e2147375.Полный текст  Аннотация

1030. Xiang HR, Cheng X, Li Y, et al. Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis. Int Immunopharmacol. 2021 Jul;96:107732.Полный текст  Аннотация

1031. ClinicalTrials.gov. Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirus. 2020 [internet publication].Полный текст

1032. Wang J, Shi P, Chen D, et al. Research status of the safety and efficacy of mesenchymal stem cells in the treatment of COVID-19-related pneumonia: a systematic review and meta-analysis. Stem Cells Dev. 2021 Aug 20 [Epub ahead of print]. Аннотация

1033. Li Y, Wei Z, Ma X, et al. Efficacy and safety of mesenchymal stromal cells therapy for COVID-19 infection: a systematic review and meta-analysis. Curr Stem Cell Res Ther. 2021 Dec 6 [Epub ahead of print]. Аннотация

1034. Kirkham AM, Bailey AJM, Monaghan M, et al. Updated living systematic review and meta-analysis of controlled trials of mesenchymal stromal cells to treat COVID-19: a framework for accelerated synthesis of trial evidence for rapid approval - FASTER approval. Stem Cells Transl Med. 2022 Jun 27 [Epub ahead of print].Полный текст  Аннотация

1035. Mesoblast Limited. Mesoblast update on COVID-19 ARDS trial. 2020 [internet publication].Полный текст

1036. Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021 Feb;9(2):196-206.Полный текст  Аннотация

1037. ClinicalTrials.gov. Interferon lambda for immediate antiviral therapy at diagnosis in COVID-19 (ILIAD). 2020 [internet publication].Полный текст

1038. Eiger BioPharmaceuticals. Eiger BioPharmaceuticals announces positive results of investigator sponsored randomized controlled trial at University of Toronto with peginterferon lambda in outpatients with mild to moderate COVID-19. 2020 [internet publication].Полный текст

1039. Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787.Полный текст  Аннотация

1040. Popp M, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. 2021 Jul 28;(7):CD015017.Полный текст  Аннотация

1041. Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021 Jun 17 [Epub ahead of print].Полный текст  Аннотация

1042. Kory P, Meduri GU, Varon J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther. 2021 Apr 22;28(3):e299-318.Полный текст  Аннотация

1043. Zein AFMZ, Sulistiyana CS, Raffaelo WM, et al. Ivermectin and mortality in patients with COVID-19: a systematic review, meta-analysis, and meta-regression of randomized controlled trials. Diabetes Metab Syndr. 2021 Jun 27;15(4):102186.Полный текст  Аннотация

1044. Kow CS, Merchant HA, Mustafa ZU, et al. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacol Rep. 2021 Mar 29 [Epub ahead of print].Полный текст  Аннотация

1045. Padhy BM, Mohanty RR, Das S, et al. Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis. J Pharm Pharm Sci. 2020;23:462-9.Полный текст  Аннотация

1046. Bartoszko JJ, Siemieniuk RAC, Kum E, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021 Apr 26;373:n949.Полный текст  Аннотация

1047. Roman YM, Burela PA, Pasupuleti V, et al. Ivermectin for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials. Clin Infect Dis. 2021 Jun 28 [Epub ahead of print].Полный текст  Аннотация

1048. Deng J, Zhou F, Ali S, et al. Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis. QJM. 2021 Sep 27 [Epub ahead of print].Полный текст  Аннотация

1049. Bitterman A, Martins CP, Cices A, et al. Comparison of trials using ivermectin for COVID-19 between regions with high and low prevalence of strongyloidiasis: a meta-analysis. JAMA Netw Open. 2022 Mar 1;5(3):e223079.Полный текст  Аннотация

1050. Azeez TA, Lakoh S, Adeleke AA, et al. Chemoprophylaxis against COVID-19 among health-care workers using ivermectin in low- and middle-income countries: a systematic review and meta-analysis. Indian J Pharmacol. 2021 Nov-Dec;53(6):493-8.Полный текст  Аннотация

1051. PRINCIPLE Trial Collaborative Group. Ivermectin to be investigated in adults aged 18+ as a possible treatment for COVID-19 in the PRINCIPLE trial. 2021 [internet publication].Полный текст

1052. Rossignol JF, Bardin MC, Fulgencio J, et al. A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19. EClinicalMedicine. 2022 Mar;45:101310.Полный текст  Аннотация

1053. Blum VF, Cimerman S, Hunter JR, et al. Nitazoxanide superiority to placebo to treat moderate COVID-19: a pilot prove of concept randomized double-blind clinical trial. EClinicalMedicine. 2021 Jun 27;100981.Полный текст  Аннотация

1054. Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021 Jul 8;58(1):2003725.Полный текст  Аннотация

1055. Sukhatme VP, Reiersen AM, Vayttaden SJ, et al. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021 Apr 20;12:652688.Полный текст  Аннотация

1056. Guo CM, Harari O, Chernecki C, et al. Fluvoxamine for the early treatment of COVID-19: a meta-analysis of randomized clinical trials. Am J Trop Med Hyg. 2022 Mar 9 [Epub ahead of print].Полный текст  Аннотация

1057. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2021 Oct 27 [Epub ahead of print].Полный текст  Аннотация

1058. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020 Dec 8;324(22):2292-300.Полный текст  Аннотация

1059. Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021 Feb;8(2):ofab050.Полный текст  Аннотация

1060. Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021 Apr 9 [Epub ahead of print].Полный текст  Аннотация

1061. Baker JR, Mahdi M, Nicolau DV Jr, et al. Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. Lancet Respir Med. 2022 Apr 7 [Epub ahead of print].Полный текст  Аннотация

1062. Griesel M, Wagner C, Mikolajewska A, et al. Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2022 Mar 9;(3):CD015125.Полный текст  Аннотация

1063. Yu LM, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021 Aug 10 [Epub ahead of print].Полный текст  Аннотация

1064. Medicines and Healthcare products Regulatory Agency. COVID-19 therapeutic alert: antimicrobials (azithromycin and doxycycline) not beneficial in the management of COVID-19 (SARS-CoV-2) positive patients. 2021 [internet publication].Полный текст

1065. Popp M, Stegemann M, Riemer M, et al. Antibiotics for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Oct 22;(10):CD015025.Полный текст  Аннотация

1066. Mangkuliguna G, Glenardi, Susanto N, et al. Efficacy and safety of azithromycin for the treatment of COVID-19: a systematic review and meta-analysis. Tuberc Respir Dis (Seoul). 2021 May 20 [Epub ahead of print].Полный текст  Аннотация

1067. Ayerbe L, Risco-Risco C, Forgnone I, et al. Azithromycin in patients with COVID-19: a systematic review and meta-analysis. J Antimicrob Chemother. 2021 Nov 17 [Epub ahead of print].Полный текст  Аннотация

1068. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 Feb 13;397(10274):605-12.Полный текст  Аннотация

1069. Butler CC, Yu LM, Dorward J, et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Respir Med. 2021 Jul 27 [Epub ahead of print].Полный текст  Аннотация

1070. Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020 Apr 2;12(4).Полный текст  Аннотация

1071. McCartney DM, Byrne DG. Optimisation of vitamin D status for enhanced immuno-protection against Covid-19. Ir Med J. 2020 Apr 3;113(4):58.Полный текст  Аннотация

1072. Jakovac H. COVID-19 and vitamin D: is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E589.Полный текст  Аннотация

1073. Jolliffe DA, Camargo CA Jr, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrinol. 2021 May;9(5):276-92.Полный текст  Аннотация

1074. National Institute for Health and Care Excellence. COVID-19 rapid guideline: vitamin D. 2020 [internet publication].Полный текст

1075. Stroehlein JK, Wallqvist J, Iannizzi C, et al. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 May 24;(5):CD015043.Полный текст  Аннотация

1076. Shah K, Saxena D, Mavalankar D. Vitamin D supplementation, COVID-19 & disease severity: a meta-analysis. QJM. 2021 Jan 24 [Epub ahead of print].Полный текст  Аннотация

1077. Pal R, Banerjee M, Bhadada SK, et al. Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis. J Endocrinol Invest. 2021 Jun 24 [Epub ahead of print].Полный текст  Аннотация

1078. Szarpak L, Filipiak KJ, Gasecka A, et al. Vitamin D supplementation to treat SARS-CoV-2 positive patients: evidence from meta-analysis. Cardiol J. 2021 Oct 13 [Epub ahead of print].Полный текст  Аннотация

1079. Tentolouris N, Samakidou G, Eleftheriadou I, et al. The effect of vitamin D supplementation on mortality and intensive care unit admission of COVID-19 patients: a systematic review, meta-analysis and meta-regression. Diabetes Metab Res Rev. 2021 Dec 29 [Epub ahead of print].Полный текст  Аннотация

1080. Shah K, Varna VP, Sharma U, et al. Does vitamin D supplementation reduce COVID-19 severity? A systematic review. QJM. 2022 Feb 15 [Epub ahead of print]. Аннотация

1081. Hosseini B, El Abd A, Ducharme FM. Effects of vitamin D supplementation on COVID-19 related outcomes: a systematic review and meta-analysis. Nutrients. 2022 May 20;14(10):2134.Полный текст  Аннотация

1082. da Rocha AP, Atallah AN, Aldrighi JM, et al. Insufficient evidence for vitamin D use in COVID-19: a rapid systematic review. Int J Clin Pract. 2021 Jul 26:e14649.Полный текст  Аннотация

1083. Castillo ME, Entrenas Costa LM, Vaquero Barrios JM, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020 Aug 29;105751.Полный текст  Аннотация

1084. Abioye AI, Bromage S, Fawzi W. Effect of micronutrient supplements on influenza and other respiratory tract infections among adults: a systematic review and meta-analysis. BMJ Glob Health. 2021 Jan;6(1):e003176.Полный текст  Аннотация

1085. Tabatabaeizadeh SA. Zinc supplementation and COVID-19 mortality: a meta-analysis. Eur J Med Res. 2022 May 23;27(1):70.Полный текст  Аннотация

1086. Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition. 2020 Apr 21:100190.Полный текст  Аннотация

1087. ClinicalTrials.gov. Vitamin C infusion for the treatment of severe 2019-nCoV infected pneumonia. 2020 [internet publication].Полный текст

1088. Rawat D, Roy A, Maitra S, et al. Vitamin C and COVID-19 treatment: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2021 Oct 28;15(6):102324.Полный текст  Аннотация

1089. Kwak SG, Choo YJ, Chang MC. The effectiveness of high-dose intravenous vitamin C for patients with coronavirus disease 2019: a systematic review and meta-analysis. Complement Ther Med. 2021 Dec 22;64:102797.Полный текст  Аннотация

1090. Roach A, Chikwe J, Catarino P, et al. Lung transplantation for Covid-19-related respiratory failure in the United States. N Engl J Med. 2022 Jan 26 [Epub ahead of print].Полный текст  Аннотация

1091. Kurihara C, Manerikar A, Querrey M, et al. Clinical characteristics and outcomes of patients with COVID-19-associated acute respiratory distress syndrome who underwent lung transplant. JAMA. 2022 Jan 27 [Epub ahead of print].Полный текст  Аннотация

1092. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020 [internet publication].Полный текст

1093. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-8.Полный текст  Аннотация

1094. Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med. 2020 Nov;14(11):1149-63.Полный текст  Аннотация

1095. Dmytriw AA, Chibbar R, Chen PPY, et al. Outcomes of acute respiratory distress syndrome in COVID-19 patients compared to the general population: a systematic review and meta-analysis. Expert Rev Respir Med. 2021 Apr 21 [Epub ahead of print]. Аннотация

1096. de la Calle C, Lalueza A, Mancheño-Losa M, et al. Impact of viral load at admission on the development of respiratory failure in hospitalized patients with SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021 Jan 7 [Epub ahead of print].Полный текст  Аннотация

1097. Elezkurtaj S, Greuel S, Ihlow J, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021 Feb 19;11(1):4263.Полный текст  Аннотация

1098. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res. 2020 Sep;188:109890.Полный текст  Аннотация

1099. Sumner MW, Kanngiesser A, Lotfali-Khani K, et al. Severe outcomes associated with SARS-CoV-2 infection in children: a systematic review and meta-analysis. Front Pediatr. 2022 Jun 9;10:916655.Полный текст  Аннотация

1100. Smith C, Odd D, Harwood R, et al; medRxiv. Deaths in children and young people in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data. 2021 [internet publication].Полный текст

1101. Qian Z, Lu S, Luo X, et al. Mortality and clinical interventions in critically ill patient with coronavirus disease 2019: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Jul 23;8:635560.Полный текст  Аннотация

1102. Docherty AB, Mulholland RH, Lone NI, et al. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021 May 14 [Epub ahead of print].Полный текст  Аннотация

1103. Gray WK, Navaratnam AV, Day J, et al. COVID-19 hospital activity and in-hospital mortality during the first and second waves of the pandemic in England: an observational study. Thorax. 2021 Nov 24 [Epub ahead of print].Полный текст  Аннотация

1104. Asch DA, Sheils NE, Islam MN, et al. Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic. JAMA Intern Med. 2021 Apr 1;181(4):471-8.Полный текст  Аннотация

1105. Nguyen NT, Chinn J, Nahmias J, et al. Outcomes and mortality among adults hospitalized with COVID-19 at US medical centers. JAMA Netw Open. 2021 Mar 1;4(3):e210417.Полный текст  Аннотация

1106. Finelli L, Gupta V, Petigara T, et al. Mortality among US patients hospitalized with SARS-CoV-2 infection in 2020. JAMA Netw Open. 2021 Apr 1;4(4):e216556.Полный текст  Аннотация

1107. Anesi GL, Jablonski J, Harhay MO, et al. Characteristics, outcomes, and trends of patients with COVID-19-related critical illness at a learning health system in the United States. Ann Intern Med. 2021 Jan 19 [Epub ahead of print].Полный текст  Аннотация

1108. Ioannidis JPA. Reconciling estimates of global spread and infection fatality rates of COVID-19: an overview of systematic evaluations. Eur J Clin Invest. 2021 Mar 26:e13554.Полный текст  Аннотация

1109. Axfors C, Ioannidis JPA. Infection fatality rate of COVID-19 in community-dwelling populations with emphasis on the elderly: an overview [preprint]. 2021 [internet publication].Полный текст

1110. Rajgor DD, Lee MH, Archuleta S, et al. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020 Jul;20(7):776-7.Полный текст  Аннотация

1111. Ghayda RA, Lee KH, Han YJ, et al. Global case fatality rate of coronavirus disease 2019 (COVID-19) by continents and national income: a meta-analysis. J Med Virol. 2022 Jan 31 [Epub ahead of print].Полный текст  Аннотация

1112. Alimohamadi Y, Tola HH, Abbasi-Ghahramanloo A, et al. Case fatality rate of COVID-19: a systematic review and meta-analysis. J Prev Med Hyg. 2021 Jun;62(2):E311-20.Полный текст  Аннотация

1113. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 17;41(2):145-51.Полный текст  Аннотация

1114. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Jun;20(6):669-77.Полный текст  Аннотация

1115. Sorbello M, El-Boghdadly K, Di Giacinto I, et al. The Italian COVID-19 outbreak: experiences and recommendations from clinical practice. Anaesthesia. 2020 Jun;75(6):724-32.Полный текст  Аннотация

1116. Bixler D, Miller AD, Mattison CP, et al. SARS-CoV-2–associated deaths among persons aged <21 years: United States, February 12–July 31, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1324-9.Полный текст  Аннотация

1117. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 6;323(16):1574-81.Полный текст  Аннотация

1118. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020 Mar 19;323(16):1612-4.Полный текст  Аннотация

1119. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Global COVID-19 case fatality rates. 2020 [internet publication].Полный текст

1120. Mahase E. Covid-19: the problems with case counting. BMJ. 2020 Sep 3;370:m3374.Полный текст  Аннотация

1121. Centre for Evidence-Based Medicine; Spencer E, Jefferson T, Brassey J, et al. When is Covid, Covid? 2020 [internet publication].Полный текст

1122. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Reconciling COVID-19 death data in the UK. 2020 [internet publication].Полный текст

1123. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 May 12;323(18):1775-6.Полный текст  Аннотация

1124. Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One. 2020;15(11):e0241955.Полный текст  Аннотация

1125. Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One. 2021 Mar 4;16(3):e0247461.Полный текст  Аннотация

1126. Zhang L, Hou J, Ma FZ, et al. The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis. Arch Virol. 2021 Apr 2 [Epub ahead of print].Полный текст  Аннотация

1127. Dumitrascu F, Branje KE, Hladkowicz ES, et al. Association of frailty with outcomes in individuals with COVID-19: a living review and meta-analysis. J Am Geriatr Soc. 2021 May 28 [Epub ahead of print].Полный текст  Аннотация

1128. Bellou V, Tzoulaki I, van Smeden M, et al. Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis. Eur Respir J. 2021 Jun 25 [Epub ahead of print].Полный текст  Аннотация

1129. Santus P, Radovanovic D, Saderi L, et al. Severity of respiratory failure at admission and in-hospital mortality in patients with COVID-19: a prospective observational multicentre study. BMJ Open. 2020 Oct 10;10(10):e043651.Полный текст  Аннотация

1130. Shi C, Wang L, Ye J, et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. BMC Infect Dis. 2021 Jul 8;21(1):663.Полный текст  Аннотация

1131. Javanmardi F, Keshavarzi A, Akbari A, et al. Prevalence of underlying diseases in died cases of COVID-19: a systematic review and meta-analysis. PLoS One. 2020 Oct 23;15(10):e0241265.Полный текст  Аннотация

1132. Shi Q, Wang Z, Liu J, et al. Risk factors for poor prognosis in children and adolescents with COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2021 Nov;41:101155.Полный текст  Аннотация

1133. Ramzi ZS. Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients: a systematic review and meta-analysis. Am J Emerg Med. 2022 Jan;51:267-79.Полный текст  Аннотация

1134. Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020 Dec 3;383(23):2291-3.Полный текст  Аннотация

1135. Lund LC, Hallas J, Nielsen H, et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis. 2021 May 10 [Epub ahead of print].Полный текст  Аннотация

1136. Public Health England. COVID-19: investigation and management of suspected SARS-CoV-2 reinfections. 2021 [internet publication].Полный текст

1137. Mattiuzzi C, Henry BM, Sanchis-Gomar F, et al. SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis. Acta Biomed. 2020 Sep 7;91(3):e2020014.Полный текст  Аннотация

1138. Azam M, Sulistiana R, Ratnawati M, et al. Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis. Sci Rep. 2020 Nov 26;10(1):20692.Полный текст  Аннотация

1139. SeyedAlinaghi S, Oliaei S, Kianzad S, et al. Reinfection risk of novel coronavirus (COVID-19): a systematic ‎review of current evidence. World J Virol. 2020 Dec 15;9(5):79-90.Полный текст  Аннотация

1140. Arafkas M, Khosrawipour T, Kocbach P, et al. Current meta-analysis does not support the possibility of COVID-19 reinfections. J Med Virol. 2021 Mar;93(3):1599-604.Полный текст  Аннотация

1141. Vibholm LK, Nielsen SS, Pahus MH, et al. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine. 2021 Jan 30;64:103230.Полный текст  Аннотация

1142. Mao YJ, Wang WW, Ma J, et al. Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis. Chin Med J (Engl). 2021 Dec 13 [Epub ahead of print].Полный текст  Аннотация

1143. Helfand M, Fiordalisi C, Wiedrick J, et al. Risk for reinfection after SARS-CoV-2: a living, rapid review for American College of Physicians practice points on the role of the antibody response in conferring immunity following SARS-CoV-2 infection. Ann Intern Med. 2022 Jan 25 [Epub ahead of print].Полный текст  Аннотация

1144. Wang J, Kaperak C, Sato T, et al. COVID-19 reinfection: a rapid systematic review of case reports and case series. J Investig Med. 2021 May 18 [Epub ahead of print].Полный текст  Аннотация

1145. Stephens DS, McElrath MJ. COVID-19 and the path to immunity. JAMA. 2020 Oct 6;324(13):1279-81.Полный текст  Аннотация

1146. World Health Organization. COVID-19 natural immunity: scientific brief. 2021 [internet publication].Полный текст

1147. Savage HR, Santos VS, Edwards T, et al. Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021 Jul 8;15(7):e0009551.Полный текст  Аннотация

1148. Arkhipova-Jenkins I, Helfand M, Armstrong C, et al. Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living review. Ann Intern Med. 2021 Mar 16 [Epub ahead of print].Полный текст  Аннотация

1149. Flannery DD, Gouma S, Dhudasia MB, et al. Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios. JAMA Pediatr. 2021 Jan 29 [Epub ahead of print].Полный текст  Аннотация

1150. Foley MK, Searle SD, Toloue A, et al. Centenarians and extremely old people living with frailty can elicit durable SARS-CoV-2 spike specific IgG antibodies with virus neutralization functions following virus infection as determined by serological study. EClinicalMedicine. 2021 Jun 27:100975.Полный текст  Аннотация

1151. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020 Aug;26(8):1200-4.Полный текст  Аннотация

1152. Alfego D, Sullivan A, Poirier B, et al. A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. EClinicalMedicine. 2021 May 24:100902.Полный текст  Аннотация

1153. Egbert ER, Xiao S, Colantuoni E, et al. Durability of spike immunoglobin G antibodies to SARS-CoV-2 among health care workers with prior infection. JAMA Netw Open. 2021 Aug 2;4(8):e2123256.Полный текст  Аннотация

1154. Alejo JL, Mitchell J, Chang A, et al. Prevalence and durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19. JAMA. 2022 Feb 3 [Epub ahead of print].Полный текст  Аннотация

1155. Centre for Evidence-Based Medicine; Plüddemann A, Aronson JK. What is the role of T cells in COVID-19 infection? Why immunity is about more than antibodies. 2020 [internet publication].Полный текст

1156. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Jan 6 [Epub ahead of print].Полный текст  Аннотация

1157. Shrotri M, van Schalkwyk MCI, Post N, et al. T cell response to SARS-CoV-2 infection in humans: a systematic review. PLoS One. 2021;16(1):e0245532.Полный текст  Аннотация

1158. Tarke A, Sidney J, Methot N, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021 Jul 20;2(7):100355.Полный текст  Аннотация

1159. Redd AD, Nardin A, Kared H, et al. CD8+ T-cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. Open Forum Infect Dis. 2021 Jul;8(7):ofab143.Полный текст  Аннотация

1160. Guo L, Wang G, Wang Y, et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe. 2022 Mar 23 [Epub ahead of print].Полный текст  Аннотация

1161. Venet F, Gossez M, Bidar F, et al. T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19. EBioMedicine. 2022 Mar 26;78:103967.Полный текст  Аннотация

1162. Petráš M. Highly effective naturally acquired protection against COVID-19 persists for at least 1 year: a meta-analysis. J Am Med Dir Assoc. 2021 Sep 16 [Epub ahead of print].Полный текст  Аннотация

1163. Chen Q, Zhu K, Liu X, et al. The protection provided by naturally acquired antibodies against subsequent SARS-CoV-2 infection: a systematic review and meta-analysis. Emerg Microbes Infect. 2022 Feb 23:1-44.Полный текст  Аннотация

1164. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021 Apr 17;397(10283):1459-69.Полный текст  Аннотация

1165. Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021 Mar 27;397(10280):1204-12.Полный текст  Аннотация

1166. Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022 Mar 31 [Epub ahead of print].Полный текст  Аннотация

1167. Ridgway JP, Tideman S, Wright B, et al. Rates of COVID-19 among unvaccinated adults with prior COVID-19. JAMA Netw Open. 2022 Apr 1;5(4):e227650.Полный текст  Аннотация

1168. Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy. JAMA Intern Med. 2021 May 28 [Epub ahead of print].Полный текст  Аннотация

1169. Doshi P. Covid-19: do many people have pre-existing immunity? BMJ. 2020 Sep 17;370:m3563.Полный текст  Аннотация

1170. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020 Dec 11;370(6522):1339-43.Полный текст  Аннотация

1171. Vacharathit V, Aiewsakun P, Manopwisedjaroen S, et al. CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect Dis. 2021 Aug 26 [Epub ahead of print].Полный текст  Аннотация

1172. Shenai MB, Rahme R, Noorchashm H. Equivalency of protection from natural immunity in COVID-19 recovered versus fully vaccinated persons: a systematic review and pooled analysis. Cureus. 2021 Oct 28;13(10):e19102.Полный текст  Аннотация

1173. León TM, Dorabawila V, Nelson L, et al. COVID-19 cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis: California and New York, May – November 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-31.Полный текст  Аннотация

1174. Heesakkers H, van der Hoeven JG, Corsten S, et al. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. JAMA. 2022 Feb 8;327(6):559-65.Полный текст  Аннотация

1175. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020 Jul;18(7):1747-51.Полный текст  Аннотация

1176. Gendron N, Dragon-Durey MA, Chocron R, et al. Lupus anticoagulant single positivity during the acute phase of COVID-19 is not associated with venous thromboembolism or in-hospital mortality. Arthritis Rheumatol. 2021 Apr 21 [Epub ahead of print].Полный текст  Аннотация

1177. Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021 Feb 23 [Epub ahead of print].Полный текст  Аннотация

1178. Zaffanello M, Piacentini G, Nosetti L, et al. Thrombotic risk in children with COVID-19 infection: a systematic review of the literature. Thromb Res. 2021 Jul 16;205:92-98.Полный текст  Аннотация

1179. Centre for Evidence-Based Medicine; Kernohan A, Calderon M. What are the risk factors and effectiveness of prophylaxis for venous thromboembolism in COVID-19 patients? 2020 [internet publication].Полный текст

1180. Cui LY, Cheng WW, Mou ZW, et al. Risk factors for pulmonary embolism in patients with COVID-19: a systemic review and meta-analysis. Int J Infect Dis. 2021 Aug 18 [Epub ahead of print].Полный текст  Аннотация

1181. van Nieuwkoop C. COVID-19 associated pulmonary thrombosis. Thromb Res. 2020 Jul;191:151.Полный текст  Аннотация

1182. Belen-Apak FB, Sarıalioğlu F. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. J Thromb Thrombolysis. 2020 Aug;50(2):278-80.Полный текст  Аннотация

1183. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-73.Полный текст  Аннотация

1184. Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in hospitalized patients With COVID-19 in a New York City health system. JAMA. 2020 Aug 25;324(8):799-801.Полный текст  Аннотация

1185. Wang C, Zhang H, Zhou M, et al. Prognosis of COVID-19 in patients with vein thrombosis: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):10279-85.Полный текст  Аннотация

1186. Sabatino J, De Rosa S, Di Salvo G, et al. Impact of cardiovascular risk profile on COVID-19 outcome: a meta-analysis. PLoS One. 2020 Aug 14;15(8):e0237131.Полный текст  Аннотация

1187. Jafari-Oori M, Moradian ST, Ebadi A, et al. Incidence of cardiac complications following COVID-19 infection: an umbrella meta-analysis study. Heart Lung. 2022 Jan 10;52:136-45.Полный текст  Аннотация

1188. Changal K, Veria S, Mack S, et al. Myocardial injury in hospitalized COVID-19 patients: a retrospective study, systematic review, and meta-analysis. BMC Cardiovasc Disord. 2021 Dec 31;21(1):626.Полный текст  Аннотация

1189. Creel-Bulos C, Hockstein M, Amin N, et al. Acute cor pulmonale in critically ill patients with Covid-19. N Engl J Med. 2020 May 21;382(21):e70.Полный текст  Аннотация

1190. Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020 Apr 10;1-5.Полный текст  Аннотация

1191. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27;5(7):1-6.Полный текст  Аннотация

1192. Hua A, O'Gallagher K, Sado D, et al. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020 Jun 7;41(22):2130.Полный текст  Аннотация

1193. Singh S, Desai R, Gandhi Z, et al. Takotsubo syndrome in patients with COVID-19: a systematic review of published cases. SN Compr Clin Med. 2020 Oct 6:1-7.Полный текст  Аннотация

1194. Ammirati E, Lupi L, Palazzini M, et al. Prevalence, characteristics, and outcomes of COVID-19-associated acute myocarditis. Circulation. 2022 Apr 12;145(15):1123-39. Аннотация

1195. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020 Jul 1;5(7):831-40.Полный текст  Аннотация

1196. Liu PP, Blet A, Smyth D, et al. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020 Jul 7;142(1):68-78.Полный текст  Аннотация

1197. Hendren NS, Drazner MH, Bozkurt B, et al. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020 Jun 9;141(23):1903-14.Полный текст  Аннотация

1198. Li X, Pan X, Li Y, et al. Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review. Crit Care. 2020 Jul 28;24(1):468.Полный текст  Аннотация

1199. Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020 May 14;41(19):1798-800.Полный текст  Аннотация

1200. Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022 Feb 7 [Epub ahead of print].Полный текст  Аннотация

1201. Raina R, Mahajan ZA, Vasistha P, et al. Incidence and outcomes of acute kidney injury in COVID-19: a systematic review. Blood Purif. 2021 Jun 15:1-14.Полный текст  Аннотация

1202. Cai X, Wu G, Zhang J, et al. Risk factors for acute kidney injury in adult patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Dec 6;8:719472.Полный текст  Аннотация

1203. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. 2021 [internet publication].Полный текст

1204. Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. 2021 [internet publication].Полный текст

1205. Taquet M, Dercon Q, Luciano S, et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021 Sep;18(9):e1003773.Полный текст  Аннотация

1206. Wildwing T, Holt N. The neurological symptoms of COVID-19: a systematic overview of systematic reviews, comparison with other neurological conditions and implications for healthcare services. Ther Adv Chronic Dis. 2021 Jan 28;12:2040622320976979.Полный текст  Аннотация

1207. Matta J, Wiernik E, Robineau O, et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern Med. 2021 Nov 8 [Epub ahead of print].Полный текст  Аннотация

1208. Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, et al. Frequency, signs and symptoms, and criteria adopted for long COVID: a systematic review. Int J Clin Pract. 2021 May 11 [Epub ahead of print].Полный текст  Аннотация

1209. Iqbal FM, Lam K, Sounderajah V, et al. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinicalMedicine. 2021 Jun;36:100899.Полный текст  Аннотация

1210. Aminian A, Bena J, Pantalone KM, et al. Association of obesity with post-acute sequelae of COVID-19 (PASC). Diabetes Obes Metab. 2021 Jun 1 [Epub ahead of print].Полный текст  Аннотация

1211. Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med. 2021 Jun 16 [Epub ahead of print].Полный текст  Аннотация

1212. Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021 Oct 1;4(10):e2128568.Полный текст  Аннотация

1213. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021 Apr;27(4):626-31.Полный текст  Аннотация

1214. Office for National Statistics. Technical article: updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. 2021 [internet publication].Полный текст

1215. Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021 May 5 [Epub ahead of print].Полный текст  Аннотация

1216. Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021 Aug 28;398(10302):747-58.Полный текст  Аннотация

1217. Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022 May 11 [Epub ahead of print].Полный текст  Аннотация

1218. Havervall S, Rosell A, Phillipson M, et al. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA. 2021 Apr 7 [Epub ahead of print].Полный текст  Аннотация

1219. Augustin M, Schommers P, Stecher M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021 Jul;6:100122.Полный текст  Аннотация

1220. Stavem K, Ghanima W, Olsen MK, et al. Persistent symptoms 1.5 to 6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax. 2020 Dec 3;76(4):405-7.Полный текст  Аннотация

1221. Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021 Mar;110(3):914-21.Полный текст  Аннотация

1222. Radtke T, Ulyte A, Puhan MA, et al. Long-term symptoms after SARS-CoV-2 infection in children and adolescents. JAMA. 2021 Jul 15 [Epub ahead of print].Полный текст  Аннотация

1223. Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. 2022 May 18;377:e069676.Полный текст  Аннотация

1224. Antonelli M, Pujol JC, Spector TD, et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022 Jun 18;399(10343):2263-4.Полный текст  Аннотация

1225. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep. 2022 Jun 23;12(1):9950.Полный текст  Аннотация

1226. Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020 Aug 11;370:m3026.Полный текст  Аннотация

1227. Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021 Sep;6(9):e005427.Полный текст  Аннотация

1228. Zhang X, Wang F, Shen Y, et al. Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. JAMA Netw Open. 2021 Sep 1;4(9):e2127403.Полный текст  Аннотация

1229. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022 Mar 21 [Epub ahead of print].Полный текст  Аннотация

1230. Chopra V, Flanders SA, O'Malley M, et al. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021 Apr;174(4):576-8.Полный текст  Аннотация

1231. So M, Kabata H, Fukunaga K, et al. Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis. BMC Pulm Med. 2021 Mar 22;21(1):97.Полный текст  Аннотация

1232. Watanabe A, So M, Iwagami M, et al. One-year follow-up CT findings in COVID-19 patients: A systematic review and meta-analysis. Respirology. 2022 Jun 12 [Epub ahead of print].Полный текст  Аннотация

1233. Mandal S, Barnett J, Brill SE, et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2020 Nov 10 [Epub ahead of print].Полный текст  Аннотация

1234. Hama Amin BJ, Kakamad FH, Ahmed GS, et al. Post COVID-19 pulmonary fibrosis: a meta-analysis study. Ann Med Surg (Lond). 2022 May;77:103590.Полный текст  Аннотация

1235. American Academy of Physical Medicine and Rehabilitation. Multidisciplinary quality improvement initiative. 2021 [internet publication].Полный текст

1236. Li G, Yang Y, Gao D, et al. Is liver involvement overestimated in COVID-19 patients? A meta-analysis. Int J Med Sci. 2021;18(5):1285-96.Полный текст  Аннотация

1237. Bzeizi K, Abdulla M, Mohammed N, et al. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. Sci Rep. 2021 May 19;11(1):10599.Полный текст  Аннотация

1238. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. United European Gastroenterol J. 2020 Jun;8(5):509-19.Полный текст  Аннотация

1239. Sodeifian F, Seyedalhosseini ZS, Kian N, et al. Drug-induced liver injury in COVID-19 patients: a systematic review. Front Med (Lausanne). 2021 Sep 20;8:731436.Полный текст  Аннотация

1240. Wong GL, Wong VW, Thompson A, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):776-87.Полный текст  Аннотация

1241. Guerrero JI, Barragán LA, Martínez JD, et al. Central and peripheral nervous system involvement by COVID-19: a systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings. BMC Infect Dis. 2021 Jun 2;21(1):515.Полный текст  Аннотация

1242. Favas TT, Dev P, Chaurasia RN, et al. Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurol Sci. 2020 Dec;41(12):3437-70.Полный текст  Аннотация

1243. Sullivan BN, Fischer T. Age-associated neurological complications of COVID-19: a systematic review and meta-analysis. Front Aging Neurosci. 2021 Aug 2;13:653694.Полный текст  Аннотация

1244. Chua TH, Xu Z, King NKK. Neurological manifestations in COVID-19: a systematic review and meta-analysis. Brain Inj. 2020 Oct 19:1-20. Аннотация

1245. Kubota T, Kuroda N. Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: a systematic review. Clin Neurol Neurosurg. 2020 Nov 1;106349.Полный текст  Аннотация

1246. Lu Y, Li X, Geng D, et al. Cerebral micro-structural changes in COVID-19 patients: an MRI-based 3-month follow-up study. EClinicalMedicine. 2020 Aug;25:100484.Полный текст  Аннотация

1247. LaRovere KL, Riggs BJ, Poussaint TY, et al. Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome. JAMA Neurol. 2021 May 1;78(5):536-47.Полный текст  Аннотация

1248. Lu Y, Zhao JJ, Ye MF, et al. The relationship between COVID-19's severity and ischemic stroke: a systematic review and meta-analysis. Neurol Sci. 2021 May 5 [Epub ahead of print].Полный текст  Аннотация

1249. Yamakawa M, Kuno T, Mikami T, et al. Clinical characteristics of stroke with COVID-19: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2020 Aug 29;29(12):105288.Полный текст  Аннотация

1250. Nannoni S, de Groot R, Bell S, et al. Stroke in COVID-19: a systematic review and meta-analysis. Int J Stroke. 2021 Feb;16(2):137-49.Полный текст  Аннотация

1251. Valencia-Enciso N, Ortiz-Pereira M, Zafra-Sierra MP, et al. Time of stroke onset in coronavirus disease 2019 patients around the globe: a systematic review and analysis. J Stroke Cerebrovasc Dis. 2020 Sep 18;29(12):105325.Полный текст  Аннотация

1252. Tu TM, Seet CYH, Koh JS, et al. Acute ischemic stroke during the convalescent phase of asymptomatic COVID-2019 infection in men. JAMA Netw Open. 2021 Apr 1;4(4):e217498.Полный текст  Аннотация

1253. Ntaios G, Michel P, Georgiopoulos G, et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry. Stroke. 2020 Sep;51(9):e254-8.Полный текст  Аннотация

1254. Qureshi AI, Abd-Allah F, Alsenani F, et al. Management of acute ischemic stroke in patients with COVID-19 infection: report of an international panel. Int J Stroke. 2020 Jul;15(5):540-54.Полный текст  Аннотация

1255. Palaiodimou L, Stefanou MI, Katsanos AH, et al. Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: a systematic review and meta-analysis. Eur J Neurol. 2021 Apr 9 [Epub ahead of print].Полный текст  Аннотация

1256. Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021 Apr;268(4):1133-70.Полный текст  Аннотация

1257. Siow I, Lee KS, Zhang JJY, et al. Encephalitis as neurological complication of COVID-19: a systematic review and meta analysis of incidence, outcomes and predictors. Eur J Neurol. 2021 May 13 [Epub ahead of print].Полный текст  Аннотация

1258. Nabizadeh F, Balabandian M, Sodeifian F, et al. Autoimmune encephalitis associated with COVID-19: a systematic review. Mult Scler Relat Disord. 2022 Apr 6;62:103795.Полный текст  Аннотация

1259. Hayek SS, Brenner SK, Azam TU, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ. 2020 Sep 30;371:m3513.Полный текст  Аннотация

1260. Khan DSA, Hamid LR, Ali A, et al. Differences in pregnancy and perinatal outcomes among symptomatic versus asymptomatic COVID-19-infected pregnant women: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2021 Dec 1;21(1):801.Полный текст  Аннотация

1261. Sun S, Savitz DA, Wellenius GA. Changes in adverse pregnancy outcomes associated with the COVID-19 pandemic in the United States. JAMA Netw Open. 2021 Oct 1;4(10):e2129560.Полный текст  Аннотация

1262. Huntley BJF, Mulder IA, Di Mascio D, et al. Adverse pregnancy outcomes among individuals with and without severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a systematic review and meta-analysis. Obstet Gynecol. 2021 Apr 1;137(4):585-96.Полный текст  Аннотация

1263. Stowe J, Smith H, Thurland K, et al. Stillbirths during the COVID-19 pandemic in England, April-June 2020. JAMA. 2021 Jan 5;325(1):86-7.Полный текст  Аннотация

1264. DeSisto CL, Wallace B, Simeone RM, et al. Risk for stillbirth among women with and without COVID-19 at delivery hospitalization: United States, March 2020 – September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1640-5.Полный текст  Аннотация

1265. Dhir SK, Kumar J, Meena J, et al. Clinical features and outcome of SARS-CoV-2 infection in neonates: a systematic review. J Trop Pediatr. 2020 Aug 28 [Epub ahead of print].Полный текст  Аннотация

1266. Allotey J, Chatterjee S, Kew T, et al. SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis. BMJ. 2022 Mar 16;376:e067696.Полный текст  Аннотация

1267. Meng X, Zhu K, Wang J, et al. Can SARS-CoV-2 positive pregnant women affect the hearing of their newborns: a systematic review. Am J Otolaryngol. 2022 Jun 2;43(5):103523.Полный текст  Аннотация

1268. Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M, et al. Coronavirus disease 2019 as cause of viral sepsis: a systematic review and meta-analysis. Crit Care Med. 2021 Jul 12 [Epub ahead of print].Полный текст  Аннотация

1269. Song JC, Wang G, Zhang W, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res. 2020 Apr 20;7(1):19.Полный текст  Аннотация

1270. Zhou X, Cheng Z, Luo L, et al. Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thromb Res. 2021 Feb 17;201:23-9.Полный текст  Аннотация

1271. Levi M, Iba T. COVID-19 coagulopathy: is it disseminated intravascular coagulation? Intern Emerg Med. 2021 Mar;16(2):309-12.Полный текст  Аннотация

1272. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 Jun 4;135(23):2033-40.Полный текст  Аннотация

1273. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-9.Полный текст  Аннотация

1274. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. Pediatrics. 2020 Jun;145(6):e20200702.Полный текст  Аннотация

1275. Jain S, Khanna P, Sarkar S. Comparative evaluation of ventilator-associated pneumonia in critically ill COVID-19 and patients infected with other corona viruses: a systematic review and meta-analysis. Monaldi Arch Chest Dis. 2021 Sep 28 [Epub ahead of print].Полный текст  Аннотация

1276. Singh A, Singh Y, Pangasa N, et al. Risk factors, clinical characteristics, and outcome of air leak syndrome in COVID-19: a systematic review. Indian J Crit Care Med. 2021 Dec;25(12):1434-45.Полный текст  Аннотация

1277. Que Y, Hu C, Wan K, et al. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol. 2021 Feb 22;1-14.Полный текст  Аннотация

1278. Kunal S, Ish P, Sakthivel P, et al. The emerging threat of multisystem inflammatory syndrome in adults (MIS-A) in COVID-19: a systematic review. Heart Lung. 2022 Mar 14;54:7-18.Полный текст  Аннотация

1279. Melgar M, Haston J, DeCuir J, et al. Multisystem inflammatory syndrome in adults (MIS-A): case finding through systematic review of electronic medical records. Clin Infect Dis. 2022 Apr 20 [Epub ahead of print]. Аннотация

1280. Abrams JY, Godfred-Cato SE, Oster ME, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review. J Pediatr. 2020 Aug 5;226:45-54.Полный текст  Аннотация

1281. Royal College of Paediatrics and Child Health. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. 2020 [internet publication].Полный текст

1282. Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). 2020 [internet publication].Полный текст

1283. Yousaf AR, Cortese MM, Taylor AW, et al. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Health. 2022 Feb 22 [Epub ahead of print].Полный текст  Аннотация

1284. Ouldali N, Bagheri H, Salvo F, et al. Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study. Lancet Reg Health Eur. 2022 Apr 29:100393.Полный текст  Аннотация

1285. Kildegaard H, Lund LC, Højlund M, et al. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study. BMJ. 2022 Apr 11;377:e068898.Полный текст  Аннотация

1286. Yasuhara J, Watanabe K, Takagi H, et al. COVID-19 and multisystem inflammatory syndrome in children: a systematic review and meta-analysis. Pediatr Pulmonol. 2021 May;56(5):837-48.Полный текст  Аннотация

1287. Rhedin S, Lundholm C, Horne A, et al. Risk factors for multisystem inflammatory syndrome in children: a population-based cohort study of over 2 million children. Lancet Reg Health Eur. 2022 Jun 22 [Epub ahead of print].Полный текст

1288. Abrams JY, Oster ME, Godfred-Cato SE, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc Health. 2021 May;5(5):323-31.Полный текст  Аннотация

1289. Shaiba LA, More K, Hadid A, et al. Multisystemic inflammatory syndrome in neonates: a systematic review. Neonatology. 2022 May 5:1-13.Полный текст  Аннотация

1290. Haghighi Aski B, Manafi Anari A, Abolhasan Choobdar F, et al. Cardiac abnormalities due to multisystem inflammatory syndrome temporally associated with Covid-19 among children: a systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2021 Mar 22:100764.Полный текст  Аннотация

1291. Zou H, Lu J, Liu J, et al. Characteristics of pediatric multi-system inflammatory syndrome (PMIS) associated with COVID-19: a meta-analysis and insights into pathogenesis. Int J Infect Dis. 2021 Jan;102:319-26.Полный текст  Аннотация

1292. Levy N, Koppel JH, Kaplan O, et al. Severity and incidence of multisystem inflammatory syndrome in children during 3 SARS-CoV-2 pandemic waves in Israel. JAMA. 2022 Jun 28;327(24):2452-4.Полный текст  Аннотация

1293. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 3. Arthritis Rheumatol. 2022 Feb 3 [Epub ahead of print].Полный текст  Аннотация

1294. Davies P, du Pré P, Lillie J, et al. One-year outcomes of critical care patients post-COVID-19 multisystem inflammatory syndrome in children. JAMA Pediatr. 2021 Aug 30 [Epub ahead of print].Полный текст  Аннотация

1295. Penner J, Abdel-Mannan O, Grant K, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study. Lancet Child Adolesc Health. 2021 May 24 [Epub ahead of print].Полный текст  Аннотация

1296. Bilotta C, Perrone G, Adelfio V, et al. COVID-19 vaccine-related thrombosis: a systematic review and exploratory analysis. Front Immunol. 2021 Nov 29;12:729251.Полный текст  Аннотация

1297. Waqar U, Ahmed S, Gardezi SMHA, et al. Thrombosis with thrombocytopenia syndrome after administration of AZD1222 or Ad26.COV2.S vaccine for COVID-19: a systematic review. Clin Appl Thromb Hemost. Jan-Dec 2021 Jan-Dec;27:10760296211068487.Полный текст  Аннотация

1298. Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021 Aug 11 [Epub ahead of print].Полный текст  Аннотация

1299. World Health Organization. Interim statement of the COVID-19 subcommittee of the WHO global advisory committee on vaccine safety on AstraZeneca COVID-19 vaccine. 2021 [internet publication].Полный текст

1300. National Institute for Health and Care Excellence. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT). 2021 [internet publication].Полный текст

1301. Palaiodimou L, Stefanou MI, Katsanos AH, et al. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: a systematic review and meta-analysis. Neurology. 2021 Oct 5 [Epub ahead of print]. Аннотация

1302. Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, et al. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination: a systematic review. J Neurol Sci. 2021 Aug 3;428:117607.Полный текст  Аннотация

1303. Salih F, Schönborn L, Kohler S, et al. Vaccine-induced thrombocytopenia with severe headache. N Engl J Med. 2021 Sep 15 [Epub ahead of print].Полный текст  Аннотация

1304. Cascio Rizzo A, Giussani G, Agostoni EC. Ischemic stroke and vaccine-induced immune thrombotic thrombocytopenia following COVID-19 vaccine: a case report with systematic review of the literature. Cerebrovasc Dis. 2022 May 5:1-13. Аннотация

1305. Kolahchi Z, Khanmirzaei M, Mowla A. Acute ischemic stroke and vaccine-induced immune thrombotic thrombocytopenia post COVID-19 vaccination; a systematic review. J Neurol Sci. 2022 Jun 20;439:120327.Полный текст  Аннотация

1306. British Society for Haematology. Guidance from the expert haematology panel (EHP) on Covid-19 vaccine-induced immune thrombocytopenia and thrombosis (VITT). 2021 [internet publication].Полный текст

1307. American Society of Hematology. Thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombotic thrombocytopenia). 2021 [internet publication].Полный текст

1308. American Heart Association/American Stroke Association Stroke Council Leadership. Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia. Stroke. 2021 Apr 29 [Epub ahead of print].Полный текст  Аннотация

1309. International Society on Thrombosis and Haemostasis. The ISTH releases interim guidance on vaccine-induced immune thrombotic thrombocytopenia (VITT). 2021 [internet publication].Полный текст

1310. Hwang J, Park SH, Lee SW, et al. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score. Eur Heart J. 2021 Sep 21 [Epub ahead of print].Полный текст  Аннотация

1311. Mitaka H, Kuno T, Takagi H, et al. Incidence and mortality of COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. Mycoses. 2021 Apr 25 [Epub ahead of print].Полный текст  Аннотация

1312. Wang J, Yang Q, Zhang P, et al. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit Care. 2020 Jun 5;24(1):299.Полный текст  Аннотация

1313. Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022 Jan 25 [Epub ahead of print].Полный текст  Аннотация

1314. Muthu V, Agarwal R, Patel A, et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. Lancet Infect Dis. 2022 Apr 4 [Epub ahead of print].Полный текст  Аннотация

1315. Muthu V, Rudramurthy SM, Chakrabarti A, et al. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia. 2021 Aug 19 [Epub ahead of print].Полный текст  Аннотация

1316. Dulski TM, DeLong M, Garner K, et al. Notes from the field: COVID-19-associated mucormycosis – Arkansas, July–September 2021. MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1750-1.Полный текст  Аннотация

1317. Pal R, Singh B, Bhadada SK, et al. COVID-19-associated mucormycosis: an updated systematic review of literature. Mycoses. 2021 Jun 16 [Epub ahead of print].Полный текст  Аннотация

1318. Singh AK, Singh R, Joshi SR, et al. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021 May 21;15(4):102146.Полный текст  Аннотация

1319. Indian Council of Medical Research. Evidence based advisory in the time of COVID-19 (screening, diagnosis and management of mucormycosis). 2021 [internet publication].Полный текст

1320. Arora N, Gudipati A, Kundu R, et al. Post-COVID-19 mucormycosis presenting as chest wall cellulitis with mediastinitis. Lancet Infect Dis. 2021 Nov;21(11):1611.Полный текст  Аннотация

1321. Kumar A. Mucormycosis in COVID-19 recovered patients. J Med Virol. 2021 Dec 14 [Epub ahead of print].Полный текст  Аннотация

1322. Pruthi H, Muthu V, Bhujade H, et al. Pulmonary artery pseudoaneurysm in COVID-19-associated pulmonary mucormycosis: case series and systematic review of the literature. Mycopathologia. 2021 Dec 22 [Epub ahead of print].Полный текст  Аннотация

1323. Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19 associated pulmonary aspergillosis (CAPA): from immunology to treatment. J Fungi (Basel). 2020 Jun 24;6(2):91.Полный текст  Аннотация

1324. Prestel C, Anderson E, Forsberg K, et al. Candida auris outbreak in a COVID-19 specialty care unit: Florida, July – August 2020. MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):56-7.Полный текст  Аннотация

1325. Gangneux JP, Dannaoui E, Fekkar A, et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med. 2021 Nov 26 [Epub ahead of print].Полный текст  Аннотация

1326. Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020 Apr 1;159(1):367-70.Полный текст  Аннотация

1327. Mutneja HR, Bhurwal A, Arora S, et al. Acute pancreatitis in patients with COVID-19 is more severe and lethal: a systematic review and meta-analysis. Scand J Gastroenterol. 2021 Aug 31 [Epub ahead of print]. Аннотация

1328. Yang F, Huang Y, Li T, et al. Prevalence and outcomes of acute pancreatitis in COVID-19: a meta-analysis. Gut. 2021 Oct 20 [Epub ahead of print].Полный текст  Аннотация

1329. Gubatan J, Levitte S, Patel A, et al. Prevalence, risk factors and clinical outcomes of COVID-19 in patients with a history of pancreatitis in Northern California. Gut. 2021 Feb;70(2):440-1.Полный текст  Аннотация

1330. Babajide OI, Ogbon EO, Adelodun A, et al. COVID-19 and acute pancreatitis: a systematic review. JGH Open. 2022 Apr;6(4):231-5.Полный текст  Аннотация

1331. Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Compr Clin Med. 2020 Sep 19:1-11.Полный текст  Аннотация

1332. Aemaz Ur Rehman M, Farooq H, Ali MM, et al. The association of subacute thyroiditis with COVID-19: a systematic review. SN Compr Clin Med. 2021 Apr 29:1-13.Полный текст  Аннотация

1333. Tutal E, Ozaras R, Leblebicioglu H. Systematic review of COVID-19 and autoimmune thyroiditis. Travel Med Infect Dis. 2022 Mar 18;47:102314.Полный текст  Аннотация

1334. El Moheb M, Naar L, Christensen MA, et al. Gastrointestinal complications in critically ill patients with and without COVID-19. JAMA. 2020 Sep 24;324(18):1899-901.Полный текст  Аннотация

1335. Ojha V, Mani A, Mukherjee A, et al. Mesenteric ischemia in patients with COVID-19: an updated systematic review of abdominal CT findings in 75 patients. Abdom Radiol (NY). 2021 Nov 10 [Epub ahead of print].Полный текст  Аннотация

1336. Keshavarz P, Rafiee F, Kavandi H, et al. Ischemic gastrointestinal complications of COVID-19: a systematic review on imaging presentation. Clin Imaging. 2020 Dec 8;73:86-95.Полный текст  Аннотация

1337. Patel S, Parikh C, Verma D, et al. Bowel ischemia in COVID-19: a systematic review. Int J Clin Pract. 2021 Oct 4:e14930.Полный текст  Аннотация

1338. Marasco G, Maida M, Morreale GC, et al. Gastrointestinal bleeding in COVID-19 patients: a systematic review with meta-analysis. Can J Gastroenterol Hepatol. 2021 Sep 1;2021:2534975.Полный текст  Аннотация

1339. Chen J, Hang Y. Characteristics, risk factors and outcomes of gastrointestinal hemorrhage in COVID-19 patients: a meta-analysis. Pak J Med Sci. 2021 Sep-Oct;37(5):1524-31.Полный текст  Аннотация

1340. Hussain N, Agarwala P, Iqbal K, et al. A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation. J Med Virol. 2021 Dec 20 [Epub ahead of print].Полный текст  Аннотация

1341. Christensen RE, Jafferany M. Association between alopecia areata and COVID-19: a systematic review. JAAD Int. 2022 Jun;7:57-61.Полный текст  Аннотация

1342. Raschke RA, Agarwal S, Rangan P, et al. Discriminant accuracy of the SOFA score for determining the probable mortality of patients with COVID-19 pneumonia requiring mechanical ventilation. JAMA. 2021 Feb 17 [Epub ahead of print].Полный текст  Аннотация

1343. George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020 Nov;75(11):1009-16.Полный текст  Аннотация

1344. Shah AS, Wong AW, Hague CJ, et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2020 Dec 3 [Epub ahead of print].Полный текст  Аннотация

1345. Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2020 Nov 25 [Epub ahead of print].Полный текст  Аннотация

1346. Chen M, Liu J, Peng P, et al. Dynamic changes of pulmonary diffusion capacity in survivors of non-critical COVID-19 during the first six months. EClinicalMedicine. 2022 Jan;43:101255.Полный текст  Аннотация

1347. Fan G, Tu C, Zhou F, et al. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. Eur Respir J. 2020 Sep 10;56(3):2002113.Полный текст  Аннотация

1348. Zou X, Li S, Fang M, et al. Acute physiology and chronic health evaluation II score as a predictor of hospital mortality in patients of coronavirus disease 2019. Crit Care Med. 2020 May 1;48(8):e657-65.Полный текст  Аннотация

1349. Ji D, Zhang D, Xu J, et al. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. Clin Infect Dis. 2020 Sep 12;71(6):1393-99.Полный текст  Аннотация

1350. van Klaveren D, Rekkas A, Alsma J, et al. COVID outcome prediction in the emergency department (COPE): using retrospective Dutch hospital data to develop simple and valid models for predicting mortality and need for intensive care unit admission in patients who present at the emergency department with suspected COVID-19. BMJ Open. 2021 Sep 16;11(9):e051468.Полный текст  Аннотация

1351. Liang W, Liang H, Ou L, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020 Aug 1;180(8):1081-9.Полный текст  Аннотация

1352. Fumagalli C, Rozzini R, Vannini M, et al. Clinical risk score to predict in-hospital mortality in COVID-19 patients: a retrospective cohort study. BMJ Open. 2020 Sep 25;10(9):e040729.Полный текст  Аннотация

1353. Berenguer J, Borobia AM, Ryan P, et al. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax. 2021 Feb 25 [Epub ahead of print].Полный текст  Аннотация

1354. Department of Health and Social Care. New technology to help identify those at high risk from COVID-19. 2021 [internet publication].Полный текст

1355. Wongvibulsin S, Garibaldi BT, Antar AAR, et al. Development of severe COVID-19 adaptive risk predictor (SCARP), a calculator to predict severe disease or death in hospitalized patients with COVID-19. Ann Intern Med. 2021 Mar 2 [Epub ahead of print].Полный текст  Аннотация

1356. Chua F, Vancheeswaran R, Draper A, et al. Early prognostication of COVID-19 to guide hospitalisation versus outpatient monitoring using a point-of-test risk prediction score. Thorax. 2021 Mar 10 [Epub ahead of print].Полный текст  Аннотация

1357. Yadaw AS, Li YC, Bose S, et al. Clinical features of COVID-19 mortality: development and validation of a clinical prediction model. Lancet Digit Health. 2020 Oct;2(10):e516-25.Полный текст  Аннотация

1358. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. BMJ. 2020 Sep 9;370:m3339.Полный текст  Аннотация

1359. Knight SR, Gupta RK, Ho A, et al. Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO clinical characterisation protocol. Thorax. 2021 Nov 22 [Epub ahead of print].Полный текст  Аннотация

1360. Corrao G, Rea F, Carle F, et al. Stratification of the risk of developing severe or lethal Covid-19 using a new score from a large Italian population: a population-based cohort study. BMJ Open. 2021 Nov 18;11(11):e053281.Полный текст  Аннотация

1361. Banerjee A, Pasea L, Manohar S, et al. 'What is the risk to me from COVID-19?': public involvement in providing mortality risk information for people with 'high-risk' conditions for COVID-19 (OurRisk.CoV). Clin Med (Lond). 2021 Nov;21(6):e620-8.Полный текст  Аннотация

1362. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): COVID-19 and animals. 2021 [internet publication].Полный текст

1363. Salman D, Vishnubala D, Le Feuvre P, et al. Returning to physical activity after covid-19. BMJ. 2021 Jan 8;372:m4721.Полный текст  Аннотация

1364. Daniels CJ, Rajpal S, Greenshields JT, et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the Big Ten COVID-19 Cardiac Registry. JAMA Cardiol. 2021 May 27 [Epub ahead of print].Полный текст  Аннотация

1365. Lemes IR, Smaira FI, Ribeiro WJD, et al. Acute and post-acute COVID-19 presentations in athletes: a systematic review and meta-analysis. Br J Sports Med. 2022 May 27 [Epub ahead of print].Полный текст  Аннотация

1366. Alosaimi B, AlFayyad I, Alshuaibi S, et al. Cardiovascular complications and outcomes among athletes with COVID-19 disease: a systematic review. BMC Sports Sci Med Rehabil. 2022 Apr 20;14(1):74.Полный текст  Аннотация